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3Abstract
In the absence of serotherapy, cord blood transplantation (CBT) is followed by a rapid and
unique CD4+ biased immune reconstitution derived from T cells within the graft. The
mechanism for this enhanced CD4+ biased reconstitution which differs from that of other stem
cell sources and correlates with rapid anti-viral and enhanced graft-versus-leukaemia responses
is not known. Lymphopoiesis following stem cell transplantation may be derived from foetal
or adult haematopoietic stem cells. We therefore sought to determine whether recapitulation of
foetal lymphopoiesis mediates rapid expansion of cord blood CD4+ T cells into the
lymphopenic environment created by transplant conditioning. We compared the foetal CD4+
T-cell transcriptome with the transcription profile of naïve CD4+ T cells from normal donor
cord blood (n=9), normal donor peripheral blood (n=9), and reconstituting naïve CD4+ T cells
following CBT (n=3) and bone marrow transplant (BMT) (n=3). Our findings confirm that
cord blood CD4+ T cells and CD4+ T cells reconstituting after CBT retain the properties of
foetal ontogenesis and can rapidly restore the CD4+ T-cell biased adaptive immunity through
enhanced T-cell receptor (TCR) signalling. TCR sensitivity dictates the ability of T cells to
respond to self-peptide and foreign antigens, and the emerging data suggests that unrelated
CBT, particularly in the context of HLA-mismatching and a T-cell replete graft, may reduce
leukaemic relapse. Therefore, I aimed to study the role of foetal-derived adaptive immune
system following T-cell replete CBT in mediating graft-versus-tumour responses and dissect
the underlying cellular mechanisms. To do this, the ability of HLA-mismatched cord blood and
adult peripheral blood T cells to eliminate Epstein-Barr virus (EBV)-driven human B-cell
lymphoma was compared, in a xenogeneic NOD/SCID/IL2rgnull mouse model. In our model,
cord blood T cells mediated enhanced anti-tumour effects by rapid infiltration of the tumour
with CCR7+ CD8+ T cells, and prompt induction of cytotoxic CD8+ and Th1 CD4+ T cells in
the tumour microenvironment. Conversely, in the peripheral blood group, this anti-lymphoma
effect was impaired because of delayed tumoural infiltration of peripheral blood T cells, and a
relative bias toward suppressive Th2 and T regulatory cells. Our data suggest that, despite being
naturally programmed toward tolerance, reconstituting T cells after unrelated T-cell replete
CBT may provide superior Tc1-Th1 anti-tumour effects against high-risk haematological
malignancies.
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1.1 History of haematopoietic cell transplantation
Haematopoietic cell transplantation (HCT) has become a life-saving procedure for malignant
haematological diseases and a wide variety of non-malignant diseases. Ironically the era of
HCT began just four years after the 1945 atomic bomb explosions when Jacobson et al.,
observed that the bone marrow of mice was protected by shielding their spleens with lead
(Jacobson et al., 1949). This was followed by a report in 1951, stating that the intravenous
infusion of bone marrow also provided similar protection against radiation in murine models
(Lorenz et al., 1951). This observation led to the humoural hypothesis of bone marrow
regeneration, with growth factors being secreted by the spleen or bone marrow. However, it
was not until the mid-1950s, when it was shown that this radiation protection was due to
regeneration of protected or transplanted stem cells (Barnes et al., 1954; Ford et al., 1956;
Nowell et al., 1956). Finally, the bone marrow cells of recipients were shown to have
cytogenetic features of the donor (Ford et al., 1956). These observations confirmed the cellular
hypothesis of protection against radiation.
These exciting and novel discoveries were thought to have therapeutic applications, especially
in the field of haematological malignancies. However, the first attempts to understand this
process in a laboratory were not very successful, and it was thought that overcoming the
transplantation barrier between individuals might not be possible (Uphoff et al., 1958). Further
experiments with large non-bred animals gave encouraging results (Storb et al., 1967), and this
set the stage for treating patients with haematological diseases. The initial therapeutic test was
performed using increasing doses of radiation to kill the recipient bone marrow, along with the
malignant cells. The radiotherapy-conditioned recipient bone marrow was then rescued with an
intravenous infusion of donor bone marrow.
Barnes et al., demonstrated that murine leukaemia could be cured by supralethal radiation,
followed by bone marrow infusion (Barnes et al., 1956). This was followed by attempts to treat
human patients with intravenous infusion of allogeneic marrow after chemotherapy and
radiotherapy in 1957 (Thomas et al., 1957). This also led to autologous harvesting of marrow
prior to high dose chemotherapy and then infusing it after high dose chemotherapy to facilitate
the marrow recovery (Kurnick et al., 1958). In 1959, Thomas et al., reported the treatment of
advanced leukaemia with supralethal radiation, followed by marrow infusion from identical
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twins leading to prompt haematological recovery (Thomas et al., 1959). Although a relapse of
leukaemia was observed a few months later, this provided the proof-of-principle for using
allogeneic bone marrow to cure haematological diseases.
In 1956, the immune-reaction of donor marrow against the host was reported as a wasting
syndrome known as graft-versus-host disease (GvHD) (Barnes et al., 1956), which was shown
to be ameliorated with the use of methotrexate (Uphoff et al., 1958; Lochte et al., 1962). In
parallel to the discovery of immunosuppressive drugs to tame the immune system,
approximately 200 human allogeneic stem cell transplantations were carried out between 1950
and 1960. However, the only successful transplants were those carried out using the marrow of
an identical twin (Thomas et al., 1959), which demonstrated the role of histocompatibility in
marrow grafting. Therefore, experiments were conducted in dogs to understand the process of
marrow grafting, such as engraftment failure, graft rejection, and GvHD.
Dausset et al. and van Rood et al., identified the human leukocyte antigen (HLA) groups, and
these were thought to be important in transplantation (Dausset, et al., 1958; van Rood, et al.,
1958). The proof-of-principle that determined the importance of the HLAs was obtained from
studies in dogs and showed that dog leukocyte antigen-matched marrow grafts significantly
improved survival (Epstein, et al., 1969). The canine experiments also confirmed the role of
methotrexate in suppressing GvHD (Storb et al., 1970a), and also encouraged trials using
sibling bone marrow grafts.
During these trials in the second half of the 1960s, high dose conditioning regimens with or
without radiotherapy were developed (Buckner et al., 1970; Thomas et al., 1975). Alongside
these advances in conditioning regimens, an improved understanding of HLA allowed grafting
from an histocompatible donors. Despite using histocompatible donors and methotrexate,
GvHD was still a problem in 50% of marrow recipients (Thomas et al., 1975; Storb et al.,
1977), which led to studies optimizing the use of methotrexate and calcineurin inhibitors, such
as ciclosporin and tacrolimus for inhibiting T-cell activation. Thus, these advances in
conditioning regimens, GvHD prophylaxis, alongside improvements in supportive care and
blood component technology set the stage for the modern era of HCT.
During this modern era of HCT, which started towards the end of the 1960s, three successful
transplantation procedures were carried out in children with severe combined
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immunodeficiencies (SCID), using HLA-matched sibling grafts (Gatti et al., 1968; Bach et al.,
1968; deKoning et al., 1969). These were followed by more than 100 allogeneic bone marrow
transplant (BMT) procedures for aplastic anaemia and leukaemia across the USA (Thomas, et
al., 1972; Storb et al., 1974), which included some patients with advanced leukaemia becoming
long-term survivors. In particular, this led to the use of HLA-matched grafts for treating chronic
myeloid leukaemia (CML) with very encouraging results (Fefer et al., 1973; Clift et al., 1982).
The success of BMTs in the 1970s led to the application of bone marrow grafting for a variety
of other non-malignant disorders. After 1975, non-malignant haematological conditions, such
as thalassaemia and sickle cell disease were grafted using HLA-matched sibling donors
(Thomas et al., 1982; Lucarelli et al., 1984; Johnson et al., 1984). In 1980, this was followed
by the first HLA-matched sibling bone marrow transplant in a child with Hurler’s syndrome
(Hobbs et al., 1980). Thus, providing proof-of-concept that bone marrow transplant corrects
not only haematological defects, but also enzyme deficiencies, and halts the clinical
deterioration of inherited metabolic disorders like Hurler’s syndrome. By the year 2008, more
than 1000 transplants had been performed world-wide for inherited metabolic disorders (Prasad
et al., 2008).
The success of bone marrow grafting has led to an increased number of bone marrow donors
registered world-wide (van Rood et al., 2008). New techniques for isolating haematopoietic
stem cells (HSCs) from peripheral blood using G-CSF stimulation were developed in 1980 (To
& Juttner, 1987; Kessinger et al., 1988; Gianni et al., 1989; Juttner et al., 1990). This led to the
easy collection of stem cells through apheresis of the donor’s peripheral blood, providing adult
donors with the choice of donating stem cells without general anaesthesia.
In the late 1980s it was discovered that cord blood was a source of HSCs, and provided another
vital discovery in the field of stem cell transplantation (Broxmeyer et al., 1989). In 1988, the
first successful cord blood transplantation (CBT) for Fanconi anaemia was performed
(Gluckman et al., 1989), and in 1992, another patient with leukaemia was successfully
transplanted with cord blood (Rubinstein et al., 1998). In the past three decades, more than
30,000 cord blood transplants have been performed for haematological and inherited metabolic
disorders (Ballen et al., 2013). In instances, where a single unit of cord blood has an insufficient
cell dose, two units of cord blood (double cord blood transplantation) are used (Majhail et al.,
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2006). The growing adult donor registry has made it relatively easy to find an unrelated 10/10
HLA-matched donor in the Caucasian population, but less frequently in ethnic minorities
populations. The cord blood registry has benefited ethnic minority populations by targeting
cord collections in areas of ethnic diversity and because of less stringent requirements of HLA-
matching for cord blood compared to an adult donor. These advances in stem cell grafting and
molecular HLA matching, along with the exponential growth of donor registries over the past
two decades have set the stage for the current transplantation program worldwide. Finally, if
both adult and cord donors are not available, advances in haploidentical transplantation, such
as post-transplant cyclophosphamide (Berger et al., 2016) and T-cell receptor alpha/beta, and
B-cell depletion (Bertaina et al., 2014) have made it possible to transplant with acceptable
morbidity and mortality.
These advances have made stem cell grafting safer and provided a number of different ways of
performing transplant procedures. There is a choice of stem cell source, in vivo T-cell depletion
using anti-thymocyte globulin or alemtuzumab, T-cell replete haploidentical transplant using
post-transplant cyclophosphamide vs TCR alpha-beta and B-cell deplete haploidentical
transplant; each may have a role in specific diseases. For instance, cord blood graft may mediate
better enzyme delivery in metabolic disorders (Aldenhoven et al., 2015). Similarly, in myeloid
leukaemia, graft-versus-leukaemia (GvL) effects may be more pronounced with cord blood
(Boelens et al., 2016; Milano et al 2016), and conditioning, particularly the use of in vivo T-
cell depletion, could also play a crucial role. In the context of our work, T-cell replete CBT may
facilitate rapid T-cell reconstitution with undifferentiated foetal-derived cord blood T cells, and
this may have distinct immunogenic effects compared with T-cell replete BMT.
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1.2. T-cell reconstitution after haematopoietic cell transplantation
T-cell reconstitution after HCT occurs via thymus-independent and thymus-dependent
pathways (Mackall et al., 1993; Williams et al., 2007).
1.2.1 Thymic dependent T-cell expansion
T cells carried with the stem cell graft have the ability to undergo lympopenia-induced
proliferation or proliferation in response to antigens immediately after transplantation
(Mackall et al., 1996; Mackall et al., 1997; Ge et al., 2002). T-cell proliferation in the
lymphopenic environment is thought to occur in the peripheral lymphoid organs, such as
the lymph nodes and gut. The benefit of such a T-cell reconstitution is mostly observed in
sibling grafts that are performed using preparative regimens without any T-cell depletion.
Generally early T-cell reconstitution is mediated by CD8+ memory T cells, and CD4+ T
cells do not appear till thymopoiesis is restored (Mackall et al., 1996).
1.2.2 Thymic independent T-cell expansion
Thymopoiesis provides a de novo pool of naïve T cells and is essential for the diverse T-
cell repertoire. The dynamics of thymus dependent T-cell reconstitution depends on the
state of the thymus after transplantation; therefore, thymopoiesis is determined by the age
of the recipient and the occurrence of acute or chronic GvHD.
Children have relatively preserved thymic function compared to adults, so generally
thymic output in children begins before six months, and in adults it can sometimes take 9
to 12 months. Early T-cell reconstitution generally exhibits a skewed T-cell repertoire, and
with the onset of thymopoiesis the repertoire begins to diversify (Mackall et al., 1996).
1.2.3 Effects of T cell depletion on T-cell reconstitution
The thymus-independent T-cell reconstitution is abrogated using in vivo or ex vivo T-cell
depletion as a part of the conditioning regimen. (Keever et al., 1989). These are used to
reduce the risk of severe GvHD in the setting of unrelated or mismatched donors. However,
T-cell depletion leads to delays in immune-reconstitution, and hence increases the risk of
viral reactivation/infection (Bacigalupo et al., 2001; Socie et al., 2011; Veys et al., 2012).
T-cell depletion may also increase the risk of leukaemic relapse, because GvHD and GvL
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are mediated by similar effector T-cell functions. Thus, T-cell depletion has both
advantages and disadvantages and hence both, T-cell deplete and T-cell replete grafts are
being performed world-wide, depending on the local practices.
Ex vivo depletion of donor T cells has been used for over three decades, and in vivo T-cell
depletion has been used in the last 2 decades (Champlin et al., 2000). Ex vivo T-cell
depletion is frequently performed via positive selection of CD34+ cells, using immuno-
magnetic beads. Recently, an advance in the T-cell depletion technique, using depletion of
T-cell receptor alpha/beta and CD19+ lymphocytes has made it to the clinic, whereby
negative selectin of CD34+ cells also retains NK cells and gamma delta T cells within the
graft allowing haploidentical grafts with a very low incidence of GvHD, and an infection-
related mortality of less than 10%. This is an attractive option for non-malignant diseases
without an HLA-matched donor, giving improved immune-reconstitution, despite T-cell
depletion (Bertaina et al., 2014).
Immune-reconstitution is delayed when T-cell depletion strategies are used. In the setting
of cord blood graft, ex vivo T-cell depletion cannot be used because of the low number of
CD34+ cells. Hence, preparative regimens, consisting of anti-thymocyte globulin (ATG)
have been used for in-vivo T cell depletion. However, in vivo T-cell depletion significantly
delays immune-reconstitution after cord blood graft, because cord blood T cells appear to
be particularly sensitive to ATG, either because of their low number or naivety (Admiraal
et al., 2015). Because cord blood grafts were associated with a lower incidence of GvHD
(Rubinstein et al., 1998; Rocha et al., 2000; Rocha et al., 2001) and require less stringent
HLA-matching, non-serotherapy conditioning regimens were used to improve immune-
reconstitution.
We observed an unprecedented, thymus independent T-cell expansion with a CD4+ bias,
in contrast to the normal expansion of CD8+ memory cells after transplantation following
the omission of serotherapy from the cord blood transplant conditioning regimens at Great
Ormond Street hospital (Chiesa et al., 2012). Further investigation of this unique
phenomenon formed the basis of this thesis. But, what are the primary drivers of thymic-
independent T-cell reconstitution. This type of T-cell expansion is called “lymphopenia-
induced proliferation” and is distinct to the steady state homeostatic proliferation.
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1.3 Mechanisms of T-cell expansion
1.3.1 Lymphopenia-induced (spontaneous) vs homeostatic proliferation
Many studies have used the terms “homeostatic” and “lymphopenia-induced” proliferation
interchangeably. However, there are at least two mechanistically distinct modes of proliferation
referred to as spontaneous proliferation and homeostatic proliferation.
Spontaneous proliferation or lymphopenia-induced proliferation occurs in extreme
lymphopenic settings such as after myelo-ablative HCT without T-cell depletion.
Spontaneously proliferating cells divide more than a cell division per day in the absence of
cytokines. These spontaneously proliferating cells rapidly differentiate in to memory
phenotype cells and thus acquire the ability to produce inflammatory cytokines after
stimulation (Min et al., 2005; Keiper et al., 2005).
In contrast, homeostatic proliferation occurs in lymphoreplete or mildly lymphopenic
conditions. This is a slow process. Homeostatically proliferating CD4+ T cells undergo cell
division every 3 to 4 days, although CD8+ T cells proliferate rapidly compared to CD4+ T
cells.
Tonic TCR signalling and cytokines such as IL-7 play role in both homeostatic and
lymphopenia-induced proliferation (Do et al., 2009; Tan et al., 2002). It is intriguing that one
is rapid and other is a slow process. Min proposed quantitative and qualitative signalling models
for explaining spontaneous proliferation in the lymphopenic environment and steady-state
homeostatic proliferation (Min et al., 2018). The quantitative signalling model for homeostatic
proliferation postulates that the relative amount of resources such as IL-7 and self-MHC
determines T-cell proliferation [Figure 1 (a)]. In contrast, the qualitative signalling model for
spontaneous proliferation postulates the nature of signals that T cells receive is fundamentally
different from those that T cells receive in the lymphocyte replete environment [Figure 1 (a)].
The model further proposes relative TCR signal strength determines which T cells undergo
spontaneous proliferation in extreme lymphopenic environment [Figure 1 (b)].
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Figure 1: Model for homeostatic and spontaneous proliferation. Quantitative and qualitative
signalling model. (a) The model depicts potential signalling mechanisms during homeostatic
and spontaneous proliferation. Homeostatic proliferation is triggered by excessive soluble
resources available under lymphopenic environments. In contrast, spontaneous proliferation is
triggered by different types of signalling mechanism only available under lymphopenic
conditions. (b) Relative T-cell receptor signal strength against self-MHC:peptide determines
which T cells undergo lymphopenia-induced (spontaneous) proliferation vs homeostatic
proliferation. Higher the TCR signal strength is, the more likely T cells undergo spontaneous
proliferation. Adapted from Min et al., 2018.
1.3.2 TCR signalling
Adaptive immunity represents a system of intercellular communication mediated by soluble
molecules, where two cells can transmit signals through membrane-associated receptors and
(a)
(b)
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ligands. Typically, during an adaptive immune response, the major histocompatibility complex
(MHC) protein on the surface of antigen-presenting cells interacts with the TCR on T
lymphocytes initiating TCR signalling.
The antigen specificity of T-cell is defined by its TCR, which acts as an antigen detector. The
interaction between TCR and peptide-bound MHC of the right complementarity results in
tyrosine phosphorylation of the TCR (referred to as TCR “triggering”) and the initiation of
signals that activate the T-cell. Adhesion molecules stabilise this immunological synapse, and
costimulatory pathways must also be triggered to deliver co-ordinated signals to the nucleus of
the T cell, resulting in effective activation. The most important of these being binding of CD28
on the T-cell by CD80/86 on the target antigen presenting cell, although several other possible
costimulatory pathways that can substitute for CD28. Although TCR is sufficient for pMHC
recognition, the associated invariant CD3 and zeta chains are required for signalling to occur.
The cytoplasmic domains of CD3 and zeta chains contain sequence motifs called
immunoreceptor tyrosine-based activation motif (ITAMs).
The TCR has no intrinsic kinase activity, unlike many other receptors, and instead relies upon
on a T-cell specific kinase called Lck. Also distinct from other systems,
the phosphorylatable tyrosine residues of the TCR (the ITAMs) do not reside on the
polypeptides that contact the pMHC (α, β) but instead are contained on tightly associated CD3 
subunits (γ, δ, ε2, ζ2).
On pMHC binding to the TCR, the kinase Lck is recruited to the TCR complex by the
colocalization of CD4 or CD8 coreceptors to pMHC molecules where Lck can phosphorylate
ITAM signalling motifs. ITAM motifs each contain two tyrosines that, when phosphorylated,
create binding sites for the tandem SH2 domains of the Zap70 kinase.
The phosphorylated ITAMs then bind a second kinase, ZAP70, which is subsequently activated
and drives downstream signalling.
Before TCR engagement, Zap70 predominately resides in the cytoplasm where it is
autoinhibited. By binding to phosphorylated ITAMs, Zap70 is recruited to the plasma
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membrane and its autoinhibited conformation is disrupted. The active conformation of Zap70
is further stabilized through phosphorylation of its interdomain linker and activation loop by
Lck.
Following ligation of the TCR, several phosphatases are activated and initiate signalling
through four main pathways. With help from the CD45 molecule, the Src family kinases Lck
and Fyn dephosphorylate ZAP-70 and Syk. Once recruited and activated, Zap70 is then able to
propagate signalling events from the TCR. Specifically, Zap70 phosphorylates the linker for
activation of T cells (LAT), which serves as a signalling hub (Balgopalan et al., 2010; Wange
et al., 2000) leading to activation of phospholipase Cγ1 (PLCγ1). This results in hydrolysis of 
Phosphatidylinositol-5,4-bisphosphate (PIP2) to diacyl glycerol (DAG) and inositol
phosphate3 (IP3), simultaneously activating three pathways: the Ras pathway, resulting in Erk
translocation to the nucleus, protein kinase C θ (PKCθ) activation initiates the NFκB pathway 
(nuclear factor kappa light chain enhancer of activated B cells), and the
Calmodulin/Calcineurin pathway activating the nuclear factor of activated T cells (NFAT).
In contrast to IP3, DAG remains in the plasma membrane where it activates protein kinase C
(PKC) and RasGRP, which can activate Ras. In addition, recruitment of SOS to LAT via Grb2
results in the activation of the RAS pathway. The combined actions of RasGRP and SOS lead
to rapid, bistable amplification of Ras activation. Ras-mediated activation of Raf leads to
activation of MEK, and ultimately the MAP kinase ERK (Das et al., 2009). The MAP kinases
respond to diverse signalling inputs and activate p38 and Jnk, allowing entry to the nucleus and
the presence of activated Fos and Jun. Binding of CD28 leads to activation of PIP3, which in
conjunction with PKCθ (activated by DAG), leads to activation and translocation of NFκB 
(Aringer et al., 2002). Thus, complex signalling pathways and network regulate T-cell
activation (Smith-Garvin et al., 2009). T cell activation remains under continued investigation,
however a simplified illustration of the understanding of these pathways to date in shown in
Figure 2.
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Figure 2: Illustration of T cell receptor signal pathways. From Cell Signalling
Technologies (http://www.cellsignal.com/reference/pathway/T_Cell_Receptor.html)
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1.4 T-cell differentiation
1.4.1 Models of T-cell differentiation
T-cell differentiation is still being understood (Ganusov et al., 2007). Currently, there are 3
models of T-cell differentiation – 1) stem cell associated differentiation 2) linear differentiation
and 3) progressive differentiation.
Stem cell differentiation model – In this model, during expansion phase, memory “stem” cells
divide and differentiate into nondividing activated effectors. During the contraction phase,
effectors die.
Linear differentiation model - In this model, during the expansion phase, activated cells
proliferate and become effectors. During the contraction phase, some activated cells (having
phenotype of effector cells) die and others differentiate into memory cells.
Progressive differentiation model – In this model, activated cells proliferate during the
expansion phase and progressively differentiate from naïve to memory to effectors. During the
contraction phase, activated effectors die and are survived by memory cells.
1.4.2 Phenotypic classification of T cells
Although, the mechanisms of T-cell differentiation is less understood, T-cell phenotypic
classification is better understood. Using four markers i.e. CD45RA, CCR7, CD27 and CD28,
CD4+ T cells can be classified in to naïve, central memory, Th0 effector memory, Th2 effector
memory and Th1 or Th2 effector T cells (Okada et al., 2008) [Figure 3].
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Figure 3: Differentiation pathway of human CD4+ T cells. (TCM=central memory,
TEM=effector memory) Adapted from Okada et al., 2008.
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1.5 Cord blood transplantation
The first successful HLA-identical, sibling cord blood transplant for Fanconi anaemia was
performed in 1988 (Gluckman et al., 1989), and provided proof-of-concept for the feasibility
of cord blood transplantation (CBT). Following this success, the development of cord blood
banks for related and unrelated transplants started in Paris, Dusseldorf, New York, and Milan,
The first unrelated cord blood transplant was performed in 1993 (Kurtzberg et al., 1993). The
success of these cord blood transplants prompted the development of the Eurocord Netcord
network. It was soon realized that cord blood was less HLA-restricted, and hence led to less
GvHD compared to adult stem cell sources, but with comparable long-term leukaemia free
survival in both children and adults (Rubinstein et al., 1998; Rocha et al., 2000; Rocha, et
al., 2001; Barker et al., 2015; Ponce, et al., 2015). The low cell dose in cord blood grafts led
to a high incidence of graft failures in adults, but this was significantly reduced by using double
cords to increase the cell dose (Barker et al., 2005). The cord blood grafts were also observed
to mediate a distinct immunological reaction in the form of an increased incidence of
engraftment syndrome (Kanda et al., 2013; Park et al., 2013; Patel et al., 2010). Thus, the
propensity to mediate an engraftment syndrome yet with low incidence of GvHD, and with
comparable rates of long-term leukaemia-free survival, suggested that there might be
significant differences in the properties of T cells contained within cord blood grafts and bone
marrow grafts.
1.5.1 Differences in graft composition - cord blood vs adult sources
Compared with stem cells from adult sources (bone marrow or peripheral blood), cord blood
is a distinct source because of the following seven reasons: (1) cord blood contains one log
lower CD34+ cells compared to an adult source (Table 1); (2) cord blood has one log lower T
cells compared to an adult source (Table 1); (3) the majority of T cells in cord blood are
undifferentiated naïve T cells, compared with a mixture of naïve, memory, and effector T cells
in bone marrow and peripheral blood stem cell grafts (De Waele et al., 1988; Zhao et al.,
2002); (4) cord blood lymphocytes have been shown to have reduced expression of
transcription factors associated with T-cell activation (Kaminski et al., 2003); (5) cord blood
lymphocytes have a diminished ability to secrete cytokines (Nitsche, et al., 2007); (6) cord
blood T cells are skewed towards a Th2/Tc2 phenotype (Marchant et al., 2005; White et al.,
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2002); and (7) cord blood dendritic cells have a Th2 bias, associated with lower antigen
presenting activity, reduced expression of co-stimulatory molecules, reduced cytokine
production, and induction of a Th2 bias (Langrish, et al., 2002).
Cell
source Target cell dose
Median number of
CD34+ cells
(x 106/kg)
Median number of T
cells
(x 106/kg)
CB > 3 x 107 TNC/kg 0.2 2.5
BM > 2 x 108 TNC/kg 2-3 25
PBSC 5-10 x 106 CD34+/kg 8 250
Table1. Main differences between haematopoietic cell sources (Gluckman et al., 2012)
1.5.2 T-cell deplete cord blood transplantation
As mentioned earlier, in vivo T-cell depletion was routinely employed in the context of unrelated
bone marrow grafts in Europe, and this practice also extended to unrelated cord blood grafts. In
studies of CBT employing in vivo T-cell depletion in the conditioning regimen, T-cell
reconstitution was delayed (Renard et al., 2011; Niehues et al., 2001). A study by Renard et
al., showed that after unrelated CBT, the median time to achieve a CD4+ T-cell count of 0·2 ×
109/L and 0·5 × 109/L was five and nine months, respectively. Similarly, CD8+ T-cell count
was delayed after in vivo T-cell depletion and took approximately eight months to reach a count
of 0.25 x 109/L. In adult recipients, cord blood grafting with in vivo T-cell depletion results in
a significant delay in T-cell reconstitution, with a recovery of absolute CD4+ and CD8+ T-cell
number after 9 to 12 months. The delayed immune-recovery is often characterized by impaired
thymopoiesis and late memory T-cell skewing (Komanduri et al., 2007).
1.5.3 T-cell replete cord blood transplantation
In contrast, following T-cell replete CBT in children, we observed unprecedented CD4+ T-cell
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recovery. Two months post-CBT, the median CD4+ T-cell count was 0·56 x 109/L and CD8+ T-
cell count was 0.25 x 109/L (Chiesa et al., 2012). Following T-cell replete double cord blood
transplantation in adults, the median time to reach a CD4+ T-cell count > 0·2 x 109/L was four
months, and six months to reach a CD8+ T-cell count > 0.09 x 109/L (Sauter et al., 2011). In a
report comparing practices in two different centres, circulating CD4+ T-cell count was 1 log
higher at two months in the no ATG group compared with the group that received ATG
(Lindemans et al., 2014).
Within our own centre, we compared the immune-reconstitution following CBT with ATG (n
= 7) and without ATG (n = 30). Following CBT without ATG, we found unprecedented
recovery of CD4+ T cells, with median CD3+/CD4+/CD8+ T cell counts of 840/560/150 x 106/L
at two months, compared to 70/20/20 x 106/L following conventional CBT incorporating ATG
serotherapy [Figure 4].
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Figure 4: Comparison of immune-reconstitution two months after CBT with and without ATG.
Median CD3+, CD4+ and CD8+ T cells are shown. Unprecedented early immune-reconstitution
was observed after CBT, when ATG was omitted.
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Thus, CBT without in vivo T-cell depletion mediates a rapid T-cell reconstitution with a striking
asymmetric CD4+ T-cell bias, especially at early time-points. Hence, the characteristic
CD4:CD8 inversion observed after adult sources, such as bone marrow and peripheral blood
stem cells, is not observed after CBT. Further analysis suggested that this CD4+ T cell
expansion after CBT is thymic independent (i.e. in the absence of an increase in T-cell receptor
excision circle (TREC) numbers) [Figure 5] and involved a rapid shift from naïve to central
memory phenotype (Chiesa et al., 2012). Thus, omission of in vivo T-cell depletion promotes
a unique thymic-independent CD4+ T cell reconstitution after unrelated CBT in children.
Figure 5: Early CD4+ T-cell expansion is thymic-independent. Median CD4+ T-cell count (red
line) and the median number of TRECs (blue line) after CBT are shown. CD4+ T-cell recovery
over the first six months after CBT is due to peripheral expansion of the lymphocytes infused
with the graft, since TRECs are low during this period. Six months after unrelated CBT, there
is a concomitant increase in both CD4+ T cells and TRECs, suggesting a return of thymopoiesis.
Figure adapted from Chiesa et al., 2012.
Interestingly, we also noted that the early and rapid T-cell reconstitution also occurred with a
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diverse T-cell repertoire. Cord blood CD4+ T cells are enriched in recent thymic emigrants
(RTEs) compared to peripheral blood CD4+ T cells (Swainson et al., 2007). This may be the
reason for the robust proliferation of cord blood CD4+ T cells. However, using a RAG2p-GFP
mouse model, Opiela et al., have shown that RTEs from murine neonates and adults are
phenotypically and functionally distinct, and that neonatal, but not adult, RTEs showed early
proliferation in response to stimulation with interleukin-7 (IL-7) alone (Opiela et al., 2009).
This observation suggests that preferential CD4+ T-cell proliferation may be a property,
peculiar to foetal T-cell homeostasis.
It is also important to note that the average CD4/CD8 ratio is 3.9 ± 1.3 in the cord blood,
compared to 1.9 ± 0.7 in the adult blood, and this ratio declines gradually with age (Gasparoni
et al., 2003; Neubert et al., 1998). Thus, the observation of a CD4+ T-cell biased immune
system following CBT, and CD8+ T-cell biased immune system following BMT, coupled with
a higher CD4/CD8 ratio in neonates compared to adults, suggests that (1) CD4+ T-cell
proliferative and survival mechanisms are significantly up-regulated in cord blood compared
to peripheral blood, and (2) the equilibrium of proliferative and survival advantage shifts from
CD4+ to CD8+ T cells as the transition from foetal to adult immune system occurs.
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1.6 Are cord blood and adult blood T cells distinct?
T-cell reconstitution patterns observed after CBT and BMT indicate that T cells carried
with the cord blood and bone marrow graft may be distinct. Here, I have therefore
attempted to layout the development of T cells in foetus and phenotypic, functional, and
homeostatic differences between cord blood and peripheral blood T cells.
1.6.1 Snapshot of haematopoiesis in the foetus
The first stage of human foetal haematopoiesis occurs in the mesoderm of the yolk sac and the
extraembryonic mesenchymal tissue. Pluripotent erythroid and granulo-macrophage
progenitors can be detected in the yolk sac at 3 to 4 weeks of gestation. These primitive cells
then migrate to the liver and are hence detected in circulation from 4 weeks of gestation. Liver
becomes a major site of haematopoiesis from 5 to 6 weeks onwards. From 5 weeks onwards,
liver – the key foetal haematopoietic organ, and thymus – the key organ for T-cell development
undergo dramatic increase in size. From 12 weeks onward bone marrow starts to develop and
gradually becomes the key organ for haematopoiesis [Figure 6].
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Figure 6: Illustration of establishment of definitive HSC pools in human foetus.
(a) Hematopoietic development starts as primitive streak mesoderm (gray) into hematopoietic
and vascular fates. Nascent HSCs undergo a maturation process (blue) that allows them to
engraft, survive and self-renew in future hematopoietic niches. Subsequently, foetal HSCs
expand rapidly, after which a steady state is established in which HSCs reside in a relatively
quiescent state in the bone marrow.
(b) The ages at which human haematopoietic sites are active. Gray bars, mesoderm; red bars,
active hematopoietic differentiation; yellow bars, HSC genesis; blue bars, presence of HSCs.
Broken yellow bars for yolk sac and placenta indicate that de novo HSC genesis has not been
experimentally proven.
AGM – aorto-gonad mesonephros; Adapted from Mikkola et al., 2006
The transition of foetal to adult haematopoiesis could be dependent on generation of foetal vs
adult haematopoietic stem cell from a single precursor or could be related to the environment
of haematopoiesis such as liver vs bone marrow [Figure 7].
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Figure 7: Mold et al., 2010 proposed the model of transition of foetal to adult haematopoiesis.
The two proposed theories of switch from foetal to adult haematopoiesis and therefore switch
from foetal to adult immune system are 1) generation of separate i.e. foetal vs adult
haematopoietic stem cells from a single precursor population 2) a transition from foetal to adult
haematopoiesis may be related to environment in which they reside for eg. liver vs bone
marrow. Adapted from Mold et al., 2010.
1.6.2 T-cell development in the foetus
7 to 10 weeks
T-cell progenitors can be identified in the foetal liver from 7 weeks of gestation (Haynes et al.,
1989). These are highly proliferative cells positive for CD7, CD45, and cytoplasmic CD3,
without surface CD3, TCR β chain, or terminal deoxynucleotidyl transferase (TdT is involved 
in diversification of the DJ region of Ig heavy chain and the TCR).
Initially the T-cell precursors are not TCR δ or β positive. Rearranged TCR δ genes are seen in 
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the liver and primitive gut between 6 and 9 weeks of gestation prior to being detectable in the
thymus (McVay et al., 1998). T-cell precursors start seeding the thymus at 8 to 9 weeks of
gestation. TCR β cells are detected from 9 to 10 weeks of gestation and percentage of these 
cells increase to form over 90% of the CD7+ population at birth (Campana et al., 1989).
10 to 18 weeks
T-cell progenitors with surface CD3 are detected after week 10 of gestation (Haynes et al.,
1988; Haynes et al., 1989). Foetal gastrointestinal tract is most likely to be the site of
extrathymic differentiation of T cells, as has been demonstrated in the mouse (Fichtelius et al.,
1967). Human foetal intestinal mucosa has T cells detectable in the lamina propria and
epithelium from 12 to 14 weeks of gestation (Spencer et al., 1986). T cells in foetal ileum
epithelium are mostly CD8+, and many of these express CD8αα. Almost half of the CD8+ T 
cells in the lamina propria are also CD8αα. Peyer’s patches start to develop between 16 to 19 
weeks, and unlike dominance of CD8αα T cells in the lamina propria and epithelium, CD8αβ 
T cells predominate in the Peyer’s patches (Latthe et al., 1994).
18 to 24 weeks
T cells from 18 weeks of gestation are most studied because of access to the circulating T cells
in the foetus, pre-term and term neonates. The peripheral compartment is populated with single
positive CD4+ and CD8+ mature T cells from second trimester on onwards. More than 90% of
circulating T cells are CD45RA+ naïve T cells from 18-week onwards. The mesenteric lymph
nodes are also populated with high percentage of CD45RA+ naïve T cells but very few B cells
or monocytes and the foetal spleen has equal numbers of T cells, B cells and
monocytes/macrophages (von Hoegen et al., 1995). Interestingly, spleen has relatively higher
numbers of CD45RO+ T cells compared to circulating cells, lymph nodes.
Lymph node and thymus T cells at these gestational ages do not proliferate in response to the
mitogen phytohaemagglutinin or anti-CD3 stimulation. In contrast, splenic T cells do
proliferate to phytohaemagglutinin and anti-CD3. T cells from foetal spleen have adult levels
of CD3, CD4, and CD8, and expressed CD2 and CD11a. Thus, the spleen is considered already
fully immunocompetent by 18 weeks of gestation, having sufficient accessory cells to ensure
T-cell activation, whereas the mesenteric lymph nodes are deficient in accessory cells
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numerically or functionally (von Hoegen et al., 1995).
24 weeks to term
Neonatal T cells differ significantly from adult T cells. CD4+ T cells outnumber CD8+ T cells
during foetal life. CD4:CD8 ratio is significantly CD4+ T-cell biased during the foetal life with
higher frequency of T-regulatory cells. At 25 weeks of gestational age, 12% of CD4+ T cells
are T-regulatory cells and at term the frequency of T-regulatory cells is 3% i.e. similar to adults
(Michaelsson et al., 2006). The foetal exposure to foreign antigens is largely restricted to non-
inherited maternal allo-antigens. Hence, the function of early-life T cells is different from adult
T cells. For example, foetal naive CD4+ T cells respond strongly to allo-antigens, but they tend
to develop towards Foxp3+ CD25+ regulatory T cells (Treg) through the influence of TGF-β 
(Mold et al., 2010), and thus rapidly promote tolerance.
Activation of foetal and neonatal T cells with allo-antigens results in a response that is skewed
towards Th2 immunity (Hebek et al., 2014). Th2 biased response is also supported by the
neonatal dendritic cells and T-cell epigenetics. Very early-life adaptive T-cell immunity is thus
characterized by enhanced allogeneic responses with a tolerogenic bias.
In contrast to the conventional αβ T cells that recognize peptide antigens in the context of 
classical MHC molecules, there are populations of MHC independent innate-like T cells. These
include functionally competent γδ TCR-positive T cells and iNKT cells that rapidly produce 
IFN-γ, mucosal-associated invariant T (MAIT) cells (Leeansyah et al., 2014) and the recently
described interleukin-8 (CXCL8)-secreting naive T cells (Gibbons et al., 2014). MAIT cells
develop in the thymus, but their maturation can take place in foetal mucosal tissues before
microbial colonization. The CXCL8-producing T cells produce important effector functions in
human newborns as they have the potential to activate antimicrobial neutrophils and γδ T cells. 
They appear to be particularly active at the mucosal barriers of premature and term infants,
though their frequency decreases with age. In contrast to adult blood, where the repertoire of
γδ TCR is restricted, neonatal blood γδ T cells display a variety of receptor chain combinations 
that change with gestation (Silva-Santos et al., 2012). γδ T cells can produce significant 
amounts of IFN-γ, after brief polyclonal stimulation, compensating for the immaturity of the 
more classical Th1-type T-cell response to neonatal infections (Gibbons et al., 2009). Thus, the
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immune system carried with the cord blood graft is distinct to the immune system carried with
related or unrelated peripheral blood or bone marrow graft.
1.6.3 Phenotypic differences in cord blood and adult blood T cells
Peripheral blood T cells comprise approximately 45% CD4+ T cells and 70% CD8+ T cells
with a naïve phenotype, whereas more than 90% of cord blood CD4+ and CD8+ T cells
have a naïve phenotype (De Waele et al., 1988; Zhao et al., 2002). In cord blood, approx.
80% of these naïve T cells are thymic naïve (CD31+), and the remaining 16 to 18% are
central naïve (CD31-). The percentage of thymic naïve CD31+ CD4+ T cells and central
naïve CD31- T cells decreases to 65% and 10%, respectively, towards the end of the first
year. This decrease in percentage parallels with the increase in CD45RA-CD31- memory
T cells (Collier et al., 2015).
Analysis of lymphocyte subsets shows that 0.35 - 9.07% and 1.7 - 7% of T-regulatory cells
have been reported in cord blood and peripheral blood, respectively (Kim et al., 2012).
Although, T-regulatory content is not dissimilar between cord blood and peripheral blood, the
percentage of resting T-regulatory cells, activated T-regulatory cells, and activation-induced
FoxP3 T cells gradually increase in the first year of life (Collier et al., 2015). Whereas the
increase in resting regulatory T cells is modest, from 4 to 5%, and the increase in activated T-
regulatory cells and activation-induced FoxP3 T cells is reported to be significant. Activated
T-regulatory cells and activation-induced FoxP3 T cells have been reported to increase from
0.72% to 1.91%, and 0.53% to 2.65% respectively. Thus, these phenotypic differences may
have an influence on immune-reconstitution after T-cell replete CBT.
1.6.4 Functional differences between cord blood and adult blood T cells
Components of the naïve immune system carried with the cord blood graft have to undergo
memory-effector differentiation and gain functionality. IL-12 secretion and expression of
co-stimulatory molecules by antigen-presenting cells (APCs) supports the process of
memory-effector differentiation. Neonatal APCs have diminished IL-12 secretion and
defective expression of co-stimulatory molecules. These features in neonatal dendritic cells
have been reported to play a role in the defective secretion of Th1 cytokines by naïve cord
blood CD4+ T cells (Langrish et al., 2002). Although the APCs present in cord blood mediate
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a Th2 biased response, the residual host antigen presentation may mediate a Th1 response.
In addition, it is well established that cord blood T cells, in particular cord blood CD4+ T
cells, have decreased ability to secrete Th1 cytokines compared with peripheral blood
CD4+ T cells (Marchant et al., 2005). This is because cord blood CD4+ T cells are
hypermethylated at CpG and non-CpG sites within the IFN-γ promoter compared to adult naive 
T cells, and hence produce lower levels of IFN-γ (White et al., 2002).
This lack of ability to mediate Th1 responses in vitro explains why neonates and infants cannot
efficiently develop responses to certain vaccines or cannot fight viral infections. In particular,
infants develop lower Th1 responses to vaccines, such as hepatitis B, measles, and oral polio
vaccine (Ota et al., 2004; Vekemans et al., 2002; Gans et al., 2001). They also develop
attenuated responses to CMV, HSV, and HIV infections (Tu et al., 2004; Feeney et al., 2003;
Burchett, et al., 1992). Furthermore, the foetal immune system is immunotolerant (Silverstein
et al., 1964a; Silverstein et al., 1964b). It is well-established that although cord blood and
peripheral blood have similar percentages of T-regulatory cells, a significant proportion of cord
blood T cells have a propensity to acquire T-regulatory phenotype in a mixed lymphocyte
reaction (Mold et al., 2010).
However, despite the immunotolerant immune system and the lack of ability to mediate Th1
responses in vitro, and to vaccines, and viral infections as described above, neonates can mount
efficient Th1 responses to Bordetella pertussis and BCG vaccine, and also develop an adult-
like CD8+ response to Trypanosoma cruzi infection (Henderson et al., 1997; Tonon et al., 2002;
Hermann et al., 2002).
These observations indicate that cord blood T cells can mount efficient antigenic responses
under appropriate conditions. Leukaemia-free survival rates following CBT are comparable to
adult sources (Wagner, et al., 2014; Brunstein, et al., 2011; Barker, et al., 2015), and we also
have observed early CMV-specific and ADV-specific immune responses after T-cell-replete
CBT (Chiesa, et al., 2012). Thus, these observations make it important to understand how the
early adaptive immune system could mediate anti-leukaemic responses to haematological
malignancies after T-cell replete CBT.
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1.6.5 T-cell homeostasis in cord blood and adult blood T cells
Three processes drive T-cell expansion following HCT, lymphopenia-induced expansion,
antiviral expansion and allo-reactive expansion (Maury et al., 2001). Non-host reactive donor
T cells proliferate in response to lymphopenic space and homeostatic signals, and thus
contribute to a beneficial T-cell peripheral reconstitution. In contrast, host reactive donor T
cells proliferate in response to allo-antigens, causing GvHD and virus-specific T cells
expansion occurs in response to viral reactivation.
Lymphopenia-induced expansion is predominantly dependent on MHC class I and II and/or
cytokines (Tan et al., 2001; Seddon et al., 2002; Kieper et al., 2004). Allo-reactive expansion
depends on the recognition of MHC/antigen complex by the T-cell receptor, and subsequent
engagement of co-stimulatory molecules and clonal expansion of T cells. The most well
characterized co-stimulatory molecule is the CD28/B7 family (Acuto et al., 2003), however,
the role of several members of the tumour-necrosis factor receptor (TNFR) superfamily -
OX40, CD40, 4-1BB, CD27, CD30, and HVEM (herpes-virus entry mediator) - in providing
co-stimulation that is distinct to that of CD28/B7 has also been recognized (Croft et al., 2003).
The allo-reactive expansion is largely inhibited with immunosuppression following HCT, and
homeostatic expansion is thought to be the primary mechanism of replenishing the
lymphopenic environment.
In the lymphopenic and lymphoreplete environment, CD4+ and CD8+ T cells compete for
proliferation and survival (Butz et al., 1998; Kedl et al., 2000; Kedl et al., 2002) [Figure 8]. It
has been suggested that CD8+ T cells are better competitors than CD4+ T cells, hence, CD8+ T
cells have a proliferative and survival advantage over CD4+ T cells (Bender et al., 1999; Ernst
et al., 1999; Ferriera et al., 2000). This may also be because the homeostatic expansion of CD8+
T cells (but not CD4+ T cells) can occur outside of the normal secondary lymphoid organs (Dai
et al., 2001). It has also been suggested that dendritic cell-secreted IL-7, rather than stromal-
secreted IL-7 controls CD4+ T-cell proliferation (Saini et al., 2009; Guimond et al., 2009;
Martin et al., 2010; Kaye et al., 2009). These findings indicate that CD4+ T cells have a more
stringent requirement, such as lymphoid APCs, compared to CD8+ T cells, which may
contribute to the control of CD4+ and CD8+ T-cell expansion.
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Figure 8: Naive and memory T cells in lymphopenic versus normal (lympho-replete)
environments. (a) In the lymphopenic host, naive T cells have increased access to IL-7 and self-
MHC molecules on APCs, which allows the cells to homeostatically proliferate. (b) In the
lympho-replete host, the presence of competitor naive T cells restrains clonal expansion and
limits survival by competing for these resources. Memory CD8+ T cells can proliferate in
response to IL-15 or IL-7, but competition with naive T cells limits access to IL-7 in lympho-
replete hosts. Figure adapted from Jameson et al., 2002.
The rapid CD4+ T-cell biased peripheral expansion after T-cell-replete CBT, but relatively
delayed CD8+ T-cell biased expansion after T-cell-replete BMT, indicates that the cord blood
and peripheral blood T cells may have distinct interactions with APCs and/or cytokines during
lymphopenia-induced proliferation. It has been reported that compared to peripheral blood,
cord blood CD4+ and CD8+ T cells are explicitly responsive to IL-7, and cord blood CD8+ T
cells are selectively responsive to IL-15 (Schonland et al., 2003). Similarly, cord blood T cells
are in a state of high proliferative turn over despite retaining a naïve (resting) phenotype. In
addition, there are 10-fold higher Ki67-expressing naïve T cells in the cord blood, than in the
peripheral blood (Schonland et al., 2003).
Since naïve T cells require both MHC and IL-7 for homeostatic expansion, how do these two
signals co-operate to keep naïve cord blood T cells in a state of high proliferative turn over? It
is well-established that there is a co-ordinated network between these two pathways. The
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ligation of IL7R increases the expression of TCR co-receptors, and thus, allows TCR to signal
when bound to MHC self-ligands. The TCR signal blocks the IL-7 signal, down-regulating the
TCR co-receptors, and allowing T cells to respond to IL-7 again (Takada et al., 2009; Surh et
al., 2008; Sprent et al., 2011; Seddon et al., 2003; Goldrath et al., 1999; Tscheltzoff et al.,
2013). Using T cells from normal mice and 7RTg mice, researchers recently showed that
normal T cells grow in TCR sufficient conditions but failed to grow in TCR deficient mice.
However, T cells from 7RTg mice did proliferate in both TCR sufficient and deficient
conditions, although fewer T cells were isolated from the TCR deficient animals. Thus, it was
concluded that IL-7 can promote T-cell proliferation but fails to promote survival in the absence
of a TCR signal. They further showed that in 7RTg cells, continuous exposure of IL-7 initially
led to proliferation, followed by IFN-γ induced cell death, and intermittent exposure of IL-7 
maintained naïve CD8+ T cells in a quiescent state, without proliferation. It was further shown
that the stronger the TCR signal, the more IL-7 signal was interrupted, and the more cells
survived. Therefore, it appears that the TCR mediated interruption of IL-7 signalling is required
for the survival of T cells in vivo (Kimura et al., 2013).
Given the complex interplay between the TCR and IL-7 signalling pathways to maintain T-cell
homeostasis, and the distinct feature of early T-cell immune-reconstitution after T-cell-replete
CBT and BMT, it is likely that the distinct regulation of these homeostatic pathways during the
developing immune system may endow cord blood T cells with the enhanced ability to
reconstitute in a lymphopenic environment, such as following CBT.
1.6.6 The foetal versus adult adaptive immune system
The phenotypic differences between cord blood and peripheral blood T cells are a result of the
immune system being at different stages of maturation. Cord blood T cells are predominantly
undifferentiated naïve T cells, whereas peripheral blood T cells are a mixture of naïve, memory, and
effector T cells. Thus, the undifferentiated naïve cord blood T cells may proliferate with a CD4 bias,
whereas the differentiated immune system proliferates with a CD8 bias because of the relatively
enhanced proliferative capability of memory CD8+ T cells, compared with memory CD4+ T cells.
However, the functional differences, such as the ability to secrete cytokines and distinct T-cell
homeostasis - in particular, the rapid kinetics of immune-reconstitution after CBT, despite one log
lower T cells carried with a cord blood graft, compared to an adult graft source may indicate the
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influence of foetal ontogeny. The evidence of two distinct lymphoid systems derived from foetal
and adult haematopoietic stem cells is increasing (Mold et al., 2010; Copley et al., 2013), a so-called
a layered immune system, similar to that of avian and murine species (Morrison et al., 1995;
Zanjani et al., 1993; Harrison et al., 1997; Ikuta et al., 1990; Montecino-Rodriguez et al., 2006;
Havran et al., 1988). It has been shown that the Lin28b-let7 axis determines the self-renewal
potential of HSCs, and upregulation of Lin28b in adult HSCs mediates a foetal-like erythroid and
lymphoid differentiation (Copley et al., 2013; Yuan et al., 2012; Lee et al., 2013). These findings
suggest that the physiological demands of the foetal-stage haematopoietic system are met by Lin28b
upregulated HSCs. Foetal lymphopoiesis derived from Lin28b upregulated HSCs is therefore likely
to be distinct to adult lymphopoiesis that is influenced by let-7 miRNA biogenesis. Foetal
lymphocytes may be endowed with the ability to rapidly repopulate the lymphopenic environment
of the foetus. It is possible that a significant population of cord blood T cells may be derived from
Lin28b upregulated foetal HSCs and could retain the property of foetal ontogenesis. Hence, it is also
possible that the rapidly repopulating lymphoid systems after T-cell replete cord blood
transplantation could also mediate distinct immunological effects.
51
1.7 Graft-versus-Leukaemia effect
An immune response mediated by allogeneic cells to suppress residual leukaemia is termed as
graft-versus-leukaemia effect. The rationale for using allogeneic transplantation to cure
leukaemia is based upon the following observations.
1. The risk of leukaemic relapse is associated with the absence of alloreactivity. For example,
there is increased risk of relapse after syngeneic transplant, and after T-cell depleted BMT
(Gale et al., 1994; Apperley et al., 1888; Marmont et al., 1991; Goldman et al., 1988).
2. An association between GvHD and risk of relapse is well-known; patients who get GvHD have
an increased chance of leukaemia-free survival (Weiden et al., 1979 and 1981).
3. Donor lymphocyte infusions for leukaemia relapse, following allogeneic stem cell transplant,
can mediate an anti-leukaemic effect, especially in chronic myeloid leukaemia and juvenile
myelomonocytic leukaemia (Levine et al., 2002; Yan et al., 2012).
4. Withdrawal of immunosuppression can sometimes reinduce remission especially in patients
with relapsing chronic myeloid leukaemia (Elmaagacli et al., 1999; Mehta et al., 1996).
Donor lymphocyte infusion is less effective in other haematological malignancies, such as
acute myeloid leukaemia (AML), myelodysplasia, myeloma, Hodgkin’s lymphoma, chronic
lymphocytic leukaemia (CLL), and Philadelphia positive acute lymphoblastic leukaemia. Thus
the GvL effect depends upon the type of leukaemia, the burden of leukaemia, and the potential
for alloreactivity.
1.7.1 Mechanisms of the GvL effect
The cell populations capable of recognizing and killing malignant targets are: T cells and
natural killer cells. T cells mediate the GvL effect in an HLA-restricted manner, and it is
thought that T cells mediate the GvL effect in three ways:
1) Direct killing by cytotoxic lymphocytes (CD4+, CD8+, and NK cells) via perforin and
granyzymes (Kagi et al., 1994).
2) Apoptotic death, induced by cytotoxic lymphocytes (CD4+ and CD8+ T cells) via the Fas/Fas
ligand pathway (Kagi et al., 1994).
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3) Cytokine-mediated leukaemia cell death (e.g. IFN-γ, TNF-α), or control of proliferation by 
CD4+ T cells; (Susskind et al., 1996).
CD4+ T cells are now thought to play a dual role as orchestrators and effectors in the GvL
response (Barrett et al., 1997) [Figure 9]. CD4+ T cells are central to immune system function,
and CD4+ helper T-cell activity is crucial for promoting CD8+ T-cell and NK cell activity. Both
CD8+ T cells and NK cells have been implicated in the GvL effect following CBT.
Figure 9: A three phase model of the GvL response. CD4+ T cells have dual roles, as
orchestrators and effectors. Figure adapted from Barrett et al., 1997
Cytotoxic CD8+ T cells have been shown to be responsible for single unit predominance
following double CBT (Gutman et al., 2010). As early as 28 days following a double CBT,
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CD8+ T cells from the winning cord exhibits cytotoxicity against targets from the losing cord.
There is also increasing evidence, both in animal (Xie Y et al., 2010; Quezada SA et al., 2010)
and clinical studies (Hunder et al., 2008), for the direct anti-tumour effects of CD4+ T cells.
Furthermore, in clinical studies of chronic myeloid leukaemia, it has been demonstrated that
CD4+ donor lymphocyte infusions (DLI), to treat CML relapse after HCT have induced durable
remissions (Shimoni et al., 2001). More elaborate studies, however, have shown that CD4+
lymphocyte infusions led to the expansion of CD8+ donor T cells, inducing their cytotoxic
activity (Zorn et al., 2002). Another recent study has also demonstrated that the response to
CD4+ DLI is predicted by the percentage of pre-DLI bone marrow CD8+ T-cell infiltrates
(Bachireddy et al., 2014). These observations indicate that although cytotoxic T cells mediate
an effector response, CD4+ T cells play a crucial role in orchestrating an immune response
against recipient malignant cells.
1.7.2 Targets for the GvL effect
Cytotoxic T cells (CTLs) recognize recipient haematopoietic and malignant cells as foreign.
Donor CTL responses against the recipient leukaemic cells are directed against five broad
classes of antigen, (1) major histocompatibility antigens, (2) minor histocompatibility antigens,
(3) tumour associated antigens, (4) viral antigens, and (5) killer cell immunoglobulin (KIR)-
ligand incompatibility
1) Major histocompatibility antigens
Cord blood grafts pose a lower risk and severity of chronic GvHD compared to adult grafts
(Rubinstein et al., 1998; Rocha et al., 2001). HLA-mismatched CBT is now being
recommended for leukaemia in the absence of a matched adult donor (Grewal et al., 2003;
Apperley et al., 2012). For the same reason, while adult grafts are increasingly matched for 10
HLA loci (A, B, C, DR, and DQ), cord blood grafts are matched only for six HLA loci (A, B,
and DR). Thus, in contrast to unrelated donor BMT, unrelated CBTs are frequently
mismatched, so, T cells that recognize ubiquitous antigens presented by mismatched-HLA
alleles may play a key role in mediating a GvL effect. This has been indicated by the powerful
GvL effect observed after HLA-mismatched CBT (Eapen et al., 2007). Additionally, CBT is
increasingly performed without in vivo T-cell depletion for treating acute leukemia, and such,
a T-cell replete CBT may significantly augment this alloreactive effect (Wagner et al., 2014;
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Brunstein, et al., 2011; Barker et al., 2015). One major difference between the alloreactivity
mediated by CBT and BMT, is that the incidence of chronic GvHD is significantly lower
following CBT, compared to an adult source such as bone marrow or peripheral blood stem
cells (Rubistein et al., 1998; Rocha et al., 2001). Thus, T-cell replete CBT may mediate
enhanced GvL effects with minimal risk of chronic GvHD.
2) Minor histocompatibility antigens
Another crucial mechanism of the GvL effect is through recognition of mismatched minor
histocompatibility antigens. Minor histocompatibility antigens (mHAgs) are highly
immunogenic peptides, recognized by T cells in an HLA restricted manner. mHAgs are also
highly polymorphic, and hence, incompatibility between the donor and the host allows a strong
alloreactive effect.
A well-known example of such an alloreactive effect is GvHD observed in male recipients of
an HLA identical graft from the female donors. This effect is due to the recognition of minor
antigen (HY), encoded by the Y chromosome. Some mHAgs are present ubiquitously (e.g.
HY), and thus, CTLs directed against these antigens will result in GvL and GvHD. Others, such
as HA-1 and HA-2, are only present on haematopoietic tissues, and should only elicit GvL
responses, although in fact, HA-1 mismatching has been associated with GvHD (Goulmy et
al., 1996).
HA-1 and HA-2 are encoded by bi-allelic gene systems, with one being immunogenic, and the
other non-immunogenic (Di Terlizzi et al., 2006). The immunogenic peptides encoded by HA-
1H and HA-2V are presented on HLA-A2 molecules, which are solely recognized by HLA-A2-
restricted CTLs. A GvL effect through HA-1 mismatching is estimated to occur in 10-15% of
sibling transplants (Schetelig et al., 2005). After infusion of DLI, following HA-1/HA-2
mismatch transplant, only 33% of CTL clones were specific for HA-1 and HA-2. The other
67% of leukaemia-reactive CTLs were thought to be against a variety of antigens of unknown
specificity (Scheteli, et al., 2005), showing that the immune system reacts against a variety of
antigens to eradicate leukaemic clones.
55
3) Tumour associated antigens
Tumour associated antigens are those that are expressed in cancer cells, but at low levels, or
not at all, in normal tissue. Whilst considerable effort has been made to identify tumour specific
neo-epitopes created by leukaemic fusion genes, such as BCR-ABL, there is little evidence that
such epitopes are processed and presented in vivo, or that they are significant targets for a GvL
response. However, an increasing body of evidence suggests that over expressed tumour-
associated antigens may be used as targets to augment GvL responses.
Proteinase 3 is a tumour-associated antigen that is over expressed in both CML and AML. PR1
is an HLA-A2 restricted peptide derived from proteinase 3. PR1-specific CTLs have been
shown to kill myeloid leukaemic colonies that over express proteinase 3, but not normal
marrow cells (Molldrem et al., 1999). High avidity PR1 CTLs are increased in CML patients
who develop cytogenetic remission in response to IFN-α (Schetelig et al., 2005). PR1 CTLs
are also found in healthy donors, albeit in low frequency (Rezvani et al., 2003).
Wilm’s Tumour Protein (WT1) is another tumour-associated antigen that is over expressed in
myeloid malignancies. WT1, a zinc-finger transcription factor, was initially described as a
tumour-suppressor gene in childhood Wilms' tumours. It is abundantly over-expressed in most
human leukaemia cells, including AML, CML, and ALL, with higher levels associated with a
worse prognosis. Leukaemia stem cells express from 10- to >100-fold more WT1 protein than
normal CD34+ cells. T cells can distinguish this difference in protein expression because CD8+
CTLs generated against WT1 lyse leukaemic CD34+, but not normal CD34+ cells, and inhibit
the growth of leukaemic, but not normal myeloid colonies (Appelbaum et al., 2001). Therefore,
like PR3, WT1 might serve as a useful target for adoptive T-cell therapy.
4) Viral antigens
Latent EBV infection is associated with non-Hodgkin’s lymphoma, Burkitt’s lymphoma, NK
cell lymphoma, lymphoproliferative disease, Hodgkin’s lymphoma, and nasopharyngeal
carcinoma, making adoptive T-cell strategies that target EBV a potential option (Rooney et al.,
1998).
56
5) Killer cell immunoglobulin (KIR) ligand incompatibility
The importance of NK activity in this setting has also been demonstrated by the observation
that killer cell immunoglobulin (KIR)-ligand incompatibility in the graft-versus-host direction
is associated with reduced relapse incidence, and improved leukaemia and overall survival,
after CBT for acute leukaemia (Willemze et al., 2009; Sekine et al., 2016).
1.7.3 GvL in acute lymphoblastic leukaemia
There is very little effect of T-cell depletion on leukaemia-free survival following allogeneic HCT
for B-cell acute lymphoblastic leukaemia (ALL) (Veys et al., 2012). Similarly, the response of
ALL to DLI is significantly inferior to that of AML (Collins et al., 1997). In the NSG mouse
model of ALL, the effect of DLI in suppressing tumour growth only lasted for a few weeks
(Nijmeijer et al., 2002). The limited effect of DLI in B-cell ALL is thought to be associated with
tolerance induction because of the lack of co-stimulatory molecules (Cardoso et al., 1996). In T-
cell ALL, and particularly cutaneous T-cell lymphoma, DLI has been shown to mediate durable
responses. Despite DLI having little effect in ALL, the role of GvHD in mediating GvL against
both T-cell and B-cell ALL has been observed (Passweg et al., 1998).
1.7.4 GvL in Acute myeloid leukaemia
The effect of T-cell depletion on AML relapse is not as pronounced as CML (Horowitz et al.,
1990). This is thought to be because of the pace of the disease itself, and because more than 80%
of patients with AML do not express CD86 co-stimulatory molecules (Dermime, et al., 1996).
The effect of DLI in AML is significantly inferior compared to CML, and the best results of DLI
in relapsed AML are obtained in patients who relapse six months post-transplant (Levine et al.,
2002). Although generally, the GvL effect in AML is inferior, foetal-derived cord blood T cells
may mediate a distinct GvL effect, compared to peripheral blood T cells. Interestingly, the GvL
effect mediated by cord blood T cells was observed in AML, but not in ALL (Admiraal et al.,
2016), and very recently in AML with minimal residual disease prior to transplantation (Milano
et al., 2016).
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1.8 Humanized mouse models of GvL
Immuno-deficient IL2rynull mice permits engraftment with many primary tumours (Shultz et al.,
2007). Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice,
generate a faster and more efficient leukaemia model, compared to other NOD/scid strains,
such as NOD-scid β2mnull mice (Agliano et al., 2008). Hence, NOD/LtSz-scid/IL-2Rgamma
null mice have been favoured for studying graft-versus-tumour effects. In these models,
primary tumours, such as lung tumours, have been tested to recapitulate in vivo tumour
characteristics, including maintenance of stroma and conversion of naïve to effector T cells in
the tumour microenvironment (Simpson-Abelson et al., 2008). Therefore, we decided to use
this triple knock out model for studying potential GvL effects of cord blood T cells.
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1.9 Measurement of tumours in vivo
Palpation of subcutaneous tumours and/or calliper measurement of accessible lesions were
the key methods of assessing tumour progression in early studies of tumour development.
More recently, bioluminescent imaging technology has allowed the precise tracking and
quantification of xenografted tumour cells.
Bioluminescence refers to the production and emission of light by naturally occurring
luciferase enzymes. The light is emitted upon oxidation of luciferin substrates to non-reactive
oxyluciferins (Berger et al., 2008). The most widely used luciferase-luciferin system is
from the common firefly, Photinus pyralis (Chandran et al., 2009). Isolation of firefly
luciferase, and purification of the D-luciferin substrate has allowed the application of this
technology to scientific research.
Luciferase reporter assay, a technology using in vitro reporter genes, has been routinely
used for many years, and allows the easy detection through luminometers, due to the low
background in biological systems and concurrent low signal-to-noise ratio (Nguyen et al.,
1988). The development of sensitive charged coupled device (CCD) cameras, and subsequently the
Xenogen IVIS imaging system, has also allowed the application of bioluminescence to in vivo
systems (Contag et al., 1998). The serial measurement of bioluminescent signal allows a
sensitive, non-invasive technique for monitoring tumour progression and regression (Foste et
al., 2008).
Bioluminescent imaging has become widely used for in vivo monitoring, including application to
the EBV-PTLD model. These studies have shown serial tumour monitoring using luciferase
transduced LCL, demonstrating progression and regression upon treatment (Foster et al., 2008).
These studies have established that bioluminescent imaging does not interfere with the utility of the
SCID mouse EBV-PTLD model. We, therefore, used a similar technique to monitor
xenografted tumours in our triple knockout mouse model.
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1.10 Project aims
 To characterize CD4+ T-cell reconstitution and study the differences in immune-reconstitution
after T-cell-replete cord blood and bone marrow transplantation.
 To study the role of homeostatic signals in cord blood CD4+ T-cell proliferation.
 To investigate the role of foetal ontogeny in rapid CD4+ T-cell reconstitution after T-cell-
replete CBT and explore the underlying mechanisms.
 To establish a tumour model for comparing the GvL effect mediated by rapidly reconstituting
cord blood T cells and dissect the underlying immune mechanisms.
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Chapter two
Materials and Methods
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2.1 Materials
2.1.1 Reagents
General reagents and enzymes:
Cyclosporin A (Sandimmune) 478941 Sandoz Pharmaceuticals
D-Luciferin - K+ Salt 122796 Perkin Elmer
Ficoll-Paque PLUS 17-1440-02 Amersham Biosciences
Matrigel HESC Matrix 5ml 354277 Beckton Dickinson
Recombinant human IL-2 200-02 Peprotech
Recombinant human IL-7 200-07 Peprotech
Recombinant human IL-15 200-15 Peprotech
AP-1 inhibitor (SR 11302) 2476/10 Tocris Bioscience
CellTrace CFSE Cell Proliferation Kit C34554 Invitrogen
Penicillin-Streptomycin, liquid 15140122 ThermoFisher scientific
Red cell Lysis Buffer 00-4333 EBioscience
Retronectin T100B TaKara
PMA V1171 Promega
Ionomycin 0215961101 ThermoFisher scientific
GolgiPlug™ (containing brefeldin A) 555029, BD
Tissue culture media and supplements:
Medium Supplements
Foetal Bovine Serum (Sigma F7524)
Complete RPMI (Invitrogen 61870-010) 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin
2x freezing medium 60% FBS, 20% DMSO (Sigma D2650), 20% complete RPMI
AIM V (Invitrogen 12055- 091) No additions
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2.1.2 Buffers and solutions
All buffers and solutions were prepared in double distilled water (ddH20), sterile solutions were
prepared in ddH20, autoclaved for 15 minutes at 121OC or sterile filtered through a 0.22.im filter.
Composition of buffers and solutions is listed below.
Buffer Ingredients
Flow Cytometry staining buffer (FACS
buffer)
PBS, 0.5% FBS
Flow cytometry fixing buffer (FACS
fixing buffer)
FACS buffer + 0.5% Paraformaldehyde (Sigma 441244)
Fixation buffer No additions (BD Cytofix 554655)
PhosFlow Perm Buffer III No additions (BD 558050)
FoxP3 Staining Buffer set No additions (eBioscience 00-5523)
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2.1.3 Kits
Human IL-7 Ultra-Sensitive Kit K151AMC-1 Meso Scale discovery
Human Th1/Th2/Th17 Phenotyping Kit 560751 BD Pharmigen
64
2.1.4 Magnetic selection beads (Milteyni)
CD3 microbeads human, 130-050-101
CD45RA microbeads, 130-045-901
CD235a microbeads, 130-050-501
Pan T Cell Isolation Kit II, human 130-091-156
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2.1.5 Flow cytometry antibodies
CD8 BV 421 anti-human, BioLegend, 301036
CD8 PE anti-human, BD, 555635
CD4 BV 605 anti-human, BioLegend, 317438
CD4 FITC anti-human, BD, 555346
CD4 PerCP/Cy5.5 anti-human, BioLegend, 344608
CD25 BV 421 anti-human, BioLegend, 302629
CD45 RO PerCP-Cy5.5 anti-human, BioLegend, 304222
FoxP3 APC anti-human, eBioscience, 17-4777-42
CD3 APC/Cy7 anti-human, BioLegend, 300426
CD197 (CCR7) APC anti-human, BioLegend, 353214
CD197 (CCR7) PE antihuman, eBioscience, 12-1979-42
CD45RA APC anti-human, BioLegend, 304112
CD127 FITC anti-human, BD, 561697
MHC Class I FITC anti-human, BD, 557348
HLA-DRB PE anti-human, BD, 557348
CD80 FITC anti-human, BD, 557226
CD86 PE anti-human, BD, 560957
CD83 PE anti-human, BD, 556855
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2.1.6 Reagents for RNA isolation
RNase-Free DNase Set (Qiagen 79245) - RNase-free DNase I, RNase-free Buffer RDD, and
RNase-free water for 50 RNA minipreps. For DNase digestion during RNA purification.
RNeasy Plus Micro Kit (Qiagen 74034) - For 50 micropreps: RNeasy MinElute Spin
Columns, gDNA Eliminator Spin Columns, Collection Tubes, Carrier RNA, RNase-Free
Water and Buffers. For purification of total RNA from small cell and tissue samples using
gDNA.
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2.1.7 Reagents for gene profiling
NuGEN WT-Ovation, NuGEN - 3302-12
QIAquick PCR purification kit, Qiagen - 28104
Ovation RNA Amplification System V2, NuGEN - 3100-12
Affymerix HuGene ST 1.0 arrays
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2.1.8 Cell lines
B95-8 Marmoset cell line releases high titres of EBV. This cell line is used for
transforming B-cell lymphocytes from normal donors to lymphoblastoid cell lines
LCL Human lymphoblastoid cell line (EBV-transformed)
Kasumi 1 Human acute myeloid leukaemia t(8;21) cell line
MV4-11 Human biphenotypic B-myelomonocytic leukaemia cell line
THP-1 Human monocytic leukaemia cell line
K562 Human erythroleukaemia cell line
Human cell lines namely LCL, Kasumi 1, MV4-11, THP-1 and K562 were studied for
their antigen presenting properties. Expression of antigen presenting molecules such as
MHC Class I, HLA-DR, CD80, CD86 and CD83 in these cell lines is shown below
[Figure 10].
Figure 10: High expression of MHC Class I, HLA-DR, CD86 and CD83 in all cell lines.
However, CD80 was highly expressed in LCL, Kasumi 1 and MV 4-11 only. Thus, suggesting
these cell lines may have good antigen-presenting ability.
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2.2 Methods
2.2.1 Cell isolation
Mononuclear cells were isolated from 1) random healthy adult and cord blood donors and 2)
peripheral blood of patients following CBT or BMT using standard cell separation techniques
(Ficoll-Paque, GE Healthcare 17-1440-03).
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2.2.2 CD4+ T-cell subset analysis
CD4 T-cell subset analysis was performed on day 30, day 60 and day 180 following CBT
without serotherapy. This was compared with those receiving BMT without serotherapy. All
our recipients were children between 0.1 and 12 years of age, with median age of 2 years.
2.2.2.1 T-regulatory staining
Surface staining of PBMCs was performed using anti-mouse human CD4 PerCP Cy5.5, CD25
PE, CD127 FITC (BD Biosciences) for 20 mins.
Intracellular staining for Foxp3 protein was performed using fixation and permeabilization
buffers provided by the Foxp3 kit (eBioscience) and Foxp3APC (eBioscience). RatIgG2a K
APC was used for isotype control. Ten thousand lymphocyte gate events were acquired on BD
LSR II flow cytometer and analysed by FACSDiva software (BD Biosciences).
2.2.2.2 Th1, Th2, Th17 staining
Th1, Th2, Th17 staining was performed using HumanTh1/Th2/Th17 Phenotyping Kit from BD
Pharmingen™. 1 million PBMCs were stimulated with PMA/Ionomycin (at 50 ng/ml and 1
μg/ml respectively) in the presence of BD GolgiStop™ Protein Transport Inhibitor for 5 hours 
at 37oC. A negative control was 1 million PBMCs incubated at 37oC without any stimulation.
Significant down regulation of CD4 receptor is observed after PMA/Ionomycin stimulation52,
hence to reliably identify CD4+ T cells additional surface staining of CD3 APC-Cy7
(eBioscience) was performed. Manufacturer’s instructions were followed for fixation and
permeabilization. Human Th1/Th2/Th17 Phenotyping Cocktail was used for surface staining
of CD4 and cytokine staining of IFN-y, IL-4 and IL-17. A minimum of 2000 CD4 T cell events
were acquired on BD LSR II flow cytometer and analysed by FACSDiva software (BD
Biosciences).
2.2.2.3 Naïve-memory-effector differentiation
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T cells were classified using PerCP-Cy5.5-conjugated CD4, APC-conjugated CD45RA and
PE-conjugated CD27PE. CD45RA+CD27+ were classed as naïve, CD45RA-CD27+ cells were
classed as central memory, and CD45RA+CD27- were classed as effectors.
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2.2.3 CFSE proliferation assay
For measurement of cell proliferation, cells were incubated at 37oC with 10μM carboxy-
fluorescein diacetate succinimidyl ester (CFSE; Invitrogen) in X-VIVO 10 for 7 minutes.
CFSE-labelled cells were washed 3 times in X-VIVO 10 containing 10% Human AB serum to
remove the excess CFSE. The cells were then suspended in X-VIVO 10 media and incubated
at the appropriate concentration in 24-well flat bottom plates. Cells were either unstimulated
(control) or stimulated with irradiated (30Gy) allogeneic LCLs (at ratio 10:1) or stimulated
with IL-2 (20 U/ml; Pepro Tech), IL-7 (10 ng/ml; Pepro Tech) and IL-15 (12 ng/ml; Pepro
Tech). Concentrations of cytokines were chosen based on previous work by other co-workers
(Swainson et al., 2007; Schonland et al., 2003; Dardhalon et al., 2001) Unstimulated samples
were analysed on day 0 to verify CFSE labelling of cells and were used as negative controls.
Stimulated samples were analysed at day 7 following allogeneic stimulation or day 9 following
cytokine stimulation. At least 10,000 lymphocyte gate events were acquired on BD LSR II flow
cytometer and analysed by FACSDiva software (BD Biosciences).
Proliferative index was calculated as follows -
Sum of the cells in all generations ÷ Calculated number of original parent cells
73
2.2.4 STAT5 phosphorylation
One million PBMCs and CBMCs were isolated and stimulated with varying concentrations of
IL-7 and IL-2 for 10 minutes at 37oC. IL-7 was used at the concentration of 10 ng/ml, 1 ng/ml,
0.1 ng/ml and 0.01 ng/ml and IL-2 was used at the concentration of 1000 U/ml, 100 U/ml and
20 U/ml. Unstimulated PBMCs and CBMCs were used as controls. The cells were then fixed
using Phos flow lyse/fix buffer, washed and permeabilised using Phos Flow Perm Buffer III
(BD Biosciences). The cells were then incubated for 30 minutes at 4oC. At the end of the
incubation, cells were washed twice and stained with CD4 PerCP (SK3 clone, BD Biosciences)
and Alexa Fluor 488 Anti-Stat5 (pY694) (BD Biosciences). Flow cytometry was performed on
FACS Calibur and at least 10,000 lymphocyte gate events were acquired. The acquired flow
cytometry files were analysed using CellQuest software (BD Biosciences).
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2.2.5 Measurement of plasma cytokines
Plasma samples of children were stored at day+30, day+60 and day+90 following CBT (n=6)
and BMT (n=6). Plasma IL-7 levels were measured in these samples.
All reagents were provided with the Meso-scale discovery kit. Each 96-well plate had a carbon
electrodes in the bottom of each well, pre-coated with anti-IL-7 antibody. The standards were
reconstituted in the assay diluent provided. Assay diluent (25 µl) was added to all wells and
the plate sealed and incubated for 30 sec at room temperature on an orbital shaker (600 rpm).
Following addition of 25 μl diluent to each well, samples and standards were added at 25 µl 
per well. The plate was sealed and incubated for 2 hours at room temperature on an orbital
shaker (600 rpm). At the end of the incubation the wells were washed three times using 200 µl
PBS + 0.05%Tween 20, soaking for 30 sec and then discarding. Detection antibody was added
at 25 µl per well, and the plate sealed and incubated for 1 hour at room temperature on an
orbital shaker (600 rpm). At the end of the incubation the plate was washed three times as
before. 150 µl of the MSD Read Buffer was added to each well and the MSD plates were
measured on the MSD Sector Imager 2400 plate reader. The raw data was measured as
electrochemiluminescence signal (light) detected by photodetectors and analysed using the
Discovery Workbench 3.0 software (MSD). A 4-parameter logistic fit curve was generated for
IL-7 using the standards and the concentration of each sample calculated. The limit of detection
was between 0 and 2500 pg/ml.
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2.2.6 Fluorescence Activated Cell Sorting (FACS)
Mononuclear cell preparations were incubated in FACS staining buffer (PBS with 2% FBS and
2mM EDTA) with surface antibodies conjugated to fluorochromes. CD4-FITC (BD
Biosciences), CCR7-PE (eBioscience), CD45RA-APC (BD Biosciences) were used for surface
staining of naïve CD4+ T cells and FACS sorting was performed on BD FACS Aria III cell
sorter.
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2.2.7 Preparation of RNA for microarray analysis
CD4+CD45RA+CCR7+ naïve T cells from blood samples of 1) normal donor cord blood and
peripheral blood and 2) patients 2 months after receiving T-replete CBT and BMT were
checked for high purity (>98%) after cell sorting. Naïve CD4+ T cells were then immediately
resuspended in RNA lysis buffer (RNAeasy mini-kit) and stored at -80°C. RNA was isolated
according the manufacturer’s protocol and yield was determined on a Nanodrop
spectrophotometer (Thermo Scientific). Samples that had an appropriate yield (typically >10
nanograms total RNA) were subsequently analyzed for RNA integrity using an Agilent
Bioanalyzer (Agilent 2100, Agilent Technologies). RNA that was determined to be of high
quality was then converted to cDNA and amplified (NuGEN WT-Ovation, NuGEN), purified
to remove residual RNA (QIAquick PCR purification kit, Qiagen), fragmented (NuGEN WT-
Ovation Kit), and labeled (FL-Ovation cDNA biotin module, NuGEN) for subsequent
microarray analysis. Fragmented and labelled cDNA was hybridized to microarray chips
(Affymerix HuGene ST 1.0 arrays). Hybridization of samples and data acquisition was
performed by the Department of Genomics at University College London.
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2.2.8 Experimental design
Three experiments comparing biological replicates of samples from normal donor cord blood
(n=3) and normal donor peripheral blood (n=3) were performed. In the third experiment,
samples from cord blood and peripheral blood of same donors were compared, thus allowing a
paired analysis of these samples. Along with these paired normal donor samples, biological
replicates of reconstituting naïve CD4+ T cells isolated two months after CBT (n=3) and BMT
(n=3) were also performed.
To decipher the relationship of foetal CD4+ T-cell transcriptome with naïve CD4+ T cells from
normal donor cord blood, normal donor peripheral blood and during early T-cell reconstitution
following T-replete CBT and BMT, Affymetrix Human Genome U133 Plus 2.0 Array dataset
of naïve CD4+ T cells isolated from the foetal lymph nodes (18-22 week gestational age) was
retrieved (GSE25119; Mold et al., 2010).
An Affymetrix Human Genome U133 Plus 2.0 Array dataset of T-regulatory cells isolated from
fetal lymph nodes (18-22 weeks gestational age) and adult PB were also retrieved (GSE25119;
Mold et al., 2010). Thus, the relationship between CD4+ T-regulatory cell transcriptome and
naive CD4+ T cells from normal donor CB and during early reconstitution after CBT was also
elucidated.
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2.2.9 Microarray data analysis – Quality control and statistical analysis
All gene expression profiles were determined to be of good quality after a quality control
analysis [Figure 11]. Assessment of hybridization quality was performed using Bioconductor
package affyPLM (Bolstad et al., 2005).
Figure 11: Box plot of log intensities for each microarray. The distribution of data as well as
median values are similar for all the arrays. This confirms minimum variability and good
quality of gene expression data.
Preprocessing of Affymetrix dataset followed these procedures: background correction,
normalization using the quantile method, summarization of probe set values using the RMA
(Robust Multi-array Average) method, which fits a specified robust linear model to the probe
level data.
Probe sets were mapped to genes using Bioconductor package AnnotationDbi (Pages et al.,
2017). Where multiple probe sets representing a gene were available, the probe with maximum
average value was chosen. Thus, we identified 17522 genes common to the Affymerix HuGene
ST 1.0 and Affymetrix Human Genome U133 Plus 2.0 platform.
The dataset of 17522 genes was combatted to remove the batch effects using Combat function
in R as previously described (Johnson et al., 2007). Three-dimensional and two-dimensional
principal component analysis was performed on the combatted datasets using DUDI.PCA
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function. Hierarchical clustering of gene expression samples on combatted dataset was
performed using ward agglomerative hierarchical method.
Differentially expressed genes were identified by comparing the uncombatted data from each
individual experiment. Bioconductor package limma - a “moderated t test” application was
used, and unpaired or paired analysis was performed to identify differentially expressed
genes.20 The threshold for identifying significant genes was set at a p value of < 0.05 and fold-
change (greater than 2) thresholds. All analysis was performed using R (cran.r-project.org) and
Bioconductor (www.bioconductor.org).
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2.2.10 Pathway analysis
Gene Set enrichment analysis (GSEA) on the data sets was performed to identify differentially
regulated pathways (Subramanian et al., 2005). In our analysis, default metric of signal to noise
ratio was used to rank the differentially expressed genes. To identify the differentially
expressed genes pathways in the naïve CD4+ T cells from normal donor cord blood vs
peripheral blood, the datasets from the three experiments were pooled and combatted using
Combat function in R. When GSEA compared the gene expression profiles from the same
experiment, Combat function was not used.
We used Biocarta signalling and KEGG gene set pathways to identify the differentially
expressed canonical pathways, and biological gene sets to identify differentially expressed
biological processes. Cytoscape software was used to perform enrichment mapping of the
pathways upregulated at p value < 0.005 and fdr value < 0.1.
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2.2.11 Proliferation assays
CFSE dye dilution experiments were performed to assess the role of upregulated pathways and
relevant transcription factor in proliferation of naïve CD4+ T cells.
CD3+ T cells were positively selected from the cord blood and peripheral blood mononuclear
cells using human CD3+ microbeads from Milteyni (130-050-101). For measurement of cell
proliferation, cells were incubated at 37oC with 10μM carboxy-fluorescein diacetate 
succinimidyl ester (CFSE; Invitrogen) in X-VIVO 10 for 7 minutes. CFSE-labelled CD3+ T
cells were washed 3 times in X-VIVO 10 containing 10% Human AB serum to remove the
excess CFSE. The cells were then suspended in X-VIVO 10 media and incubated at the
appropriate concentration in 96-well round bottom plates.
To identify the role of TCR signaling in enhanced proliferation of cord blood CD4+ T cells,
CFSE-labelled cord blood and peripheral blood T cells were cocultured with CD3 negative
cells (APC fraction) at the APC:T-cell ratio of 1:1, 2:1 and 4:1 for 7 days (Lisciandro, et al
2012).
The role of up-regulated transcription factor complex – AP-1 was tested by inhibiting AP-1
with a small molecule inhibitor SR 11302 from R and D systems. CFSE-labelled cord blood
CD3+ T cells were cocultured with CD3 negative cells (APC fraction) at APC:T-cell ratio of
4:1 and inhibition of proliferation with 1, 10 and 100 ng/ml of AP-1 inhibitor was assessed
after 7 days.
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2.2.12 Generation of lymphoblastoid cell lines
5x106 freshly isolated PBMC from healthy donors were centrifuged and resuspended in 200 µl
of EBV supernatant produced from the B95-8 cell line. 1.8 ml complete RPMI containing 1
µg/ml Cyclosporin A (CsA) to inhibit EBV-specific T cell responses and hence facilitate LCL
growth was added and 200 µl cells aliquoted into five wells of a flat-bottom 96 well tissue
culture plate (96wp) (5x105/well). 1ml complete RPMI with CsA was added to the remaining
1ml cells and 200 µl aliquotted to 10 further wells (2.5x105/well). The outer wells were filled
with sterile distilled water and the cells were incubated at 37oC in 5% CO2. The cells were
incubated for one week, at which time half media changes were performed as necessary,
determined by media colour, until cells were beginning to expand, and clumps appeared.
Subsequently, one well seeded with 5x105 cells was combined with two seeded with 2.5x105
cells in a 24 well plate and cells expanded for a further week, whereupon the LCL line was
transferred to a vented 25 cm2 tissue culture flask. Once LCL line was established it was
transferred to 75 cm2 and 150 cm2 tissue culture flask and finally frozen in aliquots of 5x106
cells/ml.
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2.2.13 Firefly Luciferase (F-Luc) transduction of EBV-driven B-cell
lymphoma cell lines (B-LCLs)
A total of 5 × 106 freshly isolated mononuclear cells from healthy cord blood or peripheral
blood donors were cultured with an EBV supernatant produced from the B95-8 cell line in the
presence of 1 µg/mL cyclosporin A to inhibit EBV-specific T-cell responses as described above
(Comoli et al., 2002). B-LCL were transduced with an SFG retroviral vector encoding green
shifted FLuc and cultured in RPMI medium with 10% fetal calf serum + 1%
penicillin/streptomycin (RF10). One week after transduction, LCLs were FACS sorted based
on expression of the eBFP reporter gene, to select for transduced cells. The sorted LCLs were
then grown and these cells maintained high FLuc expression in cultures. The LCLs were
checked for FLuc expression prior to every in vivo experiment and cultures with > 90% of
LCLs expressing FLuc were used for all the experiments. FLuc allows for non-invasive
monitoring of xenografted tumors in mice by luminescent imaging in vivo.
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2.2.14 T-cell selection
Mononuclear cells were separated from CB and PB using Ficoll-Paque PLUS. Negatively
selected CD3+ T cells were isolated using Milteyni Pan T-cell Isolation Kit, human (130-096-
535) and counted using a Sysmex XE-5000 automated hematology system. The purity of
negatively selected T cells was > 94%.
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2.2.15 Xenograft model and tumour imaging
NOD/SCID/IL2rgnull mice were obtained from a breeding colony maintained in our institute and
housed in individually ventilated cages. Autoclaved food, water and bedding were utilised for
these animals and mice were handled under aseptic conditions at all times. Ethical approval
for murine work was obtained as per project licence number PPL 70/7294.
All animal studies were approved by the University College London Biological Services
Ethical Review Committee and licensed under the Animals (Scientific Procedures) Act 1986
(Home Office, London, United Kingdom). The primary murine modeling experiments were
performed to study the differential GvL effect between cord blood and peripheral blood T cells.
2.2.15.1 Subcutaneous injection of LCL
5 million LCLs transduced with the FLuc_eBFP firefly luciferase retroviral vector per animal
were washed three times with PBS and resuspended in 50 µl cold plain RPMI. This was
mixed with 50 µl cold Matrigel and loaded into a 0.5ml 27-gauge (G) tuberculin syringe.
Animals were restrained by scruffing and cells were injected subcutaneously on the nape of
the neck on day –2.
2.2.15.2 T-cell injections
To evaluate the anti-tumor activity, 5 × 106 comparably HLA-mismatched CB or PB CD3+ T
cells were injected i.v. (by tail vein injection) after 2 days on day +0. HLA typing was
performed for A, B, C, DRB1 and DQB1 antigens.
In the first experiment, 10 of 10 and in the second experiment, 7 of 10 HLA antigens were
mismatched between CB T cells vs LCLs and PB T cells vs LCLs.
5 million T cells from cord blood and peripheral blood donors were resuspended in 100 µl
plain RPMI and transferred to a 0.5ml syringe. Animals were warmed at 37oC for 10
minutes and T cells were injected into the tail vein using a 27G needle. Pressure was applied
to the injection site following administration to reduce bleeding.
2.2.15.3 Monitoring of LCL tumours
The size of LCL tumours was assessed with callipers bi-weekly, in addition to monitoring with
bioluminescent imaging using the IVIS imaging system (Xenogen; Caliper Life Sciences,
Hopkinton, MA). For imaging, anaesthesia was induced by inhalation of isofluorane with
oxygen. 2mg D-Luciferin was injected intraperitoneally in 200 µl volume and animals were
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placed in the imaging chamber. Anaesthesia was maintained by delivery of isofluorane and
oxygen to individual animals within the imaging chamber. A region of interest (ROI) was
delineated around the tumour site and images were captured at two-minute intervals until
the signal from each ROI plateaued. Animals recovered individually in warmed chambers.
Animals were imaged on day +10, +20, +25, +30, and +35. Photon emission from FLuc+ LCLs
expressed in photon per second per cm2 per steradian (p/s/cm2/sr) within each ROI was
quantified using Living Image software (Xenogen) as previously described (Savoldo et al.,
2007). In addition to monitoring the tumour bioluminescence, two-dimensional caliper
measurements of the tumor were performed and tumor volume was derived using the following
formula: Tumour volume = 1/2 × (length × width2). Mice were sacrificed if the tumor growth
exceeded the permitted threshold of 10 mm.
Secondary murine modeling experiments were performed to compare the mechanisms of the
GvL effect between CB and PB T cells. In these experiments, I examined the differences in
xeno-reactive potential of CB and PB T cells and examined the correlation between xeno-
reactivity and GvL effect. I also tested if the observed GvL effect was an allo-reactive or an
anti-viral effect. Finally, I studied the tumour-infiltrating lymphocytes, their phenotype, stages
of differentiation and effector function.
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2.2.16 Tumor-infiltrating lymphocytes (TILs)
2.2.16.1 Isolation of TILs
Tumors were minced and incubated in RF10 medium with 0.1 mg/mL collagenase A (Roche)
and 60 U/mL DNase I (Sigma-Aldrich) for 30 min at 37°C. Tumors were then homogenized,
filtered through a nylon filter (70 µm), and the lymphocytes were isolated in RF-10. TILs were
studied for 1) IFN-γ, TNF-α, IL-4 responses, 2) perforin expression, 3) naïve-memory-effector 
differentiation and FoxP3 staining as detailed below (Law et al., 2009).
2.2.16.2 IFN-γ, TNF-α, IL-4 responses 
TILs were separated from lymphoma cells using CD20 microbeads (Milteyni Biotec). Isolated
TILs were then re-stimulated at 37°C for 6 h with lymphoma cells from the same donor at the
effector:target ratio of (1:10) in the presence of 10 µL of Brefeldin A (1 mg/mL) in 1 mL of
RF-10. TILs were then surface stained with mouse anti-human antibodies, including APC-Cy7-
conjugated CD3, BV605-conjugated CD4, and BV421-conjugated CD8. Following fixation
and intracellular permeabilization with the eBioscience buffer set (00-5523), TILs were stained
for PE-conjugated INF-γ, FITC-conjugated TNF-α, and APC-conjugated IL-4.  
2.2.16.3 Perforin expression
Unstimulated TILs were surface stained with mouse-antihuman antibodies, including APC-
Cy7-conjugated CD3, BV605-conjugated CD4, and BV421-conjugated CD8 for 20 mins. For
intracellular perforin staining, TILs were fixed with 1% PFA in PBS for 20 min at room
temperature and incubated 10 min with BD perm/wash buffer 1X (BD Biosciences). Cells were
washed twice with BD perm/wash buffer 1X and then stained with PE-conjugated mouse anti-
human perforin mAb (δG9, IgG2b; BD Biosciences) in BD perm/wash buffer 1X for 30 min at 
room temperature. Unbound antibodies were removed by washing with perm/wash buffer 1X
and fixed again with 1% PFA.
2.2.16.4 Naïve-memory-effector differentiation
Unstimulated TILs were surface-stained with mouse anti-human antibodies, including APC-
Cy7-conjugated CD3, BV605-conjugated CD4, BV421-conjugated CD8, PerCP-Cy5.5-
conjugated CD45RO, and APC-conjugated CCR7.
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2.2.16.5 FoxP3 staining
Unstimulated TILs were surface stained for mouse anti-human antibodies, including FITC-
conjugated CD4, PE-conjugated CD8, and BV421-conjugated CD25. Following fixation and
intra-cellular permeabilization with the eBioscience FoxP3 buffer set (00-5523), TILs were
stained for APC-conjugated FoxP3. T-regulatory cells were identified as CD4+CD25+FoxP3+
cells using a gating strategy based on CD4+ CD25- “non-T-regs” (Law et al., 2009).
2.2.16.6 Th1/Th2 TILs
CD4+ TILs were identified as IFN-γ or TNF-α secreting Th1 cells and IL-4 secreting Th2 cells.
Th1/Th2 balance of CD4+ TILs was quantified using IFN-γ/IL-4 and TNF-α/IL-4 ratios. 
2.2.16.7 Histology
Immunohistochemical mouse anti-human CD3 staining of tumor sections was performed to
study the extent of T-cell infiltration. Using Image J, 10 RGB images of 40× magnification for
each tumor slide were converted to black and white mask output using a calibrated threshold
for each stack of images and average density of T cells per mm2 of tumor was calculated as
shown in Figure 70 (Loughlin et al., 2007).
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2.2.17 Statistics
Statistical analysis was done using GraphPad Prism software. Tumour volumes either
photons/sec/cm2/sr or mm3 are expressed as mean and standard deviation. Two-tailed t-test was
performed for comparisons of experimental groups. A log-rank (Mantel-Cox) test was used to
compare survival between different groups of mice.
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2.2.18 Ethics
Ethics approval for studying cellular immune-reconstitution following haematopoietic stem
cell transplantation was obtained from Central London REC (REC reference 05/Q0508/61).
Ethical approval for comparing the paired gene expression profile of naïve CD4+ T cells from
the cord blood and peripheral blood of the same donor was obtained from NRE Committee
London – Dulwich (REC reference 11/LO/15089). This ethical approval allowed us to contact
families known to Great Ormond Street Hospital who had family-directed cord blood donation
in the past but was now no more required for clinical purpose, and hence could be used for
research. These families were contacted so that we could collect 20 mls of peripheral blood
from the cord blood donor. This allowed paired comparison of naïve CD4+ T cells isolated
from the peripheral blood and cord blood of same donors.
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Chapter three
Rapid CD4+ T-cell biased immune-
reconstitution following CBT may be driven by
increased sensitivity of cord blood T cells to
homeostatic signals
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3.0 Aims
1) To study the kinetics of early immune-reconstitution after T-cell replete cord blood and bone
marrow transplantation
2) To perform flow-cytometric phenotyping of CD4+ T cells after T-cell replete cord blood and
bone marrow transplantation
- Th1, Th2, Th17 analysis after PMA/Ionomycin stimulation using IFN-γ, IL-4, IL-17 
staining
- T-regulatory cell analysis using 4-color (CD4+CD25+CD127-Foxp3+) staining
3) To perform naïve, memory and effector subset analysis of reconstituting CD4+ T cells after
T-cell replete cord blood and bone marrow transplantation
4) Measuring IL-7 levels after cord blood and bone marrow transplantation
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3.1 Introduction
CD4+ T-cell reconstitution after HCT is predominantly thought to be mediated by the thymic-
dependent pathway (Mackall et al., 1997; Williams et al., 2007). Therefore, CD4+ T-cell
reconstitution occurs late, typically after 3 to 6 months following transplantation (Mackall et
al., 1997; Williams et al., 2007). In contrast, CD8+ T-cell reconstitution occurs early and is
thought to be mediated by expansion of cognate memory and effector T cells. The spontaneous
expansion of T cells infused with the graft is termed as “homeostatic proliferation (HP)”
(Mackall et al., 1996; Mackall et al., 1997; Ge et al., 2002). The relative contribution of thymic-
independent and thymic-dependent pathway to replenish the peripheral T-cell pool after HCT
depends on the use of serotherapy in the conditioning regimens. In particular, in vivo T-cell
depleting regimens have a significant effect on thymic-independent homeostatic proliferation
(Komanduri et al., 2007; Lindemans et al., 2014; Renard et al., 2011).
Omission of in vivo T-cell depletion from the conditioning regimens allows early T-cell
immune-reconstitution which is thymic-independent (Chiesa et al., 2012; Lindemans et al.,
2014). This form of conditioning regimen is particularly employed for conditioning of HLA-
matched sibling transplants in the context of chemotherapy-resistant leukaemia. Recently, such
an approach has also been used for conditioning of unrelated cord blood grafts because of low
risk of graft-versus-host disease (Chiesa et al., 2012; Sauter et al., 2011).
We published results of rapid CD4+ T-cell biased immune-reconstitution following cord blood
transplantation in 30 patients (Chiesa et al., 2012). Intrigued by this novel CD4+ T-cell biased
reconstitution following cord blood transplantation, we decided to explore the mechanisms of
early T-cell reconstitution following T-cell replete cord blood graft. Firstly, we compared the
differences in CD4+ T-cell reconstitution after transplantation from cord blood and bone
marrow. We compared the 1) kinetics of CD4+ T-cell reconstitution, 2) functionality i.e.
cytokine-secreting ability of CD4+ T cells, 3) suppressive function i.e. recovery of T-regulatory
cells and 4) phenotype of T cells i.e. naïve, memory, effector T cells. We also measured decline
in IL-7 levels following cord blood and bone marrow transplantation.
In this chapter, we have studied the differences in kinetics of early T-cell reconstitution (< 6
months) after T-cell replete cord blood and bone marrow transplantation. In addition, we also
performed phenotypic analysis of peripherally expanding T cells at early time-points after T-
cell replete grafts.
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3.2 Patient and graft characteristics of T-cell replete cord blood and bone marrow
transplants
To underline the important differences in early thymic-independent T-cell reconstitution after
T-cell replete cord blood and bone marrow grafts, we performed analysis on 70 consecutive T-
cell replete transplantations. 30 children received cord blood and 40 children received bone
marrow grafts. These demographics and relevant transplant characteristics of the two groups
are presented in Table 2.
CBT (n = 30; 26 single and 4 double cord) BMT (n = 40)
Age at
transplant
1 year (0.1 – 12) 4.3 years (0.6 – 12)
Diagnosis Acute leukaemia 12 (40%)
Myelodysplastic syndrome/Chronic
myeloid leukaemia 2 (6%)
Immunodeficiency 12 (40%)
Haemophagocytic lymphohistiocytosis 4
(14%)
Acute leukaemia 17 (42%)
Myelodysplastic syndrome/Chronic
myeloid leukaemia 3 (8%)
Immunodeficiency 13 (32%)
Haemophoagocytic lymphohistiocytosis 5
(13%)
Metabolic 2 (5%)
Conditioning Myeloablative conditioning 29 (97%)
(TBI or Bu-based or Treosulfan-based)
No conditioning 01 (3%)
Myeloablative conditioning 40 (100%)
(TBI or Bu-based or Treosulfan-based)
HLA
matching
≤8/10 = 17 
9/10 = 14
10/10 = 03
10/10 = 40
(all matched sibling donors)
Acute
GVHD
Grade II = 10 (33%)
Grade III-IV = 5 (16%)
Grade II = 07 (18%)
Grade III-IV = 03 (8%)
Viral
reactivations
CMV = 04 (13%)
ADV = 04 (13%)
CMV = 07 (17%)
ADV = 04 (10%)
Table 2 Demographics and transplant characteristics of patients receiving cord blood and bone
marrow graft
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3.3 Number of T cells infused with cord blood and bone marrow grafts
To understand if in our paediatric cohort (age range: 0 to 13 years), quantity of T cells infused
with the haematopoietic stem cell grafts from different sources influenced the T-cell
reconstitution, we compared the number of T cells infused with cord blood and bone marrow
grafts.
In our cohort, cord blood transplant recipients received a median T-cell dose of 4.75 x10^6 per
kilogram (inter-quartile range: 2.5 to 6.7). This T-cell dose was significantly less (approx. 10
times) than the T cells received by bone marrow transplant recipients (median = 45 x 10^6 per
kilogram; inter-quartile range: 27 to 67) [P < 0.0001, Figure 12]. These T-cell numbers are
similar to that described in the literature and in general, cord blood graft contains one log less
CD34+ and CD3+ cells per kilogram recipient body weight than bone marrow grafts
(Gluckman, 2012).
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Figure 12: Bar plot of T cells carried with a cord blood and a bone marrow graft. A median of
4 x 106/kg T cells are infused with a cord blood graft compared with 10 times more T cells (45
x 106/kg) infused with a bone marrow graft (unpaired t-test; p<0.0001). The bar graph
represents median and error bars represent interquartile range.
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3.4 T-cell immune-reconstitution after T-cell replete CBT and BMT
3.4.1 T-cell reconstitution - 2 months after CBT and BMT
Despite a lower number of T cells infused with the cord blood graft, we observed a higher
CD3+ T-cell recovery after cord blood transplantation. In particular, two months following cord
blood transplantation, we observed unprecedented expansion of the peripheral T-cell pool with
a median T-cell count of 840 x 106 per kilogram (interquartile range: 575 to 1115). In
comparison to the cord blood transplantation, two months following bone marrow
transplantation, CD3+ T-cell recovery was significantly lower with a median T-cell count of
500 x 106 per kilogram (P < 0.05; interquartile range: 280 to 980, Figure 13). The kinetics of
recovery of CD3+ T cells at 1, 2 and 6 months is shown in Figure 14.
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Figure 13: Absolute CD3+ T-cell count two months after cord blood and bone marrow
transplant. T-cell reconstitution after CBT was significantly higher than after BMT (unpaired
t-test; p<0.05). The bar graph represents median and error bars represent interquartile range.
p<0.05
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Figure 14: Line graph of T-cell reconstitution after T-replete CBT and BMT. Despite 10 times
lower number of T cells infused with the cord blood graft, a significantly higher CD3+ T-cell
recovery is observed 2 months post-CBT compared with after BMT. The dots represent the
median, and the error bars represent the 25th and 75th centile.
3.4.2 Comparing the kinetics of early CD4+ and CD8+ T-cell reconstitution after cord
blood and bone marrow transplantation
We further studied the differences in CD4+ or CD8+ T-cell compartment after cord blood and
bone marrow transplantation. Interestingly, this early expansion after bone marrow
transplantation was CD8+ T-cell biased which is in sharp contrast to the observed CD4+ T-cell
biased immune-reconstitution after cord blood transplantation. In particular, T-cell
reconstitution after cord blood transplantation was strikingly CD4+ T-cell biased after one
month with an asymmetric CD4:CD8 ratio of 4.5. Further the T-cell reconstitution after cord
blood transplantation continued to be numerically superior at 1, 2 and 6 months compared to
bone marrow transplantation, albeit with a CD4+ T-cell bias [Table 3 and 4; Figure 15 (a) and
(b)].
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Post-transplant BMT CBT
1 month 180 (125 – 365) 310 (100 – 580) P = NS
2 months 180 (105 – 305) 560 (340 – 800) P < 0.0001
6 months 330 (245 – 455) 690 (445 – 1062) P < 0.001
Table 3 shows statistically significant difference in CD4+ T-cell expansion at and after two
months CBT versus BMT.
Post-transplant BMT CBT
1 month 200 (105 – 685) 70 (40 – 110) P < 0.001
2 months 330 (150 – 710) 150 (100 – 340) P < 0.01
6 months 380 (255 – 795) 250 (100 – 530) P = NS
Table 4 shows statistically significant difference in CD8+ T-cell expansion at one and two
months after CBT versus BMT. There is no difference in CD8+ T cells at 6 months.
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Figure 15 (a) and (b): Line graph showing CD4+ and CD8+ T-cell recovery after BMT and CBT
respectively. The T-cell recovery observed after T-replete CBT was asymmetrically CD4+ T-
cell biased in contrast to the CD8+ T-cell biased immune-reconstitution after T-replete BMT.
The dots represent the median and the error bar represent interquartile range. The black line
represents CD4:CD8 ratio plotted on right Y axis. The dots represent the median, and the error
bars represent the 25th and 75th centile.
(a)
(b)
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3.5 Comparing the functionality of reconstituting CD4+ T cells after cord blood and bone
marrow transplantation i.e. Th1, Th2, Th17 and T-regulatory cells
Since the adaptive immune system in cord blood is predominantly biased towards adopting a
T–regulatory fate (Takahata et al., 2004; Michaëlsson et al., 2006; Silverstein et al., 1964a;
Silverstein et al., 1964b), we compared Th subsets at day 30, 90 and 180 following cord blood
(n = 10) and bone marrow (n = 10) transplantation to gain more insight into the function of
these rapidly expanding CD4+ T cells after cord blood and bone marrow transplantation.
Th1, Th2 and Th17 subsets were identified by intracellular cytokine staining following
PMA/Ionomycin stimulation for 5 hours (Baran et al., 2001). T-regulatory cells were identified
using 4 colour CD4+CD25+CD127-FoxP3+ staining.
Th1, Th2, Th17 and T-regulatory staining – one month after cord blood and bone marrow
transplantation is shown in Figure 16, 17 and 18.
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Figure 16: Representative flow cytometry dot plots of CD4+CD25+CD127+Foxp3+ T-
regulatory cells, 30days after T-replete CBT and BMT. T-regulatory cells were identified as
CD4+CD25+CD127-Foxp3+. Top two panels are cord blood (CB) and bottom two panels are
peripheral blood (PB). Isotype control and Foxp3 antibody was added at the final step. CD4+
T cells are shown as percentage of lymphocytes. CD25+CD127- cells and CD127-Foxp3+ cells
are shown as percentage of CD4+ T cells.
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Cord Blood
CB
Figure 17: Representative flow cytometry dot plots of IFN-γ secreting Th1 cells, IL-4 secreting 
Th2 cells and IL-17 secreting Th17 cells are shown on T cells isolated from T-replete CBT
recipients after 30 days of transplant. Unstimulated control and PMA-Ionomycin stimulated T
cells are shown in the top and bottom panel respectively.
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Peripheral Blood
Figure 18: Representative flow cytometry dot plots of IFN-γ secreting Th1 cells, IL-4 secreting 
Th2 cells and IL-17 secreting Th17 cells are shown on T cells isolated from T-replete BMT
recipients after 30 days of transplant. Unstimulated control and PMA-Ionomycin stimulated T
cells are shown in the top and bottom panel respectively.
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Figure 19: Median and range of T-regulatory, Th1, Th2 and Th17 cells, one month after CBT
(n=10) and BMT (n=10). T-regulatory cells were significantly higher after CBT, in contrast to
Th1 cells after BMT.
At 1-month post-transplant, we observed a higher percentage of circulating CD4+ T cells with
a T-regulatory phenotype after cord blood transplantation (median = 9.8%, inter-quartile range
= 7.4 – 16.5) compared to bone marrow transplantation (median = 6.6%, range = 3.9 – 8.4). In
contrast, a lower percentage of Th1 (IFN-γ secreting CD4+ T cells) were observed after cord
blood transplantation (median = 4.7%, inter-quartile range = 0.3 – 5.3) compared to bone
marrow transplantation (median = 5.2%, inter-quartile range = 3.6 – 31.6) [Figure 16, 17, 18
and 19]. These two observations were statistically significant (P < 0.02). No significant
differences were observed in circulating Th2 and Th17 cells in the 2 groups [Figure 17, 18 and
19].
Increased percentage of circulating T-regulatory cells observed at 1 month after cord blood
grafts reduced significantly at day 180 to a median of 5.4 (interquartile range = 8.9 to 2.1)
without increase in Th1 cells. In contrast to this finding, Th1 cells continued to increase
following bone marrow transplantation [Figure 20 and 21]. These results confirm the findings
of other co-workers suggesting the inability of cord blood CD4+ T cells to secrete pro-
inflammatory cytokines like IFN-γ (Krampera et al., 2000; Wiegering et al., 2009).
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Figure 20: Line graph showing percentage of T-regulatory cells after transplant (median and
inter-quartile range shown). A higher percentage of T-regulatory cells after CBT (n=10)
compared to BMT (n=10) was observed (p < 0.02). The higher percentage of T-regulatory
cells after CBT decreases and reaches levels similar to BMT after 6 months.
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Figure 21: Line graph showing percentage of Th1 cells after transplant (median and inter-
quartile range shown). A lower percentage of Th1 cells after CBT (n=10) compared to BMT
(n=10) was observed (P < 0.02). The percentage of Th1 cells after CBT remained lower at 6
months post-transplant.
This finding indicates that although increased percentage of CD4+ T cells adopt a T-regulatory
fate early after cord blood transplantation, the majority of circulating CD4+ T cells remain non-
regulatory. These non-regulatory T cells however do not seem to adopt a functional phenotype
such as Th1, Th2 or Th17 on PMA/Ionomycin stimulation.
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3.6 Differentiation of reconstituting CD4+ T cells after CBT and BMT
We therefore investigated how rapidly reconstituting naïve cord blood T cells switched their
phenotype to memory or effector T cells.
To investigate this CD4+, CD45RA+ and CD27+ markers were used and naïve, memory and
effector CD4+ T cells at 1, 2 and 3 after cord blood transplantation (n=10) were identified.
Figure 22 shows percentage of naïve CD4+ T cells decreased rapidly from first month with a
rapid shift towards memory phenotype. In contrast, the percentage of memory CD4+ T cells
decreased rapidly after first month with a shift towards effector phenotype in patients
undergoing bone marrow transplantation (n=10).
Figure 22: Rapid switch of phenotype from naïve to memory/effector was observed after CBT
(n=10). In contrast, switch of phenotype from memory to effector was observed after BMT
(n=10). Median percentage of naïve, memory and effector T cells are shown.
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3.7 IL-7 levels after cord blood and bone marrow transplantation
Rapid switching of naïve CD4+ T cells to memory phenotype indicated that this switching in
phenotype may be driven by homeostatic mechanisms (Cho et al., 2000). IL-7 is the key
homeostatic cytokine and, inverse correlation between CD4+ T cell reconstitution and IL-7 is
well-established (Politikos et al., 2015). We therefore investigated whether IL-7 levels declined
rapidly after CBT.
We measured plasma IL-7 level at day+30, day+60 and day+90 following CBT (CBT = 6,
BMT = 6). Median plasma level on day+30 after CBT was 14.45 pg/ml (interquartile range =
12 – 16). Plasma IL-7 level decreased significantly to median of 5.1 (interquartile range = 3.3
– 6.9) on day+90 (P < 0.0001). In contrast, there was no statistically significant difference
between day+30, day+60 and day+90 plasma IL-7 levels after BMT. Median IL-7 levels were
5.5 vs 4.1 vs 6.5 respectively [Figure 23].
Figure 23: High IL-7 levels at day+30 after CBT (n=6) declined rapidly at day+90 (P <
0.0001). There was no difference in IL-7 levels at day+30, day+60 and day+90 after BMT
(n=6).
The high day+30 IL-7 levels possibly reflect the profound lymphopenic environment due to low
number of T cells carried with the cord blood graft as previously described (Politikos et al., 2015), and
suggests that the cord blood T cells are likely to be exposed to high levels of IL-7 in vivo for a longer
period of time.
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The rapid decline in IL-7 in first 3 months after CBT indicates the role of IL-7 in mediating
CD4+ T-cell biased proliferation after CBT.
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3.8 CONCLUSION
Early T-cell reconstitution after cord blood transplantation is rapid compared to that of bone
marrow transplantation.
T-cell reconstitution after cord blood transplantation is almost always CD4+ T-cell biased
compared to CD8+ T-cell biased reconstitution after bone marrow transplantation.
Although early CD4+ T-cell reconstitution after cord blood transplantation is biased towards
T-regulatory cells, the majority of circulating T cells were non-regulatory.
In contrast, early CD4+ T-cell reconstitution after bone marrow transplantation is biased
towards Th1 cells.
Naïve cord blood T cells rapidly differentiate to memory T cells after cord blood
transplantation and this rapid switching to memory phenotype with decline in IL-7 points
towards a process of lymphopenia-induced proliferation.
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Chapter four
Cord blood T cells are highly sensitive to
homeostatic signals (such as TCR and IL-7) in
comparison to adult blood T cells
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4.0 Aims
1) To study the proliferation of cord blood and adult blood T cells after IL-7, IL-2 and IL15
stimulation using CFSE dye dilution assay
2) To study the differences in IL-7 receptor expression in cord blood and adult blood T cells
3) To study the differences in STAT5 phosphorylation after IL-7 and IL-2 stimulation
4) To study the proliferation of cord blood and adult blood T cells after TCR stimulation using
CFSE dye dilution assay
5) To study the proliferation of naïve cord blood and adult blood T cells after TCR stimulation
using CFSE dye dilution assay
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4.1 Introduction
T-cell homeostasis i.e. survival, proliferation and expansion is mediated by co-operation
between homeostatic TCR and IL-7 signals (Surh et al., 2000; Jameson et al., 2005; Deshpande
et al., 2013; Hennion-Tscheltzoff et al., 2013; Kimura et al., 2013). It is well known that T
cells do not survive in the absence of either self MHC:TCR interactions or IL-7. CD4+ and
CD8+ T cells do not survive in the absence of MHC Class II and MHC Class I deficiency
respectively. This observation has been well-established in several MHC-deficient models as
well as in patients with MHC Class II or Class I deficiency (Brocker et al., 1997; Markiewicz
et al., 2003). Similarly, a defect in the IL-7 receptor leads to a T-B+NK+ severe combined
immunodeficiency (Puel et al., 1998).
Naïve T cells, in particular require both MHC interactions and IL-7 for survival. How these
two signals co-operate and maintain T-cell homeostasis during lympho-replete and lympho-
depleted conditions is still being understood. Lymphocyte homeostasis in lympho-replete and
lympho-deplete conditions are distinct (Surh et al., 2000). In lympho-replete conditions low-
affinity TCR:MHC interactions in the periphery provide tonic “survival signals” to naïve T
cells without inducing cell division (Surh et al., 2000). However, in lymphopenic environment
same homeostatic signals induce T-cell proliferation which is commonly known as
lymphopenia-induced homeostatic proliferation (Tchao et al., 2012). In particular, the strength
of TCR affinity determines the relative fitness of naïve T cells to compete for factors that
support cell survival and homeostatic proliferation (Kieper et al 2004; Min et al., 2005).
Recently it has been shown that T-cell receptor triggering modulates the response to IL-7
(Hennion-Tscheltzoff et al., 2013). Increasing T-cell receptor stimulation augments the
response to IL-7 and reducing T-cell receptor stimulation decreases the response to IL-7.
Another interesting study showed that intermittent IL-7 signalling is essential for survival of T
cells (Kimura et al., 2013). In the absence of homeostatic T-cell receptor signalling, naïve T
cells receive persistent IL-7 signalling, which instead of promoting survival induce cytokine-
induced (IFN-γ) cell death. These reports clearly indicate that T-cell receptor signalling and 
IL-7 signalling pathways co-operate in maintaining T-cell homeostasis.
T-cell homeostasis in cord blood and adult blood may be regulated distinctly. This is because
Cord blood T cells are in a highly proliferative state driven by the relatively lymphopenic
environment of the foetus in combination with maximal thymopoiesis (Schonland et al., 2003;
Min et al., 2003). In contrast, adult blood T cells are in a state of equilibrium in the lympho-
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replete environment and reduced thymopoiesis. We therefore speculated that cord blood T cells
may be highly responsive to homeostatic signals compared to adult blood T cells.
In this chapter, we explored if there are differences in these homeostatic mechanisms between
cord blood and adult blood T cells. We compared whether cord blood and adult blood T cells
responded differently to γ-chain cytokines. In particular, we compared the proliferative 
potential of T cells to homeostatic cytokines such as IL-7 and IL15, and a conventional cytokine
such as IL-2. We also studied differences in IL-7 receptor expression in the cord blood and
adult blood T cells and the effect of IL-2 and IL-7 on down-stream signalling such as STAT-5
phosphorylation. Finally, we studied if cord blood T cells and adult blood T cells responded
distinctly to T-cell receptor stimulation.
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4.2 Comparing the proliferation of cord blood and adult blood T cells to γ-chain cytokines 
i.e. IL-7, IL-15 and IL-2 using CFSE dye dilution assay
Cord blood mononuclear cells (n = 5) and adult blood mononuclear cells (n = 5) were labeled
with CFSE and stimulated with IL-7 (10 ng/ml), IL-15 (12 ng/ml) and IL-2 (20 U/ml) for 9
days in serum-free media.
Following stimulation with IL-7 (10 ng/ml), we observed that cord blood T cells proliferated
rapidly. In comparison to the proliferative index of 1.1 in the adult blood T cells, cord blood T
cells had a significantly higher proliferative index of 3. This indicates that in the presence of
IL-7, cord blood T cells undergo robust proliferation whereas adult blood T cells undergo
minimal proliferation [Figure 24, 25, 26 and 27].
On stimulation with IL-15 (12 ng/ml), cord blood CD8+ T cells proliferated more rapidly with
a proliferative index of 1.9, compared to cord blood CD4+ T cells which proliferated at an index
of 1.4. Adult blood T cells were not responsive to IL-15 [Figure 24, 25, 26 and 27].
Cord blood and adult blood T cells were not responsive to IL-2 at the concentration of 20 U/ml
[Figure 24, 25, 26 and 27].
Thus, our observations confirmed that cord blood T cells are hyper-responsive to IL-7, in
comparison to adult blood T cells.
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Figure 24: Representative histogram plots of cord blood CD4+ T cells proliferating rapidly in
the presence of 10 ng/ml of IL-7. There was some proliferation in the presence of 12 ng/ml of
IL-15 and no proliferation in the presence of 20 U/ml of IL-2. Solid line histogram represent
cells cultured without cytokine and dashed line histogram represent cells cultured in cytokine.
An example of cord blood CD4+ T-cell proliferation in response to IL7 is used below to
demonstrate calculation of proliferative index.
Generation Total number of
cells
Total number of parent
cells
1 45 45/1=45
2 147 147/2=73.5
3 2104 2104/3=701.3
4 3116 3116/4=779
5 480 480/5=96
Total 5892 1694.8
Proliferative index = 5892/1694.8 =3.47
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Figure 25: Cord blood CD4+ T cells proliferate rapidly with proliferative index of 3 and 1.4
following stimulation with IL-7 (10 ng/ml) and IL-15 (12 ng/ml) respectively. Cord blood
CD4+ T cells do not proliferate in the presence of IL-2 (20 U/ml). In contrast, peripheral blood
CD4+ T cells do not proliferate in the presence of IL-7, IL-15 or IL-2 (n = 5 vs 5).
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Figure 26: Representative histogram plots of cord blood CD8+ T cells proliferating rapidly in
the presence of 10 ng/ml of IL-7. There was some proliferation in the presence of 12 ng/ml of
IL-15 and no proliferation in the presence of 20 U/ml of IL-2. Solid line histogram represent
cells cultured without cytokine and dashed line histogram represent cells cultured in cytokine.
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Figure 27: Cord blood CD8+ T cells proliferate rapidly with a median proliferative index of 3
and 1.9 following stimulation with IL-7 (10 ng/ml) and IL-15 (12 ng/ml) respectively. Cord
blood CD8+ T cells do not proliferate in the presence of IL-2 (20 U/ml). In contrast, peripheral
blood CD8+ T cells do not proliferate in the presence of IL-7, IL-15 or IL-2 (n = 5 vs 5).
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4.3 Comparing the IL7R expression in the cord blood and adult blood T cells
Since cord blood T cells are hyper-responsive to IL-7, we compared the IL7R expression of
cord blood and adult blood T cells. More than 90% (range = 90 to 97%) of cord blood T cells
were positive for IL7R (CD127) whereas, a median of 80% (range = 78 to 84%) and 68%
(range = 58 to 78%) of adult CD4+ and CD8+ T cells expressed IL7R (CD127) respectively
[Figure 28 and 29]. Similarly, level of IL7R expression, as assessed by median fluorescence
intensity was higher in cord blood T cells compared to adult blood T cells [Figure 30]. This
finding suggested that upregulated IL7R expression in the cord blood T cells may mediate
hyper-responsiveness of cord blood T cells to IL-7.
Figure 28: Representative histogram of IL-7R (CD127) expression in cord blood and peripheral
blood CD4+ and CD8+ T cells. CD127+ gates were defined using isotype control for each
patient.
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Figure 29: Percentage of IL7R (CD127) positive were higher in cord blood T cells than adult
blood T cells (n = 5 vs 5; unpaired t-test; p<0.001).
Figure 30: Median fluorescence intensity of IL7R (CD127) was higher in cord blood T cells
than in adult blood T cells (n = 5 vs 5; unpaired t-test; p<0.001).
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4.4 Comparing the STAT5 phosphorylation in the cord blood and adult blood T cells
IL-7 is known to activate JAK1 and JAK3 as well as STAT5, which translocates to the nucleus,
where it functions as a transcription factor. Since cord blood T cells are hyper-responsive to
IL-7 and have increased IL7R expression, we speculated that downstream signalling molecules
i.e. STAT5 may undergo increased phosphorylation on stimulation with IL-7. We therefore
measured STAT5 phosphorylation in cord blood CD4+ and peripheral blood CD4+ T cells after
stimulating CBMCs and PBMCs with varying concentrations of IL-7 (10 ng/ml,1 ng/ml, 0.1
ng/ml, 0.01 ng/ml) and IL-2 (1000 units/ml, 100 units/ml, 20 units/ml). Low level (<10%)
STAT5 phosphorylation in cord blood and peripheral blood CD4+ T cells was observed after
stimulation with IL-2, regardless of the concentration used. In contrast, following IL-7
stimulation with 10/1/0.1/0.01 ng/ml, STAT5 phosphorylation was observed in 90%, 70%,
10% and < 10% in both cord blood and peripheral blood CD4+ T cells [Figure 31 and 32].
Figure 31: Representative histogram of STAT5 phosphorylation in cord blood and peripheral
blood CD4+ T cells to varying degrees of IL-7. Percentage of STAT5 phosphorylated cord
blood and peripheral blood CD4+ T cells are shown. Gates were defined using cord blood and
peripheral blood CD4+ T cells not stimulated with cytokines.
2.12 58.079.07 84.10
2.57 8.28 64.20 85.60
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Figure 32: Line graph of STAT5 phosphorylation in cord blood and peripheral blood CD4+ T
cells to varying degrees of IL-7. Percentage of STAT5 phosphorylated cord blood and
peripheral blood CD4+ T cells are shown. Similar STAT5 phosphorylation was observed in 5
vs 5 samples.
Thus, STAT5 phosphorylation in both cord blood and peripheral blood CD4+ T cells occurs in
response to IL-7 in a dose dependent manner. This suggests similar down-stream signalling in
cord blood and peripheral blood T cells in response to IL-7. It is well-described that although
STAT5 phosphorylation occurs in the presence of 1 ng/ml of IL-7, CD4+ T cells do not
proliferate in response at the concentration of 1 ng/ml of IL-7 (Swainson et al., 2007). Thus,
ligation of IL7Ralpha receptor does not explain the differences in proliferation between cord
blood and peripheral blood T cells.
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4.5 Comparing the T-cell receptor signalling in the cord blood and adult blood T cells
Since an important downstream signalling molecule of IL-7 signalling pathway - STAT5 did
not differentially phosphorylate on stimulation with varying concentrations of IL-7, I
questioned if upregulated T-cell receptor signalling mediated enhanced proliferation of cord
blood T cells.
Cord blood mononuclear cells (n = 5) and peripheral blood mononuclear cells (n = 5) were
labelled with CFSE dye and stimulated with immobilized-CD3 antibody for 7 days in serum
free medium to examine TCR-triggered proliferation. We found that by day 7, a high
proportion of cord blood CD4+ (mean = 83%, range = 75 to 87%) and cord blood CD8+ (mean
= 92%, range = 81% to 99%) T cells go in to cell cycle compared to peripheral blood CD4+
(mean = 19%, range = 9 to 30%) and peripheral blood CD8+ (mean = 42%, range = 34 to 56%)
T cells respectively [Figure 33, 34 and 35].
Figure 33: Representative histogram plots of cord blood CD4+ T-cell vs peripheral blood CD4+
T-cell proliferation in response to allogeneic LCLs (at ratio 10 responders:1 allogeneic
stimulator). Cord blood CD4+ T cells proliferate rapidly compared to peripheral CD4+ T cells.
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Figure 34: Representative histogram plots of cord blood CD8+ T-cell vs peripheral blood CD8+
T-cell proliferation in response to allogeneic LCLs (at ratio 10 responders:1 allogeneic
stimulator). Cord blood CD8+ T cells proliferate rapidly compared to peripheral CD8+ T cells.
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Figure 35: Scatter plot of percentage of proliferating cord blood and peripheral blood T cells
after LCL stimulation (5 vs 5 samples). 80-90% of cord blood T cells (CD4+ and CD8+)
proliferate after allogeneic stimulation compared to 20-40% peripheral blood T cells (CD4+
and CD8+; unpaired t-test; p<0.0001).
Additionally, we also observed that asymmetric CD4/CD8 ratio was maintained in cord blood
T cells after T-cell receptor stimulation whereas a reduction in CD4/CD8 ratio was observed
in peripheral blood T cells (p<0.02) [Figure 36].
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Figure 36: Scatter plot of CD4:CD8 ratio in cord blood and peripheral blood samples (5 vs 5)
stimulated with allogeneic LCLs. A higher CD4:CD8 ratio was maintained after stimulation of
cord blood T cells with allogeneic LCLs. In contrast, a lower CD4:CD8 ratio was observed in
PBMC after stimulation with allogeneic LCLs compared to unstimulated PBMC.
This observation suggested that although cord blood T cells are hyper-responsive to T-cell
receptor signalling, it also raised the obvious question - whether the naivety of cord blood T
cells was responsible for the majority of cells going in to cell cycle following T-cell receptor
stimulation.
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4.6 Comparing the T-cell receptor signalling in the CD45RA+ enriched (naïve) cord blood
and adult blood T cells
We therefore bead sorted CD45RA+ cells to enrich naïve T-cell population from cord blood (n
= 5) and adult peripheral blood (n = 5) [Figure 37]. We found that naïve cord blood T cells
proliferated rapidly compared to peripheral blood naïve T-cell enriched population. These
results were similar to the previous experiment with unsorted cord blood mononuclear and
peripheral blood mononuclear cells.
Figure 37: Scatter plot of percentage of proliferating CD4+ and CD8+ T cells in CD45RA+
enriched cord blood and peripheral blood T cells after LCL stimulation (5 vs 5 samples). 80-
90% of naïve cord blood T cells (CD4+ and CD8+) proliferate after allogeneic stimulation
compared to 20-40% naïve peripheral blood T cells (CD4+ and CD8+).
Thus, cord blood T cells are hyper-responsive to T-cell receptor trigger and this hyper-
responsiveness appears to be independent of the naivety of T cells.
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4.7 CONCLUSION
Cord blood T cells undergo enhanced proliferation to IL-7 (10 ng/ml) compared to adult blood
T cells and this indicates the hyper-responsiveness of cord blood T cells to IL-7.
Although cord blood T cells express higher IL-7 receptor expression compared to adult blood
T cells, no difference in STAT5 phosphorylation was observed after stimulation with varying
concentrations of IL-7. This finding raised question about the role of IL7-STAT5 signalling
pathway in differential reconstitution of T cells after cord blood and bone marrow
transplantation.
We therefore questioned the role of TCR:MHC interactions in rapid proliferation of cord blood
T cells. On TCR stimulation, cord blood T cells were observed to undergo enhanced
proliferation compared to adult blood T cells.
Our observations of 1) hyper-responsiveness of cord blood T cells to IL-7 and 2) hyper-
responsiveness of cord blood T cells to T-cell receptor stimulation indicated that cord blood T-
cell homeostasis may be significantly distinct to T-cell homeostasis in adults. This distinction
between cord blood and adult blood T-cell homeostasis may be because of progression of foetal
to adult ontogeny and hyper-responsiveness of T cells to homeostatic signals may reduce with
the switch over from foetal to adult ontogeny.
Finally, the observation of similar STAT5 phosphorylation to varying concentrations of IL-7
also raised questions about how these homeostatic IL-7 and T-cell receptor signals co-operate
during expansion of T cells in the lymphopenic environment.
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Chapter five
T-cell replete cord blood transplantation
recapitulates foetal ontogeny with a distinct
molecular signature
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5.0 Aims
1) To establish if cord blood naïve CD4+ T cells are transcriptionally distinct to peripheral
blood naïve CD4+ T cells but similar to foetal CD4+ T cells.
2) To establish if recapitulation of foetal T-cell ontogeny occurs after T-cell replete CBT.
3) To identify the genes induced during lymphopenia induced proliferation by comparing the
transcriptional profile of naïve CD4+ T cells from steady-state lymphoreplete environment in
the peripheral blood with reconstituting T cells after BMT.
4) To identify if reconstituting naive CD4+ T cells after T-cell replete CBT are enriched in the
genes induced during lymphopenia induced proliferation.
5) To identify upregulated transcription factors, biological processes and canonical pathways
in the naïve cord blood CD4+ T cells.
6) To test the functional relevance of upregulated pathways in the cord blood T cells.
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5.1 Introduction
There is a growing evidence supporting distinct ontogenic origins of foetal and adult lymphoid
immune systems and so indeed cord blood T cells may have distinct origins compared to
peripheral blood T cells. The observations and experiments in chapter three and four indicate
that cord blood T cells have proliferative advantage over peripheral blood T cells. We observed
unprecedented CD4+ T-cell biased reconstitution after T-cell replete CBT compared with
BMT. In addition, we observed a normal T-cell spectratype as early as 30 days after T-cell
replete CBT. This suggests distinct ability of cord blood T cells to expand rapidly with a diverse
T-cell repertoire in the lymphopenic environment such as post-transplantation and hence
implicate that cord blood T cells are distinct compared to adult T cells. Thus, it is likely that
foetal origins of cord blood T cells may endow cord blood T cells with the processes that may
have a role in lymphopenia-induced proliferation. We also observed that in vitro, cord blood T
cells undergo enhanced proliferation in response to allogeneic TCR signal from
lymphoblastoid cells. Similarly cord blood T cells also show robust proliferation in the
presence of high levels of IL-7 (10 ng/ml). These observations suggest that T-cell homeostasis
at birth may be regulated distinctly driven by the highly proliferative state of cord blood T cells
and relatively lymphopenic environment of the foetus.
The process of lymphopenia-induced proliferation is dependent on TCR signals for
peptide/MHC complexes and cytokines such as IL-7 and IL-15. It is therefore plausible that
naïve cord blood T cells may have upregulated TCR signalling and/or cytokine signalling
pathways which may boost the process of lymphopenia-induced proliferation following T-cell
replete CBT.
Therefore, to determine if differential gene expression in cord blood vs peripheral blood CD4+
T cells underlies the more rapid CD4+ T-cell proliferation observed after CBT, we set out to
identify if cord blood T cells have a distinct and foetal T-cell like gene expression profile and
if this foetal ontogeny is recapitulated after T-cell replete CBT. Finally, we aimed to identify
the relevant homeostatic pathways and transcription factors that mediate enhanced proliferation
after T-cell replete CBT.
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5.2 Exploratory data analysis of naïve cord blood and peripheral blood CD4+ T cell gene
expression profile
Gene expression profile using Affymetrix Human Gene 1.0 ST array on RNA isolated from
flow cytometrically sorted naïve CD4+ T cells (CD4+CD45RA+CCR7+) from the normal donor
cord blood, adult blood and T-cell replete CBT and BMT recipients was performed.
Two experiments were performed with 3 random donor cord blood and peripheral blood
samples (biological replicates). This was followed by 3rd experiment which included 3 paired
samples of naïve CD4+ T cells from cord blood and peripheral blood of same donors (age 5 - 8
years old) and from CBT and BMT recipients during early T-cell reconstitution. Gene
expression quality control and analysis was performed using R (cran.r-project.org) and
Bioconductor (www.bioconductor.org).
The naïve CD4+ T cells from cord blood and peripheral blood clustered into two distinct groups
on 3D-principal component analysis and hierarchical clustering. These gene expression
profiles were then compared with those of reconstituting naïve CD4+ T cells two months after
CBT and BMT. The gene expression profiles of naïve CD4+ T cells after CBT and BMT
clustered with the gene expression profiles of naïve CD4+ T cells from cord blood and
peripheral blood respectively [Figure 38 and 39]. To determine if cord blood T cells have a
transcription profile similar to foetal T cells we retrieved gene expression data set of naïve
CD4+ T cells from the foetal mesenteric lymph nodes (gestational age 18 to 22 weeks, Mold et
al., 2010). Our most notable finding was that the gene expression profiles of naïve CD4+ T
cells from cord blood and during early reconstitution following CBT clustered with those of
naïve foetal CD4+ T cells [Figure 38 and 39].
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Figure 38: 3D principal component analysis of naive CD4+ T cell transcriptome from cord
blood (n=9), peripheral blood (n=12), fetal mesenteric lymph nodes (n=3) and two months
after cord blood transplantation (CBT; n=3) & bone marrow transplantation (BMT; n=3).
Naive cord blood CD4+ T cells have a distinct transcription profile to naive peripheral blood
CD4+ T cells, but similar to foetal T cells.
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Figure 39: Hierarchical clustering analysis of naive CD4+ T cell transcriptome from cord blood
(n=9), peripheral blood (n=12), fetal mesenteric lymph nodes (n=3) and two months after CBT
(n=3) & BMT (n=3). Naive cord blood CD4+ T cells have a distinct transcription profile to
naive peripheral blood CD4+ T cells, but similar to foetal T cells.
The foetal immune system is biased towards T-regulatory function. I therefore compared gene
expression profile of naïve CD4+ T cells and T-regulatory cells. Naïve CD4+ T cells and T-
regulatory cells segregated depending on the developmental stage and T-cell type [Figure 40].
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Thus, confirming the distinct gene expression profile of naïve CD4+ T cells after CBT is not
due to adoption of T-regulatory function.
Figure 40: 2D principal component analysis showing relationship between naive CD4+ T cells
from cord blood (n=9), peripheral blood (n=9), foetal mesenteric lymph nodes (n=3) and two
months after CBT (n=3) & BMT (n=3) versus T-regulatory cells from foetal mesenteric lymph
nodes (n=3) and peripheral blood (n=3). T cells segregate based on developmental stage and
T-cell type. Thus, confirming the distinct transcription profile of naive CD4+ T cells after CBT
is not due to adoption of T-regulatory function. (In this graph, each unit is 0.05 and is depicted
in the graph as d=0.05)
Thus, these observations indicate that cord blood T cells have a foetal-like transcriptional
profile which is distinct to peripheral blood T cells. Most importantly, this foetal ontogeny is
recapitulated after T-cell replete CBT thus indicating the role of distinct foetal-like
transcription profile in mediating the enhanced T-cell reconstitution after T-cell replete CBT.
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5.3 Identifying differentially expressed genes between naïve CD4+ T cells isolated from
the cord blood and peripheral blood
We identified the differentially expressed genes in three separate microarray experiments
comparing the naïve CD4+ T cells from the CB (n = 9) and PB (n = 9). In the three experiments,
288, 273 and 213 genes were differentially expressed (Table 5).
Naïve CD4+ T cells (CB vs PB) Expt 1
Random donors
Expt 2
Random donors
Expt 3
Paired donors
Differentially expressed genes 288 273 213
Up-regulated genes 206 179 125
Down-regulated genes 82 94 88
Table 5 shows differentially expressed genes in the 3 normal donor microarray experiments
Of these differentially expressed genes, sixty genes were common to the three experiments and
hence are likely to represent true molecular signature of cord blood CD4+ T cells [Figure 41
(a); Table 6 and 7].
On comparing the gene expression profile of naïve CD4+ T cells from foetal mesenteric lymph
nodes and peripheral blood, we found 1133 genes differentially expressed. Of these 1133
genes, 740 were upregulated.
Interestingly, of the sixty genes representing cord blood CD4+ T cell signature, 45 (75%) genes
were differentially regulated in the naïve CD4+ T cells from the foetal mesenteric lymph nodes
and of these 45 genes, 43 genes had the same direction of regulation [Figure 41 (b)].
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Figure 41: (a) Venn diagram of differentially expressed genes in 3 microarray experiments
comparing the naive CD4+ T cells from normal donor cord blood and peripheral blood. Sixty
genes overlapped in the 3 experiments. (b) 45 of the 60 overlapping genes were differentially
expressed in foetal CD4+ T cells and 43 of these genes had same direction of regulation,
confirming that cord blood T cells and foetal T cells have similar transcription profile.
The sixty genes that are differentially expressed are shown in Table 6 and 7 and scatterplot of
pairwise global gene expression of naive cord blood CD4+ T cells and naive peripheral blood
CD4+ T cells are shown in Figure 42.
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Table 6 Fold-change and p values of upregulated genes in the three experiments are shown
separately.
logFC p value logFC p value logFC p value
GZMA granzyme A 7.535699 1.67E-06 4.31662 0.004528 7.174216 6.45E-05
TNF tumor necrosis factor 6.706227 2.48E-05 6.332923 4.08E-05 4.187791 0.006876
JUN Jun proto-oncogene, AP-1 transcription factor subunit 6.441966 0.012674 6.140109 0.000316 8.667031 0.0001
YBX3 Y-box binding protein 3 5.890719 4.60E-05 3.855246 0.006675 3.579875 0.004035
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 5.75521 0.001653 7.430931 9.24E-08 3.450347 0.020954
ERVH48-1 endogenous retrovirus group 48 member 1 5.705971 6.88E-05 5.779196 8.64E-05 4.423607 0.000145
AUTS2 autism susceptibility candidate 2 5.671714 4.95E-06 6.198322 1.36E-07 5.871178 7.46E-05
FOS Fos proto-oncogene, AP-1 transcription factor subunit 5.429297 0.002098 2.920811 0.021043 7.93349 4.09E-05
NREP neuronal regeneration related protein 5.340234 1.62E-05 4.201117 4.23E-05 2.919033 0.000486
BCL11A B-cell CLL/lymphoma 11A 5.044081 6.81E-05 5.652298 1.77E-09 4.843203 3.60E-05
PPP1R15A protein phosphatase 1 regulatory subunit 15A 4.818382 2.31E-06 3.51651 0.000308 7.127937 1.82E-05
RNASE6 ribonuclease A family member k6 4.370133 0.005525 3.076722 0.00724 4.038208 0.001027
SGK1 serum/glucocorticoid regulated kinase 1 4.348108 0.000253 5.288891 2.89E-05 4.057468 0.007536
CKS2 CDC28 protein kinase regulatory subunit 2 4.290451 0.000255 3.210377 0.00014 2.098185 0.020831
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 4.182863 0.002524 4.77588 2.96E-05 3.087342 0.019925
RGS1 regulator of G-protein signaling 1 4.129041 0.006686 4.776981 0.000836 6.855456 0.026811
DACH1 dachshund family transcription factor 1 4.003262 3.79E-05 4.102328 5.81E-06 2.290388 0.000493
DUSP1 dual specificity phosphatase 1 3.784847 0.002561 2.173541 0.026407 6.790163 9.84E-06
RAB25 RAB25, member RAS oncogene family 3.509931 4.84E-05 4.399383 6.40E-05 4.726221 0.0007
ZNF462 zinc finger protein 462 3.493374 0.006196 3.802819 8.50E-06 4.444309 0.00019
EPHA4 EPH receptor A4 3.401745 0.003662 2.402585 0.00012 2.231014 0.016643
SOX4 SRY-box 4 3.361926 0.00019 3.878754 8.76E-07 2.052565 0.000975
CD38 CD38 molecule 3.336686 0.00035 3.672497 0.00031 2.212695 0.000832
DAPK1 death associated protein kinase 1 3.307746 0.000202 3.856168 5.42E-06 2.655965 0.000485
SERPINF1 serpin family F member 1 3.30606 0.01073 3.99432 3.43E-05 5.23202 0.000547
TNFAIP3 TNF alpha induced protein 3 3.037118 0.004832 4.137767 0.000261 4.480875 0.012172
MICAL2 microtubule associated monooxygenase, calponin and LIM domain containing 23.017118 2.69E-05 2.125189 0.002898 2.392789 0.000983
CD69 CD69 molecule 2.973675 0.004498 4.31104 0.000611 4.645605 0.005966
IER2 immediate early response 2 2.949891 0.0003 3.971943 3.28E-08 2.912484 0.000488
ITPRIP inositol 1,4,5-trisphosphate receptor interacting protein 2.941317 0.001875 2.474705 0.000519 2.446789 0.000374
KLF6 Kruppel like factor 6 2.937539 0.000956 2.44734 0.000872 3.459376 0.004316
SLC18A2 solute carrier family 18 member A2 2.91042 0.000807 4.742807 3.17E-05 2.017848 0.008874
KLRG1 killer cell lectin like receptor G1 2.790687 0.007994 2.510963 0.006052 3.407383 0.000289
HILPDA hypoxia inducible lipid droplet associated 2.71938 0.000111 2.059457 1.36E-05 2.294812 0.002073
DDIT4 DNA damage inducible transcript 4 2.55922 0.00181 2.093249 0.002463 2.944853 0.002054
NFKBIA NFKB inhibitor alpha 2.545184 0.019169 3.654324 7.91E-06 4.614546 0.000559
PDE6G phosphodiesterase 6G 2.511184 0.010125 2.262887 0.002368 3.742702 0.00023
LDB2 LIM domain binding 2 2.403874 0.002915 2.334718 0.001334 2.789985 0.000595
CACHD1 cache domain containing 1 2.392288 0.008796 2.670404 6.56E-05 2.153186 0.000715
YARS tyrosyl-tRNA synthetase 2.252624 0.000586 3.234825 6.53E-06 3.321055 0.001332
SEPT11 septin 11 2.24483 0.012034 2.933734 3.90E-06 2.192582 0.004805
DACT1 dishevelled binding antagonist of beta catenin 1 2.09791 0.033199 2.559493 0.006348 2.450052 0.000787
MCTP1 multiple C2 and transmembrane domain containing 1 2.02364 0.00102 2.239509 2.88E-05 2.016444 0.004509
Experiment 1 Experiment 2 Experiment 3
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Table 7 Fold-change and p values of downregulated genes in the three experiments are shown
separately.
logFC p value logFC p value logFC p value
TSHZ2 teashirt zinc finger homeobox 2 -6.65785 7.44E-07 -4.44503 0.000124 -4.15268 5.46E-05
GBP5 guanylate binding protein 5 -5.61794 8.58E-05 -4.78459 0.000959 -8.0585 5.87E-06
NR3C2 nuclear receptor subfamily 3 group C member 2 -5.20196 0.000108 -5.46849 4.40E-07 -5.51365 6.26E-05
ZNF204P zinc finger protein 204, pseudogene -4.46247 3.86E-06 -2.89953 0.000509 -3.1558 0.006688
ABCD2 ATP binding cassette subfamily D member 2 -3.85728 0.000231 -2.89768 0.00652 -3.75452 5.12E-05
SERPINB6 serpin family B member 6 -3.75117 9.74E-05 -4.05341 3.93E-07 -2.67129 0.001214
TBK1 TANK binding kinase 1 -3.72549 1.90E-06 -2.3558 0.000142 -2.64517 0.004132
MID2 midline 2 -3.60009 6.48E-07 -4.21845 1.85E-06 -3.60814 0.002244
BEX5 brain expressed X-linked 5 -3.55973 4.71E-05 -7.26828 3.95E-06 -5.80275 0.000302
RNF175 ring finger protein 175 -3.5569 7.81E-06 -2.53643 3.34E-05 -2.41742 0.004374
RBM11 RNA binding motif protein 11 -3.43584 0.005858 -2.8751 0.00023 -2.22189 0.001508
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1-3.06266 0.033783 -3.34038 5.26E-05 -6.31339 3.48E-05
ZBTB38 zinc finger and BTB domain containing 38 -2.63495 0.000584 -3.45025 0.000766 -4.74469 1.92E-05
RNF130 ring finger protein 130 -2.50728 0.00385 -2.50772 9.39E-05 -2.27609 0.00298
TGFBR3 transforming growth factor beta receptor 3 -2.47259 0.016178 -2.27981 0.000273 -2.33925 0.000484
ZNF14 zinc finger protein 14 -2.41439 0.014251 -2.99841 0.002076 -2.3865 0.012378
MT1F metallothionein 1F -2.05388 0.043655 -3.71048 0.000243 -3.0288 0.00138
Experiment 1 Experiment 2 Experiment 3
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Figure 42: Scatterplot of pairwise global gene expression of naive cord blood CD4+ T cells and
naive peripheral blood CD4+ T cells. Gene expression values are plotted on a log scale. Genes
that were differentially expressed between groups (determined using p value < 0.05 and fold-
change >= 2) are indicated in red and blue. Specific genes that were differentially expressed
are highlighted with arrows.
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5.4 Identifying molecular signature induced during lymphopenia-induced proliferation
However, since cord blood T cells are in a highly proliferative state, driven by the relatively
lymphopenic environment of the foetus, we speculated that a few of these genes may be
induced during the process of lymphopenia-induced proliferation.
We identified the genes induced during lymphopenia-induced proliferation taking the
advantage of a natural experiment performed during T-cell replete BMT. This allowed us to
compare the genes induced in the naïve CD4+ T cells after infusion of a steady lymphoreplete
BM graft in a lymphopenic host.
Of the identified sixty genes representing cord blood CD4+ T cell transcriptome, 19 genes were
differentially expressed in peripherally expanding naïve CD4+ peripheral blood T cells
following T-cell replete BMT. All the 19 genes remained differentially expressed in the
reconstituting T cells after CBT, further indicating a role of these genes in lymphopenia-
induced proliferation [Figure 43 and 44]. Table 8 is a list of 18 genes that are upregulated in
the lymphopenic conditions.
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Figure 43: (a) Nineteen of the 60 genes that represent naive cord blood CD4+ T cell signature
were induced in the reconstituting naive CD4+ T cells after BMT and (b) all the 19 genes
remained differentially expressed in the reconstituting naive CD4+ T cells after CBT. (c) Thus,
these 19 genes represent the signature induced in the lymphopenic environment and remaining
41 genes are likely to represent foetal signature.
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(a) (b)
Figure 44: Scatterplot of pairwise global gene expression comparison of naïve CD4+ T cells
from two post-transplant environments i.e. cord blood transplantation and bone marrow
transplantation. Gene expression values are plotted on a log scale and specific genes
upregulated in the lymphopenic environment are highlighted with arrows. (b) Nineteen genes
induced in the lymphopenic signature and 41 genes of foetal signature are shown.
Lymphopenic signature
Foetal signature
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Gene Name Alternative name/function
FOS Fos proto-oncogene, AP-1 transcription factor subunit(FOS)
JUN Jun proto-oncogene, AP-1 transcription factor subunit(JUN)
TNFAIP3 TNF alpha induced protein 3
RGS1 regulator of G-protein signaling 1
GZMA granzyme A
NFKBIA NFKB inhibitor alpha(NFKBIA)
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1
YARS tyrosyl-tRNA synthetase
CD69 CD69 molecule
PDE6G phosphodiesterase 6G
PPP1R15A protein phosphatase 1 regulatory subunit 15A
YBX3 Y-box binding protein 3
KLF6 Kruppel like factor 6
ZNF462 zinc finger protein 462
DACT1 dishevelled binding antagonist of beta catenin 1
DUSP1 dual specificity phosphatase 1
SGK serum/glucoorticoid regulated kinase 1
SERPINF1 serpin family F member 1
Table 8 List of 18 genes upregulated in the lymphopenic environment.
Deducting these 19 genes induced during the process of lymphopenia-induced proliferation,
remaining 41 genes are likely to represent the foetal signature of naïve CD4+ T cells [Figure
43]. Figure 45 shows relative transcripts values of genes representing a foetal signature and
Table 9 shows selected genes over expressed in cord blood and peripheral blood T cells.
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Figure 45: Bar plot showing transcript values (mean and standard deviation) of upregulated
and down regulated genes representing foetal signature.
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Gene Name Alternative name/function
FOS Fos proto-oncogene, AP-1 transcription factor subunit(FOS)
JUN Jun proto-oncogene, AP-1 transcription factor subunit(JUN)
SLC18A2 solute carrier family 18 member A2
TNFAIP3 TNF alpha induced protein 3
AUTS2 autism susceptibility candidate 2
RGS1 regulator of G-protein signaling 1
GZMA granzyme A
NFKBIA NFKB inhibitor alpha(NFKBIA)
IER2 immediate early response 2(IER2)
TNF tumor necrosis factor
Gene Name Alternative name/function
GBP5 guanylate binding protein 5(GBP5)
TSHZ2 teashirt zinc finger homeobox 2
ZNF204P zinc finger protein 204, pseudogene
SERPINB6 serpin family B member 6
NR3C2 nuclear receptor subfamily 3 group C member 2
Table 9 List of selected genes found overexpressed in cord blood and adult blood T cells.
Genes induced during lymphopenia-induced proliferation included 2 important transcription
factors of TCR signalling pathway namely c-fos and c-jun which forms an AP-1 complex. Both
c-fos and c-jun were highly upregulated during early T-cell reconstitution following CBT and
BMT. Interestingly, the upregulation of c-fos and c-jun was significantly higher in
reconstituting T cells after CBT than compared with BMT. This upregulation of AP-1 during
lymphopenia-induced proliferation suggests a role of TCR signalling during peripheral
expansion of T cells infused with stem cell grafts. In particular, higher transcript values of c-
fos and c-jun in the reconstituting T cells after CBT suggests that cord blood T cells may have
a proliferative advantage over peripheral blood T cells. Figure 46 shows relative transcript
values of genes induced during lymphopenia-induced proliferation.
149
Figure 46: Bar plot showing transcript values (mean and where possible
standard deviation) of 19 upregulated/downregulated genes
representing genes induced in the lymphopenic environment.
Interestingly, the differential regulation of 19 genes was higher in the
naive CD4+ T cells from the cord blood and during early reconstitution
following cord blood transplantation than compared with bone marrow
transplantation.
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5.5 Identifying the upregulated biological processes and canonical pathways in the cord
blood T cells
Given the distinct transcription profile of cord blood and peripheral blood T cells, we
speculated that distinct biological processes and canonical pathways may mediate enhanced T-
cell reconstitution after T-cell replete CBT. Firstly, we used 825 gene sets of biological
processes from the gene ontology consortium. We found that 27 biological processes were
upregulated at p value < 0.001 and fdr q value < 0.1. Table 10 lists the biological processes
upregulated in cord blood T cells.
Table 10 Biological processes upregulated in cord blood T cells.
Next I performed enrichment mapping of these pathways and found that naïve cord blood CD4+
T cells were enriched in three clusters relating to cell cycle, DNA metabolism and apoptotis
[Figure 47]. The cell cycle and apoptosis pathway were upregulated in all the lymphopenic
conditions [Figure 48]. Cell cycle and apoptosis pathway were upregulated in naïve CD4+ T
cells after T-replete CBT compared to T-replete BMT.
NAME SIZE ES NES NOM p-val FDR q-val
DNA_METABOLIC_PROCESS 247 0.5059515 2.1789281 0 0.002307
RESPONSE_TO_DNA_DAMAGE_STIMULUS 155 0.52454346 2.1087008 0 0.005804
CELL_CYCLE_CHECKPOINT_GO_0000075 48 0.6222186 2.054601 0 0.009687
INTERPHASE_OF_MITOTIC_CELL_CYCLE 62 0.5770853 2.0149944 0 0.01112
CELL_CYCLE_GO_0007049 309 0.4655104 2.0182862 0 0.013031
REGULATION_OF_CELL_CYCLE 180 0.47839648 1.9598776 0 0.018691
MITOTIC_CELL_CYCLE 151 0.4827955 1.9438541 0 0.019842
DNA_REPAIR 119 0.51513183 1.9633648 0 0.021051
INTERPHASE 68 0.54464364 1.9261076 0 0.022417
CELL_CYCLE_PHASE 166 0.47129884 1.9061838 0 0.026747
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 47 0.5757308 1.8748549 0 0.028571
CELL_CYCLE_PROCESS 189 0.45616704 1.8823042 0 0.03004
NEGATIVE_REGULATION_OF_CELL_CYCLE 79 0.51832753 1.8762827 0 0.030403
RESPONSE_TO_ENDOGENOUS_STIMULUS 191 0.4572464 1.885719 0 0.031494
CELLULAR_COMPONENT_DISASSEMBLY 33 0.5860449 1.8021057 0 0.052743
APOPTOTIC_PROGRAM 59 0.5236585 1.8059676 0.001776199 0.054009
REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 28 0.59163123 1.7378746 0.001956947 0.081819
UBIQUITIN_CYCLE 47 0.5175936 1.7416282 0.001855288 0.08269
APOPTOSIS_GO 415 0.38288313 1.6989125 0 0.086339
PROGRAMMED_CELL_DEATH 416 0.38030535 1.7039883 0 0.088013
DNA_REPLICATION 97 0.45436049 1.7076312 0.001680672 0.088296
REGULATION_OF_PROGRAMMED_CELL_DEATH 328 0.38511395 1.6878171 0 0.089241
REGULATION_OF_APOPTOSIS 327 0.38888615 1.7103146 0 0.089732
PROTEIN_UBIQUITINATION 39 0.5401635 1.7232333 0.003539823 0.090196
M_PHASE 110 0.44338146 1.7104169 0.001739131 0.093471
POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 210 0.4172443 1.7120072 0 0.09613
NEURITE_DEVELOPMENT 50 0.5046813 1.6658067 0 0.096863
CELL_STRUCTURE_DISASSEMBLY_DURING_APOPTOSIS 18 0.6780949 1.7957022 0.003787879 0.052441
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Figure 47: Enrichment map of biological processes upregulated in the naive cord blood CD4+
T cells compared with naive peripheral blood CD4+ T cells. Cell cycle and apoptosis were the
two dominant biological processes upregulated in the naive cord blood CD4+ T cells.
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Figure 48: Cell cycle
and Apoptosis were
upregulated in all the
lymphopenic
conditions and were
highly upregulated in
naive CD4+ T cells
after T-replete CBT
compared with T-
replete BMT. p values
are shown in each
enrichment plot.
P<0.000 P<0.000
P<0.000 P<0.000
P<0.000 P<0.000
P<0.05 P<0.01
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To identify the canonical pathways upregulated in naïve CB CD4+ T cells, we used 403 gene
sets from BIOCARTA and KEGG database. We found that 26 canonical biological pathways
were upregulated at p value < 0.001 and fdr q value < 0.1. Table 11 lists the canonical pathways
upregulated in cord blood T cells.
Table 11 Canonical pathways upregulated in cord blood T cells.
On performing the enrichment mapping, 19 of these pathways clustered in one group and these
pathways included TCR and MAPkinase signalling pathways [Figure 49].
NAME SIZE ES NES NOM p-val FDR q-val
BIOCARTA_STRESS_PATHWAY 25 0.747852 2.153037 0 0.002696
BIOCARTA_NTHI_PATHWAY 24 0.705878 2.029868 0 0.004694
KEGG_DNA_REPLICATION 35 0.662369 2.04498 0 0.005209
BIOCARTA_ATM_PATHWAY 20 0.792749 2.161489 0 0.005393
BIOCARTA_TNFR2_PATHWAY 18 0.747083 2.006501 0 0.005757
KEGG_NUCLEOTIDE_EXCISION_REPAIR 44 0.606687 1.968972 0 0.008272
BIOCARTA_GPCR_PATHWAY 32 0.649287 1.973769 0 0.008621
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 107 0.511906 1.956901 0 0.009042
BIOCARTA_MET_PATHWAY 35 0.63085 1.940215 0 0.010134
KEGG_P53_SIGNALING_PATHWAY 67 0.542353 1.911971 0 0.012553
KEGG_CELL_CYCLE 121 0.486363 1.889171 0 0.0141
BIOCARTA_TCR_PATHWAY 42 0.590207 1.891878 0 0.014213
KEGG_BASE_EXCISION_REPAIR 32 0.617007 1.865055 0 0.017776
BIOCARTA_MAPK_PATHWAY 86 0.490017 1.785455 0 0.023409
KEGG_MAPK_SIGNALING_PATHWAY 257 0.363248 1.548704 0.0015873 0.096791
KEGG_OXIDATIVE_PHOSPHORYLATION 110 0.460309 1.750396 0.001675 0.02975
BIOCARTA_PPARA_PATHWAY 54 0.507107 1.717286 0.0017422 0.037614
BIOCARTA_PYK2_PATHWAY 26 0.635627 1.843618 0.0017483 0.019434
BIOCARTA_TNFR1_PATHWAY 29 0.686701 2.047322 0.0018083 0.006946
BIOCARTA_NGF_PATHWAY 18 0.67646 1.788512 0.0018727 0.023704
BIOCARTA_G2_PATHWAY 24 0.623125 1.746379 0.0018797 0.030382
BIOCARTA_TID_PATHWAY 17 0.700731 1.800438 0.0018975 0.023874
BIOCARTA_INTEGRIN_PATHWAY 35 0.568651 1.794564 0.0019048 0.023841
BIOCARTA_ETS_PATHWAY 18 0.675863 1.850606 0.0019342 0.019443
BIOCARTA_HSP27_PATHWAY 15 0.698828 1.79994 0.0019531 0.023302
BIOCARTA_CDMAC_PATHWAY 16 0.768664 1.966973 0.001996 0.008
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Figure 49: Enrichment map of upregulated canonical pathways in the naive cord blood CD4+
T cells (n = 9) compared with naive peripheral blood CD4+ T cells (n = 9). The relationship of
TCR and MAPK signalling with other upregulated pathways is shown.
Figure 50 shows Blue-Pink O’gram of TCR signalling pathway and Figure 51 shows
enrichment plots of TCR and MAPK signalling. The TCR and MAPK signalling pathways
were not only upregulated in naïve CD4+ T cells from cord blood but were also upregulated in
the reconstituting naïve CD4+ T cells from the lymphopenic environment following CBT and
BMT (P < 0.001, fdr q value 0.1) [Figure 51]. This indicates induction of TCR-MAPK signals
in the lymphopenic environment. Finally, on comparing naïve CD4+ T cells from the two post-
transplant lymphopenic conditions i.e. CBT vs BMT, TCR and MAPK signalling were found
to be upregulated following CBT (P < 0.02, fdr q value 0.25) [Figure 51]. Similarly, although
c-fos and c-jun were upregulated in the cord blood, during early T-cell reconstitution following
CBT and BMT [Figure 51], their upregulation was significantly higher after CBT than after
BMT [Figure 51]. Thus, upregulated TCR-MAPK signals and distinctly regulated cell cycle
pathways may endow naïve cord blood CD4+ T cells with an enhanced cell cycling ability in
the lymphopenic environment.
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Figure 50: Blue-Pink O'gram of TCR signalling pathway
after comparing transcription profiles of naive CD4+ T
cells from the cord blood (n = 9) and peripheral blood (n
= 9).
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Figure 51: Enrichment
plots of TCR and
MAPK signalling and
the transcript values
of two important
transcription factors
FOS and JUN (AP-1
complex) in the naive
CD4+ T cells from
lymphopenic
conditions such as (a)
cord blood (b) and (c)
during early T-cell
reconstitution
following CBT and
BMT. FOS and JUN
upregulation is
expressed as mean
(and where possible
as standard deviation)
(d) When comparing
the two lymphopenic
conditions i.e. CBT vs
BMT, reconstituting
naive CD4+ T cells
were observed to have
an upregulated TCR
and MAPK signalling
following CBT.
P<0.000 P<0.002
P<0.000
P<0.000
P<0.000 P<0.000
P<0.02 P<0.03
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5.6 Testing functional relevance of enhanced TCR signalling in cord blood T cells
In order to study the role of TCR signalling in homeostatic T-cell proliferation and whether
TCR:MHC interactions assist in T-cell reconstitution after T-cell replete graft depending on
whether the graft source is foetal or adult, we cultured CFSE-labelled CB and PB CD3+ T cells
with autologous irradiated non-CD3 fractions. These cultures of non-CD3:CD3+ T-cell were
set up in round bottom 96 well plates at the ratio of 1:0 (50000:0), 1:1 (50000:50000), 2:1
(100000:50000) and 4:1 (200000:50000). After 7 days of culture, CD4+ T cells were analysed
for proliferation.
Eighty-five to 90% of cord blood CD4+ T cells entered into cell cycle compared with 75% of
peripheral blood CD4+ T cells (P < 0.05).
The proliferative indices (PIs) of cord blood CD4+ T cells with APC:T cell ratio of 1:1, 2:1 and
4:1 were 2.3 (+/– 0.05), 2.9 (+/– 0.2) and 3.5 (+/– 0.17) respectively [Figure 52 (a) and 53]. In
contrast, PIs of peripheral blood CD4+ T cells with APC:T cell ratio of 1:1, 2:1 and 4:1 were
1.8 (+/– 0.1), 1.8 (+/– 0.1) and 1.9 (+/– 0.1) respectively [Figure 52 (b) and 53]. Thus,
significantly higher proliferation of cord blood CD4+ T cells occurred compared to peripheral
blood CD4+ T cells (P < 0.05). A significant effect of increasing APC:T-cell ratio was observed
on proliferation of cord blood CD4+ T cells without such an effect on the peripheral blood
CD4+ T cells (P < 0.05).
Thus, this non-CD3:CD3+ T-cell co-culture system which mimics homeostatic T-cell
proliferation show that distinct TCR:MHC interactions occur in cord blood compared with
adult blood and this may influence T-cell homeostasis after CBT and BMT.
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Figure 52: (a) and (b) CFSE proliferation assay of cord blood and peripheral blood CD4+ T
cells in response to increasing APC:T-cell ratio of 1:1, 2:1 and 4:1. The proliferation of cord
blood CD4+ T cells (n = 3) compared with peripheral CD4+ T cells (n = 3) was significantly
enhanced.
(a) (b)
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Figure 53: Line graph showing increased proliferation of cord blood CD4+ T cells (n=3) with
increasing APC:T-cell ratio, however no such effect was observed on peripheral blood CD4+
T cells (n=3).
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5.7 Testing functional relevance of AP-1 upregulation in cord blood CD4+ T cells
To further determine the role of TCR and MAPkinase signalling in CB T-cell homeostasis, we
inhibited the most upregulated transcription factor c-fos, c-jun (AP-1) using AP-1 inhibitor (SR
11302). CFSE-labelled CB CD3+ T cells were cultured with non-CD3 fraction in the non-
CD3:CD3 ratio of 4:1 (200000:50000). These cultures were performed without AP-1 inhibitor
and with AP-1 inhibitor of 1, 10 and 100 ng/ml.
The PIs of cord blood CD4+ T cells cultured with APC’s at APC:T cell ratio of 4:1 and an AP-
1 inhibitor concentration of 1 ng/ml, 10 ng/ml and 100 ng/ml were 3.5 (+/– 0.1), 2.7 (+/– 0.1)
and 1.9 (+/– 0.1) respectively [Figure 54 and 55]. Thus, increasing concentration of AP-1
inhibitor had an increased inhibitory effect on CB CD4+ T-cell proliferation indicating that AP-
1 inhibition abrogated TCR-MAP kinase signals. This suggest that inhibiting TCR signalling
abrogates homeostatic T-cell proliferation in non-CD3:CD3+ T-cell coculture system.
Figure 54: CFSE assay showing proportional
inhibition of cord blood CD4+ T-cell proliferation at
different concentrations of AP-1 inhibitor.
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Figure 55: Line graph showing the inhibitory effect on cord blood CD4+ T cells (n=3) was
proportional to the increasing concentration of AP-1 inhibitor. The dots represent mean and
error bars represent standard deviation.
Thus, upregulated TCR signalling may endow naïve cord blood CD4+ T cells with the enhanced
ability to proliferate in the lymphopenic environment and hence contribute to unprecedented
T-cell reconstitution after CBT.
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CONCLUSIONS
We have shown that cord blood T cells and peripheral blood T cells have a distinct
transcriptional profile. It has been previously reported that foetal T cells have a distinct gene
expression profile compared with adult T cells and our work shows that cord blood T cells also
have a distinct gene expression profile compared with adult T cells and that the gene expression
profile of cord blood T cells is similar to foetal T cells. This indicates that cord blood T cells
have foetal ontogenic origins which is distinct to that of adult ontogeny. Further we have shown
that following CBT, there is recapitulation of foetal T-cell ontogeny.
More importantly, gene expression profiles show that AP-1 was significantly upregulated in
the cord blood T cells compared with the peripheral blood T cells. AP-1 is an important
activator protein which is an important regulator of cell life and death and it plays an important
role in TCR-MAPkinase signalling. Further using GSEA and enrichment mapping analysis, we
found that biological processes such as cell cycle and apoptosis and canonical pathways such
as TCR-MAPkinase signalling were significantly upregulated.
To test the relevance of AP-1 and TCR-MAPkinase signalling pathway we performed
functional analysis. Firstly, we cocultured cord blood T cells and peripheral blood T cells with
allogeneic lymphoblastoid cells to assess the differences in proliferation in response to non-
self MHC peptide. We found that cord blood T cells proliferate rapidly after stimulation with
allogeneic lymphoblastoid cells compared with peripheral blood T cells. This proliferation of
cord blood T cells was similar to rapid proliferation of foetal T cells after stimulation with
allogeneic peripheral blood mononuclear cells as shown previously. This indicates that foetal
T cells and cord blood T cells undergo robust proliferation compared with peripheral blood T
cells when stimulated with non-self MHC peptide.
To test if these differences in proliferation between cord blood and peripheral blood T cells
maintain a similar response during homeostatic proliferation, we compared the proliferation of
CD3+ T cells when stimulated with autologous non-CD3 fraction. We found enhanced
proliferation of cord blood CD4+ T cells in comparison to peripheral blood CD4+ T cells. This
indicates that cord blood T cells are more sensitive to both self and non-self peptide MHC than
peripheral blood T cells and this is represented by upregulated TCR-MAPkinase signalling
pathway and AP-1 transcription factor. Therefore, AP-1 inhibition assay was performed using
a small molecule. These assays showed that AP-1 inhibitor inhibited the proliferation of naïve
CD4+ T cells in a dose dependent manner. Thus, these observations indicate a major role of
163
TCR signalling in homeostatic proliferation following T-replete CBT. Since T cells with
enhanced sensitivity to homeostatic cues have been shown to have the ability to mediate
enhanced response to foreign antigens too (Fulton et al., 2015), we questioned if cord blood T
cells can mediate an enhanced graft-versus-leukaemia effect compared with peripheral blood
T cells.
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Chapter six
Cord blood T cells mediate enhanced anti-leukaemic
effects compared with peripheral blood T cells
165
6.0 Aims
1) To develop a human T-cell:lymphoma model in an immunodeficient mice.
2) To compare the anti-tumour effect mediated by cord blood T cells and peripheral blood T
cells in this model.
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6.1 Introduction
We have shown in the previous chapter that foetal ontogeny of cord blood T cells is
recapitulated after T-cell replete cord blood transplantation. During recapitulation of foetal
ontogeny, we observed enhanced CD4+ T-cell reconstitution with rapid memory-effector
differentiation. Thus, cord blood T cells rapidly reconstitute in the lymphopenic environment.
We also observed rapid proliferation of cord blood T cells in response to self-MHC and allo-
MHC peptides in vitro, and that these processes are mediated by upregulated TCR signalling
in cord blood T cells.
In addition to being ontogenetically foetal and despite being overtly responsive to self and
non-self MHC peptides, cord blood T cells are predominantly antigen-inexperienced
CD45RA+ cells. When compared with CD45RA+ “naive” adult T cells, cord blood T cells are
Th2-Tc2 biased with reduced inducible expression of Th1-Tc1 cytokines, such as interferon
gamma (IFN-γ) (White et al., 2002; Marchant et al., 2005). This is due to relative
hypermethylation of cord blood CD4+ T cells at CpG and non-CpG sites within the IFN-γ 
promoter (White et al., 2002). Th1 responses in cord blood T cells are further attenuated
because of reduced ability of neonatal dendritic cells to produce IL-12 (Langrish et al., 2002).
In addition, the foetal immune system is generally believed to induce immune tolerance after
exposure to foreign antigens (Silverstein et al., 1964a; Silverstein et al., 1964b). These
findings suggest that although cord blood T cells undergo enhanced proliferation in response
to self and non-self MHC peptides they may not mount efficient allo-reactive response
required for eliminating leukemia.
However, CBT is associated with a significantly lower leukemia relapse risk, particularly
after HLA-mismatched and T-cell replete CBT (Eapen et al., 2007; Milano et al., 2016).
HLA-mismatched CBT is now being recommended in the absence of a matched adult donor
because cord blood grafts pose a lower risk of chronic GvHD compared with adult grafts
(Gluckman et al., 2012). For the same reason, while adult grafts are increasingly matched for
10 HLA loci (HLA, B, C, DR, and DQ), cord blood grafts are matched only for 6 HLA loci
(HLA A, B, and DR) (Gluckman et al., 2012), and additionally, CBT is increasingly being
performed without anti-thymocyte globlin (ATG) for treating high risk hematological
malignancies (Chiesa et al., 2012; Wagner et al., 2014). We have shown that such a T-cell
replete approach leads to enhanced thymus-independent T-cell expansion of donor cord blood
T cells (Chiesa et al., 2012; Lindemans et al., 2014). This enhanced thymus-independent T-
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cell reconstitution after CBT is always CD4+ T-cell biased, a pattern not observed after
transplantation using a bone marrow or peripheral blood stem cell graft, and, intriguingly,
occurs despite one log lower T cells in the cord blood graft compared with the bone marrow
graft [Figure 12 and 13]. Furthermore, these rapidly expanding naïve cord blood T cells
differentiate into viral specific T-lymphocytes within 2 months, leading to rapid clearance of
viral infections from the blood (both cytomegalovirus and adenovirus; Chiesa et al., 2012).
These observations suggest that despite intrinsic bias towards anti-inflammatory Th2–Tc2
immune responses, naive cord blood T cells can rapidly proliferate and differentiate into
antigen-specific T lymphocytes.
Therefore, I questioned whether this rapidly expanding early-life naïve T-cell immunity
following unrelated T-cell replete CBT, which is less stringently HLA-matched compared
with an adult donor, also accounts for enhanced GvL effects. I set out to establish a model to
study the orchestration of these anti-tumour effects mediated by cord blood T cells within the
tumour microenvironment. In order to model this, I compared the ability of HLA-mismatched
cord blood and peripheral blood T cells to eliminate EBV-driven human B-cell lymphomas in
a NOD/SCID/IL2rgnull mouse model.
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6.2 Cord blood T cells mediate enhanced anti-tumour effects compared with peripheral
blood T cells
NOD/SCID/IL2rgnull (NSG) mice were chosen because they are deficient in T, B, and NK
cells and this allows rapid engraftment of human T cells (Shultz et al., 1995).
EBV-driven human B-cell lymphoma was chosen as human tumour because of our expertise
in this tumour model. This tumour can be subcutaneously grafted into the
NOD/SCID/IL2rgnull mice allowing in vivo imaging of tumour using Xenogen-IVIS. In
addition, this tumour is known to have professional antigen presenting abilities because of
strong expression of MHC Class I and Class II and other co-stimulatory molecules such as
CD80, CD86, and CD83.
I initially compared the anti-tumour effects of equivalent doses of T cells derived from cord
blood versus peripheral blood in this NSG mouse model of EBV-driven B-cell lymphoma.
EBV-driven B-cell lymphoblastoid cells were generated from random donors. These cells
were transduced with SFG retroviral vector encoding green shifted Firefly Luciferase (F-
Luc). F-Luc positive lymphoblastoid cells were sorted and then grown to perform the
experiment. Experimental design involved injecting 5 × 106 human B-cell lymphoma cells on
day –2 subcutaneously. Untouched CD3+ T cells were sorted from the fresh cord blood and
adult blood mononuclear cells on day 0 and, 5 × 106 peripheral blood or cord blood T cells
were injected via tail vein. Mice were then monitored for tumour growth by in vivo imaging
using Xenogen-IVIS and calliper on day +10, 20, 30, 35, 40, 50, and 60. Mice were also
monitored weekly for signs of xeno-reactivity such as ruffled fur, lethargy and weight loss.
Two consecutive experiments with B-cell lymphoma and allogeneic T cells derived from
different donors were performed. The degree of HLA-mismatch between the T cells from the
cord blood and peripheral blood group and the B-cell lymphoma tumour cell lines was similar
in both the experiments. In the first experiment, both the cord blood and peripheral blood T
cells were mismatched with the tumour for all 10 HLA antigens and, in the second
experiment cord blood and peripheral blood T cells were mismatched with the tumour for 7
of 10 HLA antigens (Table 12).
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HLA A HLA B HLA C HLA DRB1 HLA DQB1
CB donor 1 36
66
15
18
02
07
01
11
05
06
PB donor 1 02
32
07
44
05
07
13
15
06
06
LCL donor 1 24
30
13
51
06
1602
04
07
02
07
CB donor 2 02
29
44
51
14
16
07
11
02
03
PB donor 2 01
68
14
58
07
08
07
16
02
05
LCL donor 2 02
24
07
39
07
07
07
13
02
06
Table 12 Cord blood T cells vs LCLs and peripheral blood T cells vs LCLs show a similar
degree of HLA-mismatch in the two experiments. All 10 HLA antigens and 7 of 10 HLA
antigens were mismatched in experiment 1 and 2 respectively.
Cord blood Peripheral blood
Expt 1 95.9% 94.6%
Expt 2 95.2% 94.5%
Table 13 Representative CD3+ population obtained after negative selection is shown as APC-
Cy7 fluorescence are shown. Cell debris were excluded from the analysis based on scatter
signals. The purity of T cells obtained after negative selection was > 94% in the two primary
experiments.
Control mice receiving B-cell lymphoma without T cells (n = 6) and mice receiving B-cell
lymphoma followed by peripheral blood T cells (n = 10) exhibited tumour growth exceeding
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the threshold limit of 10 mm between 20–22 days following tumour inoculation, and hence
these mice were sacrificed. In contrast, 9/10 mice receiving cord blood T cells showed slower
tumour growth followed by complete tumour regression [Figure 56]. These findings were
confirmed by measuring tumour bioluminescence in photons/sec/cm2/sr using a Xenogen-
IVIS imaging system. The mean tumour bioluminescence of the cord blood group on day +20
was significantly lower than that of the peripheral blood and control group (9.65 × 109 +/− 
2.65 × 109 vs 3.83 × 1010 +/− 1.075 × 1010 and 3.04 × 1010 +/− 8.42 × 109, respectively; P <
0.01) [Figure 57]. These IVIS findings were mirrored by caliper-measured tumour volumes.
On day +20, the mean tumour volume in the cord blood group was 204 mm3 [Figure 58],
which was significantly lower than the mean tumour volume of the peripheral blood (814
mm3) and control (812 mm3) group (P < 0.01).
Figure 56: Representative experiment illustrates slower tumour growth followed by rapid
rejection of B-cell lymphoma in mice receiving allogeneic cord blood T cells compared with
mice receiving allogeneic peripheral blood T cells and control mice. All images are shown on
one scale (range: 1.00e8 to 1.00e9 photons/sec/cm^2/sr). Tumour size in control mice and
those receiving peripheral blood T cells exceeded threshold of 10 mm and hence these mice
were sacrificed.
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Figure 57: Tumour bioluminescence (photons/sec/cm^2/sr) was measured using Xenogen-
IVIS. Cumulative rate of tumour growth (mean and standard error of mean) from two
separate experiments are plotted. These plots show significantly slower rate of tumour growth
in the mice receiving cord blood T cells compared with the mice receiving peripheral blood T
cells and control group. (Two independent experiments)
Figure 58: Tumour volume (mm^3) was derived using calliper measurements. Cumulative
rate of tumour growth (mean and standard error of mean) from two separate experiments are
plotted. These plots show significantly slower rate of tumour growth in the mice receiving
cord blood T cells compared with the mice receiving peripheral blood T cells and control
group. (Two independent experiments)
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Figure 59: Regression of tumour following infusion of cord blood T cells led to significantly
improved survival in this group compared with the peripheral blood group (log rank test; P <
0.0003).
Surviving mice in the cord blood group were monitored for 60 days after T-cell injection, and
interestingly, there was no relapse of tumour and no evidence weight loss or other signs of
xenogeneic GvHD. This led to significantly improved survival in the cord blood group
compared with the peripheral blood group (P < 0.0003) [Figure 59]. This observation
suggests that cord blood T cells can mediate a potent GvL effect without causing xenogeneic
GvHD.
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6.3 Cord blood T cells are not xeno-reactive, whereas peripheral blood T cells have
potent xeno-reactive ability
However, because the xenogeneic GvHD mediated by peripheral blood T cells is well
established (King et al., 2009; Ali et al., 2012; Covassin et al., 2011), I next performed xeno-
reactive modelling comparing the ability of intravenously injected cord blood vs peripheral
blood T cells to mediate xenogeneic GvHD.
Untouched CD3+ T cells were sorted from freshly isolated cord blood and peripheral blood
mononuclear cells. After injecting 5 × 106 cord blood or peripheral blood T cells via tail vein,
mice were monitored for signs of xenogeneic GvHD such as ruffled fur, lethargy and weight
loss.
In mice receiving peripheral blood T cells, we observed the onset of xeno-reactivity 3 weeks
following T-cell injection. All mice receiving peripheral blood T cells begin to develop
weight loss 3 weeks following T cell injections [Figure 60]. In the following week, ruffled fur
and lethargy was noticed along with the weight loss of more than 10% and hence the mice
receiving peripheral blood T cells had to be sacrificed. In contrast, mice receiving cord blood
T cells did not develop any symptoms of xeno-reactivity, during the 60 day period of
observation after T-cell injection. This was despite the presence of circulating human T cells
at the end of the experiment.
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The presence of xenogeneic GvHD in the peripheral blood T-cell group was further
confirmed by haematoxylin/eosin staining of target GvHD organs such as liver and skin. A
significant infiltration of T cells and distortion of normal architecture around the bile ducts
and in the intra-dermal region was observed in the peripheral blood group. In contrast, scant
T cells and normal histology of liver and skin sections were observed in the cord blood T-cell
group [Figure 61].
This was further substantiated by the cleaved-caspase 3 staining to study the apoptosis in the
histopathology sections of liver and skin. We observed marked cleaved-caspase 3 staining
indicating the apoptotic changes around the bile ducts and in the intra-dermal region of the
peripheral blood group. In contrast, no apoptotic changes were seen in the cord blood group
[Figure 61].
Figure 60: shows onset of
weight loss three weeks after
peripheral blood T cell
injections. 10-15% weight
loss occurred by four weeks
in the peripheral blood group
and hence these mice were
sacrificed. No weight loss
was observed in mice
receiving cord blood T cells
up to 6 weeks after the
injection of T cells.
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Figure 61: Haematoxylin and eosin sections of liver and skin of mice receiving peripheral
blood T cells show infiltrating lymphocytes around the bile duct and in the intra-dermal
region. Cleaved caspase-3 staining was apparent at the site of lymphocytic infiltration
confirming apoptosis of bile duct epithelium and keratinocytes present in epidermis and hair
follicle. Cord blood T cells were not observed to infiltrate either liver or skin.
This indicates that cord blood T cells do not cause xenogeneic GvHD, while peripheral blood
T cells mediate potent xenogeneic GvHD.
We then asked the question whether xeno-reactive peripheral blood T cells might also
mediate a GvL effect?
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6.4 Peripheral blood T cells can mediate GvL effect correlating with the onset of xeno-
reactivity
To model any GvL effect mediated by peripheral blood T cells and how this correlates with
xenogeneic GvHD following peripheral blood T-cell injection, I performed tumour modeling
experiment with a lower burden of B-cell lymphoma. B-cell lymphoma (2.5 × 106 cells) were
injected subcutaneously on day –2 in six mice, followed by the tail vein injection of 5 × 106
peripheral blood T cells in the treatment but not the control group.
We observed that the control mice receiving B-cell lymphoma without T cells (n = 3) had
tumour growth exceeding the threshold limit of 10 mm on day +27 after tumour inoculation,
and hence these mice were sacrificed. In mice receiving peripheral blood T cells, tumours
continued to grow until 3 weeks. On day +20, there was no statistically significant difference
between the tumours in the control and peripheral blood T-cell group (mean tumour
bioluminescence = 3.89 × 108 +/− 2.15 × 108 vs 5.69 × 108 +/− 1.69 × 108; P = NS). After 3
weeks, the tumours in mice receiving peripheral blood T cells started regressing [Figure 62].
We observed signs such as ruffled fur, lethargy, and, most importantly, the onset of weight
loss, an objective measure of xeno-reactivity correlated with the onset of tumour regression
[Figure 63]. This confirms that peripheral T cells also mediate a GvL effect in this model,
although this effect was apparent only against a lower burden of B-cell lymphoma. Thus,
compared with cord blood T cells, peripheral blood T cells appear to mediate an attenuated
anti-tumour effect correlating with the onset of xenogeneic GvHD.
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Figure 62: Tumour bioluminescence measured as photons/sec/cm^2/sr using Xenogen-IVIS.
All images are shown on one scale (range: 2.00e6 to 1.00e8 photons/sec/cm^2/sec). Tumour
regression was observed in the peripheral blood T cells with the onset of signs of GvHD
(weight loss, ruffled fur).
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Figure 63: GvL effect mediated by peripheral blood T cells (5 million) against a lower burden
of B-cell lymphoma (2.5 million tumour cells) and a correlation between xenoreactivity and
tumour regression following peripheral blood T-cell injection. (A) shows serial weekly
weight measurements of mice plotted as % of baseline weight (mean and standard error of
mean) on right y-axis and bioluminescence of tumour measured as photons/sec/cm^2/sr
(mean and standard error of mean) plotted on left y-axis. In this experiment with lower
burden of tumour cells, tumour regression correlated with the onset of weight loss, which is
an objective measure of xenoreactivity. This experiment suggests that peripheral blood T
cells also mediate tumour regression but this effect may be attenuated and typically occurs
with the onset of xenoreactivity.
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6.5 Anti-tumour effects of cord blood T cells are mediated through allo-reactivity
Lymphoblastoid tumour in our model is an EBV-driven lymphoma. Therefore, it was
imperative to determine the anti-tumour effect mediated by cord blood T cells is an anti-
leukaemic (allo-reactive) effect and not an anti-EBV effect.
To model this, autologous T cells were first sorted from the cord blood mononuclear cells and
stored in liquid nitrogen. The remaining population of cells which included the B cells, were
used to generate the lymphoblastoid cells as described in the methods. Subsequently
allogeneic T cells were sorted from the cord blood mononuclear cells of another donor and
stored in liquid nitrogen.
When the lymphoblastoid cells were generated, they were transduced with SFG retroviral
vector encoding green shifted F-Luc. F-Luc positive lymphoblastoid cells were sorted and
then grown to perform the experiment.
In this experiment, I compared the ability of autologous and allogeneic cord blood T cells to
reject B-cell lymphoma. Mice were injected with B-cell lymphoma (5 × 106 cells)
subcutaneously on day –2, followed by the tail vein injection of 5 × 106 stored autologous or
allogeneic T cells on day 0.
Control mice receiving B-cell lymphoma without T cells (n = 3) and mice receiving B-cell
lymphoma followed by autologous cord blood T cells (n = 5) had tumour growth exceeding
the threshold limit of 10 mm on day +22 after tumour inoculation and were therefore
sacrificed. In contrast, mice injected with B-cell lymphoma and allogeneic cord blood T cells
(n = 5) had slower tumour growth followed by complete tumour regression. On day +22, the
autologous cord blood T-cell group had a mean tumour volume (mm3) and mean tumour
bioluminescence (photons/sec/cm2/sr) of 1223 +/− 72 and 1.323 × 1011 +/− 2.53 × 1010,
respectively. In contrast to these large tumours, the mean tumour volume (mm3) and mean
tumour bioluminescence (photons/sec/cm2/sr) in the allogeneic cord blood T-cell group were
significantly lower, 12 +/− 6 and 1.797 × 109 +/− 1.09 × 109, respectively (P < 0.01) [Figure
64, 65 and 66).
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Figure 64: Representative experiment illustrates tumour regression in mice receiving
allogeneic cord blood T cells. Tumour size in mice receiving autologous cord blood T cells
exceeded 10 mm and hence these mice were sacrificed. This observation suggest that anti-
tumour effects against B-cell lymphoma is an allo-reactive effect, and not an EBV-specific
response. All images are shown on one scale (range: 1.00e8 to 1.00e9 photons/sec/cm^2/sr).
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Figure 65: Tumour bioluminescence (photons/sec/cm^2/sr) was measured using Xenogen-
IVIS. Rapid tumour regression in mice receiving allogeneic cord blood T cells was observed.
Cumulative rate of tumour growth (mean and standard error of mean) are plotted
181
Day 10 Day 20 Day 25 Day 300
20
40
60
80
100
800
1000
1200
1400
Control (LCLs only; n=3)
Auto CB T cells + LCLs (n=5)
Allo CB T cells + LCLs (n=5)
Tu
m
ou
rv
ol
um
e
(m
m
^3
)
Figure 66: Tumour volume (mm^3) was derived using calliper measurements. Rapid tumour
regression in mice receiving allogeneic cord blood T cells was observed. Cumulative rate of
tumour growth (mean and standard error of mean) are plotted.
At sacrifice, we performed flow-cytometry on the blood of the mice from the autologous and
allogeneic groups to confirm the survival of T cells. In both the groups circulating T cells
were present. In the allogeneic group CD4:CD8 ratio was 0.9 (0.7 to 1.2) and in the
autologous group CD4:CD8 ratio was 5.4 (4.7 to 5.6) [Figure 67]. This striking reversal of
CD4:CD8 ratio in the allogeneic group, in contrast with the CD4+ T-cell biased CD4:CD8
ratio in the autologous group indicates that allogeneic cord blood T cells mediate a CD8+ T-
cell response against the B-cell lymphoma. The autologous cord blood T cells failed to
mediate any anti-tumour effect confirming that the observed anti-tumour effect is not against
EBV antigens. Thus the observed tumour regression appears to be mediated through an allo-
reactive T-cell response rather than a HLA-restricted anti-EBV effect.
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Figure 67: Reversal of CD4:CD8 ratio was observed in allogeneic cord blood T cells and not
in the autologous cord blood T cells. This further indicated alloreactivity mediated by
allogeneic cord blood T cells (unpaired t-test; p<0.0001).
Further in the additional functional experiments described in the next chapter, we continued
to observe rapid regression of tumour in the cord blood T-cell group confirming enhanced
alloreactivity mediated by cord blood T cells [Figure 68].
183
Figure 68: Cumulative tumour volumes (standard error of mean) from additional functional
experiments. The tumour volumes were significantly lower in the mice injected with cord
blood T cells compared with those who received equivalent numbers of peripheral blood T
cells thus confirming increased alloreactive effect mediated by cord blood T cells (unpaired t-
test; p<0.0001).
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CONCLUSIONS
We have thus established a tumour model to study the allo-reactive effects of T cells. In this
model, we show that cord blood T cells mediate enhanced anti-tumour effects without
mediating xenogeneic GvHD. Xenogeneic GvHD was absent in the cord blood group 60 days
after the injection of T cells. The absence of xenogeneic GvHD occurred despite the presence
of circulating cord blood T cells at the end of experiment. The cord blood T cells did not
infiltrate GvHD target organs such as liver and skin.
In contrast, 5 × 106 peripheral blood T cells failed to mediate an anti-tumour effect against 5
× 106 B-cell lymphoma cells. However, 5 × 106 peripheral blood T cells mediated an anti-
tumour effect only against a lower burden of tumour i.e. 2.5 × 106 B-cell lymphoma cells.
This attenuated anti-tumour effect correlated with the onset of xenogeneic GvHD which
occurred 3 weeks after the injection of 5 × 106 T cells.
The enhanced anti-tumour effect in this EBV-driven tumour model was not directed against
the EBV antigens but was an anti-leukaemic (allo-reactive) effect.
Our observations were intriguing because we observed enhanced anti-tumour effects
mediated by cord blood T cells without xenogeneic GvHD. Although this an artificial tumour
model this nicely mimics the clinical transplant situation with generally less GvHD than adult
stem cell sources yet maintained or enhanced GvL effects, particularly in AML (Milano et
al., 2016). This suggests that cord blood T cells which are predominantly naïve undergo
memory-effector induction exclusively within the B-cell lymphoma and not in the target
GvHD organs of NOD/SCID/IL2rgnull mice. In contrast, peripheral blood T cells mediate
attenuated anti-tumour effect correlating with xenogeneic GvHD. Thus, peripheral blood T
cells can target both the tumour and target GvHD organs. Therefore, to further investigate the
immunological basis of the differential anti-tumour and xenogeneic GvHD mediated by cord
blood T cells and peripheral blood T cells we performed experiments to study recruitment of
tumour-infiltrating lymphocytes and memory-effector differentiation in the tumour and in
circulating lymphocytes.
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Chapter seven
Tumour-infiltrating cord blood T cells mediate
enhanced Tc1-Th1 immune responses compared to
tumour-infiltrating peripheral blood T cells
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7.0 Aims
1) To compare the kinetics of tumoural recruitment of cord blood and peripheral blood T cells.
2) To examine the role of T-cell regulation in differential anti-tumour effects mediated by cord
blood and peripheral blood T cells.
3) To study the memory-effector differentiation in the circulating and tumour-infiltrating cord
blood and peripheral blood T cells.
4) To compare the Tc1 induction and Th1/Th2 balance in the tumour-infiltrating cord blood
and peripheral blood T cells.
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7.1 Introduction
Cord blood T cells mediate enhanced anti-tumour effects compared to peripheral blood T cells.
Cord blood T cells are intrinsically Tc2-Th2 biased in their natural foetal and early neonatal
environment. However, in the context of allogeneic T-cell replete CBT the functionality of
cord blood T cells is not being tested. Therefore, the mechanism of robust anti-leukaemia effect
after T-cell replete approach is not known.
Cord blood T cells rapidly undergo memory-effector differentiation and mediate anti-viral
responses after T-cell replete CBT (Chiesa et al., 2012). Similarly, T-cell replete CBT
significantly reduces the risk of leukaemia relapse without increasing the risk of chronic
GvHD. These findings therefore raise questions about the robust anti-leukaemic effect
mediated by cord blood T cells infused with the cord blood graft. How do then these
intrinsically tolerant cord blood T cells mediate anti-leukaemic responses? Are there
differences in the recruitment of cord blood T cells to the tumour? After recruitment to the
tumour are there differences in the T-cell regulation of cord blood and peripheral blood tumour-
infiltrating T cells? Do cord blood and peripheral blood tumour-infiltrating T cells distinctly
orchestrate Th1 and Type 1 cytotoxic T cell responses?
In the subsequent experiments, I set out to identify the immunological basis of enhanced
tumour rejection by studying the tumour-infiltrating lymphocytes.
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7.2 Enhanced recruitment of cord blood T cells to the tumour may mediate a potent GvL
effect
To study the immunological basis of the differential anti-tumour effect following the injection
of cord blood and peripheral blood T cells, we first studied the differences in the recruitment
of tumour-infiltrating lymphocytes. In a separate tumour modeling experiment, mice were
injected with 5 × 106 B-cell lymphoma cells on day –2 followed by 5 × 106 cord blood (n = 5)
or peripheral blood T cells (n = 5) on day 0. All mice were then sacrificed on day +15 following
T cell injections, and tumour sections were studied.
Immunohistochemistry staining of tumour sections with CD3 antibody showed higher numbers
of tumour-infiltrating lymphocytes in the cord blood group compared with the peripheral blood
group [Figure 69].
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Figure 69: Contiguous tumour sections (10×) of cord blood and peripheral blood group stained
with CD3 and CD20 immuno-histochemical stain. Higher numbers of tumour-infiltrating CD3+
T cells was seen in the cord blood group compared with to the peripheral blood group.
Using Image J, tumour-infiltrating lymphocytes in 10 random 40× sections of each tumour
were quantified as TILs/mm2. The 10 RGB images of 40× magnification for each tumour slide
were converted to black and white mask output using a calibrated threshold for each stack of
images. The black output areas corresponding to the CD3 immuno-histochemical staining
defined in the mask were outlined and measured in square microns.
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Representative RGB mask and outline images of peripheral blood and cord blood group are
shown in this figure 70. The number of infiltrating T cells in each 40× image of 94901 square
microns were calculated as = Total out-lined area/Area of T-cell.
Figure 70: Ten RGB images of 40x magnification for each tumour slide were converted to
black and white mask output using a calibrated threshold for each stack of images. The black
output areas corresponding to the CD3 immuno-histochemical staining defined in the mask
were outlined and measured in square microns. Representative RGB, mask and outline images
of peripheral blood and cord blood group are shown in this figure. The number of infiltrating
T cells in each 40x image of 94901 square microns were calculated as = Total out-lined
area/Area of T-cell. The number of infiltrating T cells per mm2 was derived for each image to
determine the average density of T cells per mm2 of tumour.
The number of infiltrating T cells per mm2 was derived for each image to determine the average
density of T cells per mm2 of tumour. A significantly higher number of tumour-infiltrating were
observed in the cord blood group compared to the peripheral blood group (4702 +/− 426 vs
1275 +/− 330; P < 0.01) [Figure 71]. This suggests that cord blood T cells are preferentially
recruited to the tumour compared to peripheral blood T cells.
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Figure 71: Density of tumour-infiltrating T cells per mm2 (shown as scatter dot plot with
median and inter-quartile range) was significantly higher in the cord blood group than in the
peripheral blood group (unpaired t-test; p<0.0002).
Interestingly, flow-cytometric analysis of isolated tumour-infiltrating lymphocytes showed that
a majority of tumour-infiltrating lymphocytes in the cord blood group were CD8+ T cells, with
a median CD4:CD8 ratio of 0.49 (range, 0.47–0.58). In contrast, CD4+ T cells were
predominant in the peripheral blood group, with a median CD4:CD8 ratio of 1.72 (range, 1.60–
1.88; P < 0.01). This inversion of CD4:CD8 ratio in the cord blood tumour-infiltrating
lymphocytes was observed despite a higher initial CD4:CD8 ratio in the injected cord blood T
cells compared with the injected peripheral blood T cells (4.9 vs 2.9) [Figure 72].
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Figure 72: A significantly lower CD4:CD8 ratio was observed in cord blood TILs compared
with peripheral blood TILs suggesting higher numbers of CD8+ T cells infiltrated the tumour
in the cord blood group.
This suggests that preferential tumoural recruitment of cord blood T cells with a CD8+ T-cell
bias may primarily mediate anti-tumour effects in this human-murine chimeric model.
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7.3 Enhanced recruitment of cord blood TILs to the tumour occurs with CD8+ T cell bias
and significantly higher CD8:CD4 and CD8:CD4+ T-regulatory cells ratio
To further gain insight into the kinetics of infiltration of cord blood and peripheral blood T
cells in this B-cell tumour and the role of T-cell regulation in this, we compared the infiltration
of CD4+, CD8+, and CD4+ CD25+ FoxP3+ T-regulatory cells on day +10 and day +20 after T
cell injections. In a separate experiment, we injected B-cell lymphoma (5 × 106 cells)
subcutaneously on day –2, followed by 5 × 106 cord blood or peripheral blood T cells on day
+0 in 8 mice each. Ten and 20 days after T-cell injections, four mice from each group were
sacrificed, and isolated tumour-infiltrating lymphocytes were studied for CD4:CD8 and
CD8:CD4+ T-regulatory cells ratio [Figure 73]. As previously observed, the CD4:CD8 ratio in
the cord blood tumour-infiltrating lymphocytes was significantly reversed compared to
peripheral blood tumour-infiltrating lymphocytes. This was despite a higher initial CD4:CD8
ratio in the injected cord blood T cells compared to the injected peripheral blood T cells (3.4
vs 2.7). At day +10 and day +20 after T-cell injection, the median CD4:CD8 ratio in the cord
blood tumour-infiltrating lymphocytes was 0.58 (range, 0.51–0.69) and 0.03 (range, 0.03–
0.06), respectively, compared with a median ratio of 1.54 (range, 1.3–1.9) and 0.26 (range,
0.14–0.33) in the peripheral blood tumour-infiltrating lymphocytes (P < 0.001 and P < 0.001,
respectively) [Figure 74].
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Figure 73: (a) Representative plots of CD4+ and CD8+ T cells and (b) CD4+CD25+Foxp3+T
cells at injection and in tumour-infiltrating lymphocytes (TILs) on day +10 and day +20.
(a) (b)
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Figure 74: Line graph showing significantly lower CD4:CD8 ratio in cord blood group
compared to peripheral blood group on day +10 (unpaired t-test; p=0.0003) and day +20
(unpaired t-test; p=0.004) plotted on log-scale as median and inter-quartile-range.
The above finding also correlated with a significantly higher CD8:CD4+ CD25+ FoxP3+ ratio
in the cord blood tumour-infiltrating lymphocytes compared to peripheral blood tumour-
infiltrating lymphocytes both at day +10 and day +20 after T-cell injection [Figure 73 and 75].
At day +10 and day +20 after T-cell injection, the median CD8:CD4+ CD25+ FoxP3+ ratio in
the cord blood tumour-infiltrating lymphocytes was 29 (range, 25–52) and 2043 (range, 950–
3288) respectively, compared with a median ratio of 11.9 (range, 7.8–15.5) and 132 (range,
72–166) in the peripheral blood tumour-infiltrating lymphocytes (P < 0.01 and P < 0.01,
respectively) [Figure 75].
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Figure 75: Line graph showing significantly higher CD8:CD4+ T-regulatory ratio in cord blood
group compared toperipheral blood group on day +10 (unpaired t-test; p=0.01) and day +20
(unpaired t-test; p=0.008) plotted on log-scale as median and inter-quartile-range.
This differential kinetics of T-cell infiltration indicate that, whilst cord blood CD8+ T cells may
be the primary mediators of the enhanced GvL effect in the cord blood group, a relatively
increased tumoural recruitment of T-regulatory cells may attenuate the GvL effect in the
peripheral blood group.
7.4 CCR7 enriched cord blood CD8+ T cells have enhanced tumour-homing ability
Since the vast majority of cord blood CD8+ T cells are CCR7high [Figure 76] and CCR7 is a
homing receptor for naïve T cells (De Waele et al., 1988; Zhao et al., 2002; Förster et al.,
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1999), we sought to identify if CCR7+ CD8+ T cells predominantly infiltrate the tumour. We
observed that CCR7 expression was similar in cord blood and peripheral blood CD8+ TILs
(median fluorescence intensity; MFI = 6854 +/– 1542 vs 6737 +/– 1626; p = NS). CCR7 MFI
expression was significantly higher in TILs compared with circulating peripheral blood CD8+
T cells (1378 +/– 10; P < 0.01), whilst circulating cord blood CD8+ T cells remained CCR7high
(MFI = 21128 +/– 534) [Figure 77 (a) and (b)]. This indicates that CCR7high CD8+ T cells were
primarily recruited to the tumour and higher expression of CCR7 may endow cord blood CD8+
T cells with the enhanced tumour-homing ability.
Figure 76: Normal donor cord blood CD8+ T
cells have significantly higher expression of
CCR7 compared with normal donor peripheral
blood CD8+ T cells (expressed as mean and
standard error of mean; n = 3 in each group;
unpaired t-test; P < 0.005).
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Figure 77: (a) Offset histogram plot
and (b) is cumulative bar plot (mean
and standard error of mean) showing
fluorescence intensity of CD8+ T cells
from normal donors, tumour-
infiltrating lymphocytes (TILs) and in
circulation.
This figure indicates that CCR7high
CD8+ T cells are primarily recruited
to the tumour in the both the groups (p
= NS), and in the peripheral blood
group CCR7low CD8+ T cells remain
in circulation (unpaired t-test; P <
0.01) indicating a role of CCR7
mediated chemotaxis in this tumour
model.
(a)
(b)
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7.5 Tumour-infiltrating naïve cord blood T cells rapidly differentiate into memory and
effector cells
In order for naïve cord blood T cells infiltrating the tumour to provide anti-tumour effects, they
must undergo memory-effector differentiation. We performed similar tumour modelling
experiments and to study whether cord blood T cells undergo memory-effector differentiation
at early time-points, mice in the cord blood group (n = 4) and peripheral blood group (n = 4)
were sacrificed 15 days after T-cell injections.
We observed that tumour-infiltrating lymphocytes in the cord blood group rapidly underwent
memory-effector differentiation, whereas circulating cord blood lymphocytes remained naïve
[Figure 78 and 79]. A similar percentage of CD8+ tumour-infiltrating lymphocytes were
observed to have a central memory (CM) and effector memory (EM) phenotype in both groups
(CM = 77.8 +/− 1.4 vs 78.0 +/− 1.8; EM = 1.48 +/− 0.3 vs 2.1 +/− 0.5; P = NS). Interestingly,
compared with peripheral blood tumour-infiltrating lymphocytes, a significantly higher
percentage of circulating lymphocytes in the peripheral blood group was found to have an
effector memory phenotype (2.1 +/− 0.5 vs 8.5 +/− 0.6; P < 0.0001) [Figure 78 and 79].
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Figure 78: Representative flow-cytometry plots of CD8+ T cells infused on day 0, CD8+
tumour-infiltrating lymphocytes and CD8+ circulating lymphocytes. Rapid switching of naïve
cord blood CD8+ T cells to memory/effector T cells was observed in the tumour
microenvironment whilst most circulating cord blood lymphocytes remained naïve.
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Figure 79: Comparison of median percentages of naive, central memory and effector memory
subsets in tumour-infiltrating (TILs) and circulating lymphocytes (CLs) on day +15 after T-
cell injection. Naive cord blood T cells rapidly switched to memory/effector phenotype in the
tumour, however circulating cord blood lymphocytes remained naive. Similar percentage of
CD8+ TILs had central memory and effector memory phenotype in both groups (p = NS).
Interestingly in the peripheral blood group, significantly higher percentage of CLs had an
effector memory phenotype compared to TILs (unpaired t-test; P < 0.0001).
Thus, naïve cord blood T cells were rapidly and selectively observed to undergo memory-
effector differentiation in this human B-cell tumour, but not in the periphery of the
NOD/SCID/IL2rgnull model.
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7.6 Naïve cord blood T cells rapidly gain IFN-γ and TNF-α effector function 
Finally, to study the differences in the effector functions gained by tumour-infiltrating
lymphocytes in the two groups, we performed similar tumour modeling experiments. In this
experiment, we allowed the tumours to grow over the previous threshold limit of 10 mm after
having obtained the permission from home office on a renewed license allowing the tumour
growth of 15 mm. This was necessary because we chose to study the effector function of
tumour-infiltraing lymphocytes at the onset of tumour regression. Mice in the cord blood group
(n = 5) never exceeded the previous threshold of 10 mm and started to regress on day +20,
whilst mice in peripheral blood group (n = 5) exceeded 10 mm size and then started to have
tumour regression on day +26. Mice in both the groups were therefore sacrificed on day +26
after the injection of T cells, and tumour-infiltrating lymphocytes were studied for cytokine
responses after a 6-hour in vitro re-challenge with lymphoma cells from the same donor.
Isolated tumour-infiltrating lymphocytes were also studied for perforin expression.
CD8+ tumour-infiltrating lymphocytes in both the groups demonstrated IFN-γ responses; 
however, despite cord blood T cells being naïve, there was no difference in the percentage of
CD8+ tumour-infiltrating lymphocytes expressing IFN-γ responses in the two groups (3.5 +/− 
0.14 vs 3.4 +/− 0.15; P = NS) [Figure 80].
Figure 80: Representative flow-cytometry plots and cumulative bar-plots (mean and standard
error of mean) of percentages of cord blood and peripheral blood CD8+ TILs secreting IFN-γ. 
No statistically significant differences were observed in the percentage of IFN-γ secreting 
CD8+ TILs in the two groups.
In contrast, a significantly higher percentage of cord blood CD8+ tumour-infiltrating
lymphocytes acquired TNF-α responses (1.2 +/− 0.07 vs 0.48 +/− 0.06; P < 0.0001) [Figure
81].
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Figure 81: Representative flow-cytometry plots and cumulative bar-plots (mean and standard
error of mean) of percentages of cord blood and peripheral blood CD8+ TILs secreting TNF-α. 
A significantly higher percentages of CD8+TILs in the cord blood group secreted TNF-α 
(unpaired t-test; p<0.0001).
Interestingly, a significantly higher percentage of cord blood CD8+ tumour-infiltrating
lymphocytes acquired dual IFN-γ+ TNF-α+ functions compared with peripheral blood CD8+
tumour-infiltrating lymphocytes (1.0 +/− 0.08 vs 0.5 +/− 0.06; P < 0.001) [Figure 82].
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Figure 82: Representative flow-cytometry plots and cumulative bar-plots (mean and standard
error of mean) of percentages of cord blood and peripheral blood CD8+ TILs secreting IFN-
γ+TNF-α+ cells are shown. Higher percentage of cord blood CD8+ T cells were polyfunctional
secreting dual cytokines compared to peripheral blood CD8+ T cells (unpaired t-test; p<0.001).
The perforin expression was measured as median fluorescence intensity (MFI) and the
percentage of CD8+ T cells was also significantly higher in cord blood CD8+ tumour-
infiltrating lymphocytes compared with peripheral blood CD8+ tumour-infiltrating
lymphocytes (MFI = 443 +/− 7 vs 365 +/− 6; percentage of CD8+ T cells = 75 +/− 1.3 vs 58
+/− 2.2; P < 0.01) [Figure 83].
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Figure 83: Representative flow-cytometry plots and cumulative bar-plots (mean and standard
error of mean) of percentages of cord blood and peripheral blood CD8+ TILs with perforin
expression shown as percentage of perforin+ cells and MFI.
We also studied effector functions gained by CD4+ tumour-infiltrating lymphocytes to gain
insight into the role of intra-tumoral Th1/Th2 balance on differential anti-tumour effects. CD4+
tumour-infiltrating lymphocytes were identified as IFN-γ or TNF-α secreting Th1 cells and IL-
4 secreting Th2 cells. Intra-tumoural Th1/Th2 balance was quantified by IFN-γ/IL-4 and TNF-
α/IL-4 ratios. A significantly higher percentage of CD4+ tumour-infiltrating lymphocytes were
identified as Th2 tumour-infiltrating lymphocytes in the peripheral blood group compared with
the cord blood group (16 +/− 0.9 vs 6.2 +/− 0.4; P < 0.001) [Figure 84]. Th1/Th2 balance
measured by IFN-γ/IL-4 and TNF-α/IL-4 ratios were significantly biased towards Th1 in the 
cord blood group compared with the peripheral blood group (0.98 +/− 0.09 vs 0.3 +/− 0.02 and 
0.88 +/− 0.02 vs 0.39 +/− 0.03; P < 0.05 and P < 0.0001, respectively) [Figure 85].
Figure 84: Representative flow-cytometry plots and cumulative bar plots (mean and standard
error of mean) of IL-4 secreting CD4+ T cells are shown. A significantly higher percentage of
CD4+ peripheral blood TILs were IL-4 secreting (plotted as mean and standard error of mean)
and hence Th2 biased compared to CD4+ cord blood TILs (unpaired t-test; p<0.0001).
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Figure 85: Representative flow-cytometry plots of IFN-γ and TNF-α secreting cord blood and 
peripheral blood CD4+ TILs and bar plots of Th1/Th2 ratio (plotted as mean and standard error
of mean) is shown. Higher Th1/Th2 ratio was observed in the cord blood TILs compared to
peripheral blood TILs. (Th1/Th2 ratio was calculated as the ratio of IFN-γ/IL-4 and TNF-α/IL-
4).
This suggests that naïve cord blood T cells can swiftly gain cytotoxic effector functions in the
tumour microenvironment; in particular, cord blood T cells were observed to gain higher TNF-
α and perforin activity compared with the peripheral blood T cells.
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7.7 CONCLUSIONS
We have shown that cord blood T cells rapidly infiltrate the tumour compared to peripheral
blood T cells. This tumoural infiltration of T cells in the cord blood group was particularly
biased towards CD8+ T cells both at early and late time points. In contrast, significant delay of
CD8+ T-cell tumoural infiltration was observed in the peripheral blood group. This differential
infiltration of cord blood and peripheral blood CD8+ T cells was observed in three separate
experiments. Together with the differential infiltration of CD8+ T cells in the two groups and
preponderance of CD4+ T-regulatory cells in the peripheral blood group may explain the
differences in anti-tumour effects mediated by cord blood T cells and peripheral blood T cells.
Although cord blood T cells are predominantly naïve, we not only observed rapid tumoural
infiltration of these naïve cord blood T cells, but these naïve cord blood tumour-infiltrating T
cells rapidly differentiated in to memory-effector T cells. The percentage of tumour-infiltrating
T cells that underwent memory-effector differentiation was similar in both the groups. The
rapid tumoural infiltration of cord blood T cells together with swift memory-effector
differentiation of tumour-infiltrating cord blood T cells may further explain the robust anti-
tumour effects mediated by cord blood T cells.
The swift memory-effector differentiation of tumour-infiltrating cord blood CD8+ T cells led
to a robust cytotoxic response. The percentage of tumour-infiltrating cord blood and peripheral
blood CD8+ T cells demonstrated similar IFN-γ responses. However, compared with tumour-
infiltrating peripheral blood CD8+ T cells a significantly higher percentage of tumour-
infiltrating cord blood CD8+ T cells demonstrated TNF-α responses. Our most interesting 
finding was significantly higher percentages of cord blood CD8+ T cells mediating dual IFN-γ 
and TNF-α responses compared with peripheral blood CD8+ T cells. Similarly, higher
percentages of tumour-infiltrating cord blood CD8+ T cells expressed perforin compared with
peripheral blood CD8+ T cells.
Similar to the robust Tc1 induction of tumour-infiltrating cord blood CD8+ T cells, CD4+ T-
cell induction also supported the cytotoxicity with a Th1/Th2 balance skewed towards Th1
induction. We observed that cord blood CD4+ tumour-infiltrating T cells were biased towards
cytotoxic IFN-γ and TNF-α responses whereas peripheral blood CD4+ tumour-infiltrating T
cells were biased towards immunosuppressive IL-4 responses.
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In contrast to the cord blood tumour-infiltrating lymphocytes, circulating cord blood T cells
did not undergo memory-effector differentiation whereas circulating peripheral blood T cells
underwent differentiation with an effector phenotype. This finding corroborates with the
absence of xenogeneic GvHD in the cord blood group and presence of severe GvHD in the
peripheral blood group.
To summarise, in this model cord blood T cells selectively mediate a cytotoxic response in the
tumour environment where as peripheral blood T cells mediate cytotoxicity against the tumour
and target GvHD organs. The findings that cord blood T cells mediated an enhanced anti-
tumour effect without exhibiting xenogeneic GvHD parallel the clinical situation in humans
where CBT may exert a powerful GvL effect yet with reduced rates of GvHD.
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Chapter eight
Discussion
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Discussion
T-cell reconstitution after HCT occurs via thymus-dependent, and thymus-independent
pathways (Mackall et al., 1997; Williams et al., 2007). Thymus dependent T-cell
reconstitution, i.e., thymopoiesis occurs late, typically three to six months following
transplantation, and results in the generation of new naïve T cells (Fallen et al., 2003). In
contrast, thymus-independent T-cell reconstitution occurs early, through the expansion of T
cells carried with the graft. This may be driven by exposure to antigens and / or expansion of
donor lymphocytes into a lymphopenic environment. This latter type of T-cell reconstitution
is termed ‘lymphopenia-induced proliferation’ (Mackall et al., 1996; Mackall et al., 1997; Ge
et al., 2002). The relative contribution of each pathway in replenishing the peripheral T-cell
pool after HCT depends on the conditioning regimens. In particular, in vivo T-cell depleting
regimens have a significant effect on early thymus-independent proliferation.
In the context of unrelated CBT, ATG is used for in vivo T-cell depletion. It is now well
established that in vivo T-cell depleting regimens lead to a significant delay in immune-
reconstitution after CBT (Komanduri et al., 2007; Lindemans et al., 2014; Renard et al.,
2011). Research has indicated that CBT not only results in prolonged T-cell lymphopenia but
also with impaired thymopoiesis, and skewing of late memory T cells (Komanduri et al.,
2007). This greatly increases the risk of viral mediated infections and mortality.
Omission of in vivo T-cell depletion from the conditioning regimens facilitates the restoration
of adaptive immunity through thymus-independent T-cell immune-reconstitution. This form
of conditioning regimen is employed for conditioning HLA-matched sibling transplants in the
context of chemotherapy-resistant leukaemia. Recently, such an approach has also been used
for the conditioning of unrelated cord blood grafts because of the low risk of GvHD (Chiesa
et al., 2012; Sauter et al., 2011).
When we omitted ATG from the cord blood grafts, we observed an unexpected thymus-
independent CD4+ T-cell biased reconstitution (Chiesa et al., 2012). In addition, we observed
normal T-cell spectratype as early as 30 days post T-cell-replete CBT, which is in contrast to
the previous reports of a skewed T-cell repertoire after T-cell-deplete CBT (Komanduri et al.,
2007). T-cell reconstitution after T-cell-replete CBT was superior to T-cell reconstitution
after T-cell-replete BMT [Figure 13]. Furthermore, the T-cell reconstitution after CBT was
always CD4+ T-cell biased, compared to the well-recognised CD8+ T-cell biased
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reconstitution observed during lymphocyte recovery, after BMT (Mackall et al., 1995; Hakim
et al., 1997; Trzonkowski et al., 2008; Unsinger et al., 2009; Cieri et al., 2015). This
observation suggests a uniquely distinct ability of cord blood CD4+ T cells to expand rapidly
in the post-transplant lymphopenic environment producing a diverse T-cell repertoire.
Thymic-independent T-cell expansion, following allogeneic stem cell transplantation is
mediated by three processes, (1) lymphopenia-induced proliferation, (2) anti-viral expansion
and (3) allo-reactive expansion.
1) Lymphopenia-induced proliferation: Non-host reactive donor T cells proliferate in
response to self-MHC Class I and II molecules and / or cytokines, such as IL-7 or IL-
15, and contribute to a beneficial peripheral T-cell reconstitution (Mackall et al.,
1996; Mackall et al., 1997; Ge et al., 2002).
2) Antiviral expansion: Proliferation of virus-specific T cells in response to viral
reactivation.
3) Allo-reactive expansion: Host-reactive donor T cells proliferate in response to allo-
antigens, causing GvHD. Allo-reactive expansion depends on the recognition of
MHC:antigen complex by the T-cell receptor, engagement of co-stimulatory
molecules, and clonal expansion of T cells. The most well characterized co-
stimulatory molecule is the CD28/B7 family (Acuto et al., 2003). However, several
members of the tumour necrosis factor receptor (TNFR) superfamily - OX40, CD40,
4-1BB, CD27, CD30, and HVEM (herpes-virus entry mediator) – are being
recognized as having a role in providing co-stimulation that is distinct to that of
CD28/B7 (Croft et al., 2003). The allo-reactive expansion is largely inhibited by
immunosuppression, following HCT, and thus lymphopenia-induced proliferation is
likely to be the primary mechanism in replenishing the lymphopenic environment.
Thus, it is plausible that the process of lymphopenia-induced proliferation could
mediate enhanced immune-reconstitution observed after T-cell replete CBT.
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Rapid CD4+ T-cell biased immune-reconstitution following cord blood
transplantation, may be driven by upregulated homeostatic mechanisms
To study the differences in T-cell homeostasis, following cord blood and bone marrow grafts,
we compared early T-cell immune-reconstitution in children (age range 0.1 to 12 years)
receiving cord blood (n = 30) and bone marrow transplantation (n = 40). We observed
enhanced and early T-cell reconstitution following CBT. The early T-cell reconstitution after
CBT was interestingly asymmetrically CD4+ T-cell biased, especially at early time-points. In
contrast, early T-cell reconstitution after BMT was CD8+ T-cell biased, and relatively slow
(Fallen et al., 2003; Fujimaki et al., 2001). The enhanced T-cell immune-reconstitution after
CBT occurred despite one log fewer T cells infused in the cord blood grafts, compared to the
bone marrow grafts [Figure 12].
The robust CD4+ T-cell expansion of cord blood T cells could be because cord blood T cells
may expand with a bias towards one particular Th subset. To identify if one particular Th
subset was expanding after CBT, I performed phenotyping of reconstituting CD4+ T cells at
one, three and six months, following CBT and BMT. A significantly increased percentage of
T-regulatory cells, particularly one month after CBT compared to BMT was observed.
However, by six months, the increased percentage of T-regulatory cells had gradually
reduced to levels similar to those of post-BMT. The T-regulatory bias, early after CBT, was
observed despite there being a similar proportion of T-regulatory cells in normal donor cord
blood and adult peripheral blood (Kim et al., 2012; Takahata et al., 2004). The early increase
in circulating regulatory T cells after CBT is an interesting finding, and perhaps reflects the
rapid expansion of T-regulatory cells, or induction of T-regulatory phenotype, following cord
blood graft. Despite the increased numbers of T-regulatory cells after CBT, the majority of
CD4+ T cells are non-regulatory cells, and hence this does not explain the enhanced CD4+ T-
cell biased expansion after CBT. We also found that a substantial number of T cells
underwent differentiation to memory T cells, as early as 30 days post-CBT (Chiesa et al.,
2012). It is well known that during lymphopenia-induced proliferation, naïve T cells acquire
a memory-like phenotype, and hence, the rapid conversion of naive cord blood T cells to a
memory phenotype suggests the role of homeostatic mechanisms in the rapid post-CBT T-
cell expansion (Surh et al., 2008; Takada et al., 2009; Hamilton et al., 2006).
Complex homeostatic mechanisms regulate the peripheral T-cell pool. Whilst naive T cells
are maintained by IL-7 and signalling from MHC-TCR contact, the memory T-cell
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population is heterogeneous, and comprised of cells derived from responses to both foreign
and self-antigens. Typical memory cells are kept alive, and induced to divide intermittently,
by IL-7 and IL-15 (Boyman et al., 2009). Therefore, to determine whether the post-CBT T-
cell reconstitution is due to similar mechanism, decline in IL-7 levels post-CBT and post-
BMT were compared. Higher day+30 IL-7 levels were observed in cord blood recipients
compared to bone marrow recipients. More interestingly, the high day+30 IL-7 levels in the
CBT recipients declined rapidly by day+90. The higher day+30 IL-7 levels in cord blood
recipients compared with bone marrow recipients, could reflect the profound lymphopenic
environment, due to low numbers of T cells carried with the cord blood graft, as previously
described. It also suggests that the cord blood T cells are likely to be exposed to high levels
of IL-7 in vivo for a longer period of time. The rapid decline in IL-7 after CBT by day+90
suggests that the T-cell expansion after CBT could be mediated by IL-7, a cytokine known to
a role in T-cell homeostasis.
I therefore tested whether cord blood CD4+ T cells are overly sensitive to homeostatic signals
by comparing the proliferation of cord blood T cells and peripheral blood T cells to IL-7, IL-
15 and IL-2 using a CFSE dilution assay. Cord blood CD4+ T cells proliferated rapidly
compared to peripheral blood CD4+ T cells in the presence of supra-physiologic IL-7
concentration and showed some response to IL-15 but no response to IL-2. This hyper-
responsiveness of cord blood CD4+ T cells to IL-7 has also been reported by Schonland et al.,
(Schonland; et al., 2003). Thus, cord blood T cells appear to be more sensitive to homeostatic
signals, compared to peripheral blood T cells, albeit at a supra-physiological dose.
In order to understand how this hyper-responsiveness to IL-7 was mediated, we studied the
differences in the IL-7 pathway using flow-cytometry. IL-7 receptor-alpha expression, an
upstream molecule of the IL-7 pathway, was highly expressed in cord blood CD4+ T cells
compared with peripheral blood CD4+ T cells. Despite the higher expression of IL-7 receptor
in the cord blood CD4+ T cells, differential phosphorylation of the most relevant downstream
molecule of IL-7 pathway (STAT5) was not observed. Thus, whilst cord blood CD4+ T cells
express higher levels of IL7R-alpha than peripheral blood CD4+ T cells, the differences in
proliferation seen between cord blood and peripheral blood CD4+ T cells are not explained by
STAT5 phosphorylation. Similar findings to these have been reported previously by
Swainson et al (Swainson et al., 2007). In addition, the group also studied the proliferation of
cord blood CD4+ T cells using 1 ng/ml of IL-7, and found that despite optimal STAT5
phosphorylation, after five days, only 10% of cord blood CD4+ T cells entered cell cycle after
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5 days. These finding suggests that mechanisms and/or biological processes other than the IL-
7:STAT5-dependent signalling cascade may contribute to the rapid proliferation of cord
blood CD4+ T cells. Therefore, I studied the differences in TCR signalling between cord
blood and peripheral blood CD4+ T cells.
Allogeneic EBV-driven B-cell lymphoblastoid cells were used to provide strong MHC
signals because they express MHC Class I and Class II molecules. After stimulation with
irradiated allogeneic lymphoblastoid cells, 80% of cord blood CD4+ T cells entered cell cycle
and proliferated rapidly, compared with only 20% of peripheral blood CD4+ T cells. This
indicates that cord blood CD4+ T cells are hyper-responsive to MHC signals compared to
peripheral blood CD4+ T cells.
The predominant CD4+ T-cell population in cord blood is naïve, and the hyper-
responsiveness of cord blood CD4+ T cells may be a function of their naivety. To determine
whether naivety mediates enhanced responsiveness to MHC signals, CD45RA+ enriched
fractions of CBMC and PBMC were stimulated with allogeneic EBV-driven B-cell
lymphoblastoid cells. The proliferative responses of CD4+ T cells in the CD45RA+ enriched
fractions were similar to those in unselected CBMC and PBMC fractions. Although, the
CD45RA-enriched T cells may have some effector cells, similar proliferation observed in
CD45RA-enriched T cells after stimulation with allogeneic LCLs suggested the hyper-
responsiveness of cord blood CD4+ T cells was not due to naivety but due to lower TCR
signalling threshold of cord blood CD4+ T cells.
Summary
The experiments described in chapter three indicate that although robust CD4+ T-cell biased
immune-reconstitution occurs after CBT, the majority of CD4+ T cells are not regulatory.
During T-cell reconstitution, naïve cord blood T cells rapidly differentiate in to memory T
cells, accompanied by a rapid decline in IL-7 levels. Therefore, the differences in sensitivity
of cord blood and peripheral blood CD4+ T cells to IL-7 were tested. Although, cord blood
CD4+ T cells had higher expression of IL7R-alpha, and were significantly more sensitive than
peripheral blood CD4+ T cells to a supraphysiological dose of IL-7, STAT5 phosphorylation
of cord blood and peripheral blood CD4+ T cells at varying concentrations of IL-7 was
similar. As this observation does not explain how the IL-7:STAT5 signalling cascade
mediates enhanced post-CBT T-cell reconstitution, the role of TCR signalling in enhanced
post-CBT T-cell reconstitution was tested. Cord blood CD4+ T cells were hyper-responsive to
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allogeneic MHC signals compared with peripheral blood CD4+ T cells, suggesting the lower
threshold for TCR signalling in cord blood CD4+ T cells could explain the robust CD4+ T-cell
reconstitution. These observations also suggest that the T cells derived from the immune
system carried with the foetal-derived cord blood graft may be distinctly regulated.
Foetal and adult lymphocytes in birds, humans, and other, mammals have been described as
having distinct ontogeneic origins (Morrison et al., 1995; Zanjani et al., 1993; Harrison et al.,
1997; Ikuta et al., 1990; Montecino-Rodriguez et al., 2006; Havran et al., 1998; Mold et al.,
2010). Foetal lymphocytes carried with the cord blood graft may have an enhanced ability to
fill the immunological void through processes involved in lymphopenia-induced
proliferation, such as TCR and cytokine signalling, and hence display distinct reconstitution
kinetics following CBT. I, therefore, set out to establish whether the early adaptive immune
system derived after T-cell-replete CBT recapitulates foetal ontogeny in a manner that is
distinct to that of adult ontogeny following T-cell-replete BMT, and if so, whether
upregulation of distinct cell signalling and biological processes during the recapitulation of
foetal ontogeny explains the enhanced lymphopenia-induced proliferation following CBT.
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T-cell replete cord blood transplantation recapitulates foetal ontogeny with
a distinct molecular signature that supports CD4+ T-cell reconstitution
There is growing evidence that supports the distinct ontogenic origins of foetal and adult
lymphoid systems (Mold et al., 2010; Copley et al., 2013; Yuan et al., 2012). Therefore, to
study the effect of foetal ontogeny on T-cell replete CBT, gene expression profiling was
performed on naïve CD4+ T cells from (1) normal donor cord blood, (2) normal donor
peripheral blood, and (3) transplant recipients two months after receiving a T-cell-replete
cord blood or (4) bone marrow graft. The gene expression profiles were compared with naïve
CD4+ T cells from foetal lymph nodes. These studies provided compelling evidence for
transcription profiles of naïve CD4+ T cells from cord blood, and during early reconstitution
following CBT, being distinct to those from peripheral blood. The cord blood T-cell profiles
were similar to the naïve CD4+ T cells from foetal lymph nodes. In contrast, the
reconstituting naïve CD4+ T cells following T-cell replete BMT, had a transcription profile
similar to the peripheral blood CD4+ T cells.
Foetal ontogeny is biased towards T-regulatory function (Silverstein et al., 1964a; Silverstein
et al., 1964b; Michaelsson et al., 2006; Takahata et al., 2004). I therefore compared the
relationship between naïve CD4+ T cells and T-regulatory cells from foetal lymph nodes and
adults. In a 2D-PCA analysis, naïve CD4+ T cells and T-regulatory cells segregated,
depending on their developmental stage and T-cell phenotype. Thus, the distinct profile of
naïve CD4+ T cells early post-CBT is due to the recapitulation of foetal ontogeny, and not
due to adoption of a T-regulatory phenotype. It is well established that foetal lymphopoiesis
originates from Lin28b+ HSCs, and postnatally, Lin28b is down-regulated, resulting in let-7
miRNA biogenesis and an adult lymphoid program. Thus, the difference in robustness of T-
cell immune-reconstitution observed after T-cell replete CBT compared with T-cell replete
BMT, may be due to the distinct foetal-like transcription profile of cord blood T cells
originating from Lin28b+ HSCs, whereas peripheral blood T cells have a let-7 miRNA
mediated adult-like transcription profile.
To establish whether the differences in transcription profiles explain the differences in
regulation of T-cell homeostasis, the differentially expressed genes in the naïve CD4+ T cells
from the cord blood and peripheral blood were identified. In three separate experiments, the
gene expression profiles of naïve CD4+ T cells from cord blood and peripheral blood were
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compared. Sixty genes overlapped in the three experiments. These 60 genes are therefore
likely to represent the signature of cord blood CD4+ T cells.
Cord blood T cells are in a highly proliferative state driven by the relatively lymphopenic
environment of the foetus (Schonland et al., 2003; van der Windt et al., 2012; Min et al.,
2003). Therefore, it was speculated that cord blood T cells may be enriched with genes
induced during lymphopenia-induced proliferation. To identify these genes, the expression
profiles of steady-state naïve CD4+ T cells from peripheral blood were compared with those
from reconstituting naïve CD4+ T cells following T-cell replete BMT. Nineteen of the 60
overlapping genes representing the ‘signature’ of naïve cord blood CD4+ T cells were also
differentially expressed in reconstituting naïve peripheral blood CD4+ T cells following T-
cell replete BMT. These 19 differentially expressed genes remained differentially expressed
in the reconstituting naïve CD4+ T cells following T-cell replete CBT. The up- or down-
regulation of all 19 genes was higher in the post-CBT reconstituting naïve CD4+ T cells than
in the post-BMT cells. Thus, the differential regulation of these 19 genes in the post-
transplant lymphopenic environment indicates their role in lymphopenia-induced
proliferation, and the remaining 41 genes are likely to represent the rest of the foetal
signature. Interestingly, of these 19 genes, fos and jun (AP-1 complex) were amongst the
most up-regulated genes. Together, fos and jun, form an AP-1 complex, and are two
important transcription factors that are activated, upon ligation of TCR, and represent a
convergence point of several TCR-initiated signalling pathways (Brownlie et al., 2013).
Importantly, AP-1 complex was found to be upregulated during all the lymphopenic states.
AP-1 complex was found to be more significantly upregulated in the reconstituting T cells
after cord blood graft than in the reconstituting peripheral blood T cells following bone
marrow graft. This finding suggests that tonic TCR signalling may be the primary driver of
lymphopenia-induced proliferation, and upregulated TCR signalling may endow cord blood T
cells with the property to re-populate rapidly in the lymphopenic environment.
TCR:MHC interactions and IL-7 are the two major homeostatic signals for proliferation
and/or survival of T cells (Surh et al., 2000; Jameson et al., 2005; Deshpande et al., 2013;
Hennion-Tscheltzoff et al., 2013), and these two signals co-operate to maintain the peripheral
T-cell pool. However, the exact contribution of the TCR and IL-7 signalling pathways during
lymphopenia-induced proliferation is not known. The distinct transcription profile of cord
blood T cells driven by their foetal origins and significant up-regulation of AP-1 transcription
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factor in the normal donor and reconstituting cord blood T cells, suggests that the TCR
signalling and its related pathways may mediate enhanced immune-reconstitution after CBT.
Therefore, I performed GSEA analysis to determine which pathways are significantly
upregulated in naïve CD4+ T cells from normal donor cord blood T cells and reconstituting T
cells after CBT and BMT, in comparison to the steady-state naïve CD4+ T cells from
peripheral blood. The TCR signalling pathway was upregulated in naïve CD4+ T cells from
all the lymphopenic conditions, such as normal donor cord blood and reconstituting T cells
after CBT and BMT. It is well-established fact that TCR signalling leads to the induction of
MAPkinase signalling pathways (Smith-Garvin et al., 2009), and interestingly, during
lymphopenic states, in addition to TCR signalling, MAPkinase signalling was also
significantly upregulated. This finding indicates an essential role of endogenous TCR
activation in driving lymphopenia-induced proliferation. If TCR activation to self or non-self-
ligands drives lymphopenia-induced proliferation, what role does IL-7 play in T-cell
homeostasis? It has been suggested that although CD4+ T cells proliferate in response to IL-7,
TCR stimulation increases the IL-7 responsiveness (Hennion-Tscheltzoff et al., 2013).
Recently it has been indicated that interruption of IL-7 signalling, with homeostatic TCR
signal, is essential for the survival of naïve CD8+ T cells, and persistent IL-7 signalling leads
to IFN-γ mediated cell death (Kimura et al., 2013). In addition, researchers have shown that
the stronger the TCR signal, the more IL-7 was interrupted, and the more cells survived. Our
data on the upregulation of the TCR signal during lymphopenia-induced proliferation,
corroborates these findings, and suggests that during lymphopenic states, IL-7 signalling may
be frequently interrupted by homeostatic TCR signal, and hence may lead to increased
survival and proliferation of T cells. Thus, upregulated TCR-MAPkinase signalling in cord
blood T cells is likely to be the potential mechanism of enhanced CD4+ T-cell reconstitution
after T-cell replete CBT.
The work done so far indicates the distinctness of TCR:MHC interactions during the
development of foetal ontogeny. Therefore, to investigate the role of TCR signalling in post-
CBT T-cell expansion, I attempted to generate a APC:T-cell culture system. Cord blood and
peripheral blood T cells were cultured in 96 well round bottom plates with increasing
concentrations of non-T cell fractions (self-APCs) to provide MHC signals. In this culture
system, there was no significant effect of increasing concentration of self-APCs on peripheral
blood CD4+ T-cell divisions. In contrast, cord blood CD4+ T cells underwent significantly
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more cell divisions with increasing concentration of APCs, indicating that cord blood CD4+ T
cells are tuned to undergo rapid proliferation in response to self-MHC signals.
Finally, to confirm the role of upregulated TCR-AP-1 signalling pathway in the
lymphopenia-induced proliferation of cord blood CD4+ T cells, increasing concentrations of
AP-1 inhibitor were used in the APC:T-cell culture system. Cord blood CD4+ T-cell
proliferation was inhibited by AP-1 inhibitor in the self APC:T-cell co-culture system, and
this inhibitory effect was proportional to the increasing concentration of AP-1 inhibitor.
These findings confirm the lower TCR signalling threshold of cord blood T cells to MHC
ligands, and the proliferation of cord blood T cells via the TCR signalling pathway. Thus,
indicating the role of TCR signalling in CD4+ T-cell biased immune-reconstitution after T-
cell replete CBT.
Model for CD4+ T-cell expansion after cord blood transplantation
Based on the findings of my thesis and previously described observations by other co-
workers, I put forward the model of CD4+ T-cell biased expansion after cord blood
transplantation.
Upregulated TCR-MAPkinase signalling in the cord blood CD4+ T cells, similar STAT5
phosphorylation of cord blood and peripheral blood CD4+ T cells to varying concentrations
of IL-7 and rapid decline in IL-7 levels during expansion of cord blood T cells were the key
findings of my work. Previously, essential role of both tonic TCR signalling and IL-7
signalling in proliferation and survival of naïve T cells (Surh et al., 2000; Jameson et al.,
2005; Deshpande et al., 2013; Hennion-Tscheltzoff et al., 2013), and T-cell death due to
persistent IL-7 signalling in the absence of MHC (Kimura et al., 2013) has been described. In
addition, increasing the TCR stimulation also increased the IL-7 responsiveness. Thus, it is
possible to conceptualise the co-operation between tonic TCR and IL-7 signalling as key
mechanisms for driving CD4+ T-cell expansion [Figure 86].
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Figure 86: Mechanism of CD4+ T cell expansion after cord blood transplantation is shown.
(a) shows interaction between self-MHC Class II peptide triggers TCR signalling (step 1 -
shown as green arrow). The TCR signalling is interrupted by IL-7 signalling (step 2 - red
arrow). This leads to downregulation of IL-7 receptor and proliferation of CD4+ T cells (step
3). (b) shows that when there is no interruption of TCR signalling by IL-7 signalling,
proliferation of CD4+ T cell does not occur. (c) shows that in the absence of TCR signalling
and continuous IL-7 signalling, CD4+ T-cell apoptosis occurs.
Based on the above model, one could speculate that the upregulated TCR-MAPkinase
signalling in cord blood CD4+ T-cell may drive the CD4+ T-cell biased expansion after cord
blood transplantation. Interestingly, it has been described recently that cord blood CD8+ T
cells have downregulated TCR-MAPkinase signalling compared to their adult counterparts,
and hence this TCR signalling based model of T-cell expansion would also explain delayed
recovery of CD8+ T cells after cord blood transplantation (Galindo-Albarrán et al., 2016).
Thus, the described model best fits with the theory of CD4+ and CD8+ T cells derived from
(a)
(c)
(b)
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lin28bhigh foetal HSC’s may be distinctly regulated to those derived from lin28blow adult
HSC’s. There are however other possible unexplored mechanisms for CD4+ T-cell biased
expansion after cord blood transplantation. The key unexplored mechanisms that could have
a role in rapid CD4+ T-cell biased expansion after cord blood transplantation are -
1) The effect of one log lower T cells transferred with the cord blood graft compared to
an adult graft source and hence increased availability of sources required for CD4+ T-
cell expansion,
2) The effect of naive immune system transferred with the cord blood graft vs partially
differentiated immune systems transferred with an adult graft source,
and last but not the least
3) The influence of gut microbiome of the host on cord blood T cells from the sterile
foetal environment.
Summary
The molecular signature of rapidly proliferating cord blood CD4+ T cells via the thymus-
independent pathway is similar to foetal CD4+ T cells, and hence supports the recapitulation
of foetal ontogeny after T-cell replete CBT. The molecular signature of naïve cord blood
CD4+ T cells was found to be enriched in genes involved in TCR-MAPkinase signalling. The
functional experiments further indicate that cord blood CD4+ T cells proliferate rapidly in
response to both self and allogeneic MHC signals. The functional experiments also show that
the proliferation of cord blood CD4+ T cells in response to self-MHC signals, is not only
TCR-dependent but also dependent on the AP-1 complex, an important transcription factor of
the TCR-MAPkinase signalling pathway. Therefore, gene expression and functional
experiments confirm that cord blood CD4+ T cells have a lower TCR threshold than
peripheral blood CD4+ T cells. The lower threshold of the TCR to MHC ligands increase
their propensity to undergo lymphopenia-induced proliferation (Kassiotis et al., 2003; Kieper
et al., 2004), and may mediate the rapid CD4+ T-cell biased reconstitution after T-cell replete
CBT. The increased sensitivity of cord blood T cells to MHC ligands may provide
qualitatively distinct effects after T-cell replete CBT (Fulton et al., 2015), therefore in the
next chapters, I investigated the role of rapidly reconstituting cord blood T cells in mediating
the GvL effect.
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Cord blood T cells mediate enhanced Tc1-Th1 anti-leukemic effects
compared with peripheral blood T cells
T-cell replete CBT is increasingly used to treat chemo-resistant leukaemia (Wagner JE Jr et
al., 2014; Barker et al., 2015; Brunstein et al., 2011; Zheng et al., 2015), and as discussed
before, such a T-cell replete approach leads to enhanced reconstitution after CBT (Chiesa et
al., 2012; Lindemans et al., 2014). We also observed that these rapidly reconstituting naïve
cord blood T cells differentiate into viral specific T-lymphocytes within two months of CBT,
and this was associated with the rapid clearance of viral infections from the blood (both
Cytomegalovirus and Adenovirus). It has been suggested that patients undergoing CBT for
acute leukaemia, who reconstituted their immunity more quickly as evidenced by immune
response to herpes viruses had a significantly reduced incidence of leukaemia relapse
(Parkman et al., 2006). Thus, despite the intrinsic bias of cord blood T cells towards anti-
inflammatory Th2/Tc2 immune responses (Marchant et al., 2005; White et al., 2002), naive
cord blood T cells can proliferate rapidly and differentiate into antigen-specific T cells
following T-cell replete CBT. Whether this early and unique pattern of cord blood T-cell
reconstitution mediated by strong TCR signals, could also provide an enhanced GvL effect
was investigated. To determine this, the ability of cord blood versus peripheral blood T cells
to mediate an anti-tumour effect in an EBV-driven B-cell lymphoma model of
NOD/SCID/IL2rgnull mice was compared.
Cord blood T cells were observed to mediate a robust GvL effect compared to peripheral
blood T cells in an EBV-driven B-cell lymphoma model. In comparison with cord blood T
cells, peripheral blood T cells mediated an attenuated GvL effect. Although cord blood T
cells mediated an enhanced GvL effect, no evidence of xenogeneic GvHD was observed.
This led to the significantly improved survival of mice receiving cord blood T cells.
Xenogeneic GvHD is a well-established feature of peripheral blood T cells. Intrigued by the
absence of xenogeneic GvHD in the cord blood T cells, I compared the xenogeneic potential
of cord blood T cells with peripheral blood T cells. Xenogeneic GvHD was exclusively
observed in the mice receiving peripheral blood T cells. This was confirmed by liver and gut
histology. There was no evidence of GvHD in the cord blood group. This confirmed that cord
blood T cells mediate an enhanced anti-tumour effect compared to peripheral blood T cells
without exhibiting xenoreactivity. I, therefore, speculated that the xeno-reactive peripheral
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blood T cells must also mediate a GvL effect, albeit an attenuated one compared with cord
blood T cells.
To test the GvL effect mediated by peripheral blood T cells, the ability of 5 million peripheral
blood T cells to reject a lower burden of B-cell lymphoma (2.5 million LCLs) was tested. In
this model, peripheral blood T cells mediated a GvL effect against a lower burden of B-cell
lymphoma, and this GvL effect correlated with the onset of xenogeneic GvHD. Thus, in
comparison with cord blood T cells, peripheral blood T cells mediated an attenuated anti-
tumour effect.
The B-cell lymphoma used in this model is an EBV-driven tumour that expresses viral
antigens. It was, therefore, important to determine whether the effective tumour control and
regression observed in the cord blood group was due to an anti-viral, or an anti-leukaemic
(allo-reactive) effect. Autologous cord blood T cells lacked the ability to reject the tumour.
This confirmed that the observed tumour regression in the cord blood group was an allo-
reactive T-cell response, rather than an HLA-restricted anti-EBV effect.
To gain immunological insights into the enhanced allo-reactive T-cell response mediated by
cord blood T cells, further tumour modelling experiments were performed to study the
tumour-infiltrating lymphocytes (TILs).
Firstly, to determine the differences in recruitment of T cells to the tumour in the cord blood
and peripheral blood groups, histological examination of the tumours was performed. Fifteen
days after T-cell injection, mice were sacrificed, and the tumours were stained with CD3+ and
CD20+ immuno-histochemical stains. T-cell infiltration was quantified using Image J
software. A significantly enhanced infiltration of cord blood T cells was observed compared
to peripheral blood T cells suggesting that cord blood and peripheral blood T cells may be
distinct. Indeed, majority of cord blood T cells are antigen-inexperienced naïve T cells
compared to adult peripheral blood T cells. At least, 30%–60% of adult peripheral blood T
cells have a memory-effector phenotype. Furthermore, as discussed before, there is growing
evidence supporting the distinct ontogenic origins of foetal and adult lymphoid immune
systems. Our observations also indicate that the early adaptive immune system derived from
T-cell replete CBT recapitulates a distinct molecular program of foetal ontogeny, which also
includes lymphopenia-induced genes. These phenotypic and ontogenic differences between
cord blood and peripheral blood T cells may not only endow cord blood T cells with the
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ability to rapidly undergo lymphopenia-induced proliferation but may also confer cord blood
T cells with the ability to mediate the enhanced allo-reactivity.
To further study the differences in recruitment of T cells to the tumour, flow-cytometric
analysis of the isolated TILs was carried out. Majority of cord blood TILs were CD8+ T cells,
but in contrast, a preponderance of CD4+ T cells were observed in the peripheral blood TILs.
Recruitment of lymphocytes to the tumour tissue is primarily mediated by an interaction
between MHC molecules expressed by the tumour cells, and the reactivity of immune cells to
these molecules. It is noteworthy that despite the strong expression of MHC Class I and II
molecules in this B-cell lymphoma model, and the robust proliferation of cord blood CD4+
and CD8+ T cells following stimulation with allogeneic lymphoma cells in vitro, most of cord
blood TILs were CD8+ T cells. This difference in the tumoural recruitment of T cells between
the two groups with significantly enhanced infiltration of cord blood CD8+ TILs was
observed in three separate experiments. Several clinical studies on human cancer have shown
that an increase in TILs is associated with a better prognosis (Leffers et al., 2009; Galon et
al., 2006; Sato et al., 2005; Zhang et al., 2003). Similarly, in our tumour model, the enhanced
tumoural infiltration of cord blood T cells (in particular cord blood CD8+ T cells) compared
with peripheral blood T cells may mediate potent anti-leukaemic effects and improve survival
in the cord blood group.
The role of CD8+ TILs in tumour immunology has been demonstrated in numerous murine
models and in cancer patients, including those with leukaemia. In one murine model of
MHC-mismatched allogeneic bone marrow transplantation for acute T-cell leukaemia,
infusion of mixed donor CD4+ and CD8+ T cells, or donor CD8+ T cells alone, mediated a
potent GvL effect, whereas GvL was not observed with donor CD4+ T cells alone (Johnson et
al., 1999). In another murine model of chronic myeloid leukaemia, GvL was also shown to be
mediated by CD8+ T cells (Lu et al., 2012). In clinical studies, however, infusions of CD4+
donor lymphocytes to treat CML relapse after HCT have induced durable remissions,
although more elaborate studies have demonstrated that CD4+ lymphocyte infusions led to
the expansion of CD8+ donor T cells and induced cytotoxic activity (Zorn et al., 2002).
Another recent study has also demonstrated that the response to infusions of CD4+ donor
lymphocytes is predicted by the percentage of pre-DLI bone marrow CD8+ T cell infiltrates
(Bachireddy et al., 2014). It is, therefore, apparent that CD8+ T cells are critical anti-leukemic
effectors at the tumour site. Hence, in this human lymphoma:T-cell model, our observation of
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the preferential infiltration of cord blood CD8+ TILs compared with peripheral blood CD8+
TILs indicates that cord blood CD8+ T cells mediate enhanced anti-tumour responses.
To mediate anti-tumour effects, naïve cord blood TILs must undergo memory-effector
differentiation. Therefore, the phenotype of TILs and circulating lymphocytes was studied
using flow-cytometry. Majority of cord blood T cells are naïve. Despite this, the percentages
of memory and effector CD4+ and CD8+ T cells in the cord blood TILs were similar to the
peripheral blood TILs. Thus, naïve cord blood TILs were observed to undergo rapid memory-
effector differentiation. Interestingly, whilst circulating lymphocytes from the peripheral
blood group underwent differentiation with an effector phenotype, circulating lymphocytes in
the cord blood group remained naïve. This phenotypic analysis of TILs and circulating
lymphocytes, supports the observation of enhanced anti-tumour effects, with the absence of
xenogeneic GvHD in the cord blood group.
To gain further insight into the enhanced anti-tumour effects mediated by cord blood T cells,
the kinetics of T-cell infiltration and the regulation of T cells in the tumour microenvironment
was studied. Monitoring of CD4:CD8 and CD8:CD4+ T-regulatory cell ratios, both at early
and late time-points was performed. A significant bias towards CD8+ T cells was observed in
the cord blood TILs compared to the peripheral blood TILs. In contrast, preponderance of
peripheral blood TILs comprised CD4+ T-regulatory cells compared to the cord blood TILs.
This indicates that the rapid infiltration of cord blood CD8+ T cells may mediate anti-tumour
effects in the cord blood group, and a preponderance of CD4+ T-regulatory cells in the
peripheral blood TILs may attenuate the anti-tumour effect. Furthermore, the role of FoxP3+
regulatory T-cell mediated immunosuppression is well-established as a crucial tumour
immune-evading mechanism (Dunn et al., 2004; Zou et al., 2005; Shevach et al., 2002;
Sakaguchi et al., 2005). In a meta-analysis of TILs in tumour sections, although CD3+ and
CD8+ TILs were associated with good prognosis and improved survival, the CD8+:FoxP3+
ratio produced a more impressive hazard ratio compared with CD3+ or CD8+ TILs alone
(Godden et al., 2011).
Naïve cord blood CD8+ TILs rapidly underwent memory-effector differentiation. Therefore,
to study which effector activity is gained by cord blood CD8+ TILs and peripheral blood
CD8+ TILs, cytokine staining for IFN-γ and TNF-α was performed, after stimulating isolated 
TILs with (B-cell) lymphoma cells in vitro. There were no differences in the percentage of
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CD8+ T cells gaining IFN-γ activity. Although, a significantly higher percentage of cord 
blood CD8+ TILs did gain TNF-α activity compared to the peripheral blood CD8+ TILs.
To further substantiate these qualitative differences between cord blood and peripheral blood
TILs, perforin expression was studied. Cord blood CD8+ TILs had higher expression of
perforin, compared with peripheral blood CD8+ TILs.  Thus, higher TNF-α activity and 
perforin expression is likely to be the possible mechanism of enhanced anti-tumour effect
mediated by cord blood CD8+ T cells in this tumour model.
Next, I questioned whether the differences in the Th1/Th2 ratio of cord blood and peripheral
blood CD4+ TILs could explain the enhanced anti-tumour effects in the cord blood group.
Th1 cells were identified as IFN-γ+ and TNF-α+ secreting cells, whereas Th2 cells were
identified as IL-4 secreting cells. In the peripheral blood group, a significantly higher
percentage of Th2 TILs was observed than in the cord blood group. On analysis of the
Th1/Th2 ratio by calculating the IFN-γ+:IL-4+ and TNF-α+:IL-4+ ratios in TILs, it was
observed that the Th1/Th2 ratio was significantly higher in the cord blood group compared to
the peripheral blood group. Whereas CD8+ TILs are apparent mediators of the GvL effect,
CD4+ TILs, in particular the Th1/Th2 balance also dictates tumour-specific immune
responses (Tsung et al., 1997; Aruga et al., 1997; Fowler et al., 1996). The role of the
Th1/Th2 balance has also been tested in leukaemia models (Hu et al., 1998). In general,
immune-deviation towards Th1 effector cells mediates an anti-tumour response, whereas
immune-deviation towards Th2 prevents tumour rejection. In this study, peripheral blood
TILs were found to have a significantly higher Th2 responses (measured as IL-4 secreting
CD4+ T cells) compared to cord blood TILs, and the Th1/Th2 intra-tumoural balance
(measured as IFN-γ/IL-4 and TNF-α/IL-4 ratios) in the cord blood TILs was relatively 
skewed toward Th1 responses compared to the peripheral blood TILs.
It is not surprising that a similar percentage of cord blood and peripheral blood CD8+ TILs
secrete IFN-γ because naïve cord blood and peripheral blood CD8+ T cells have a comparable
IFN-γ promoter methylation pattern (White et al., 2002). However, the relative skewing of
the Th1/Th2 balance towards Th1 in the cord blood TILs is noteworthy. This occurred even
though naïve cord blood CD4+ T cells are reported to be physiologically biased towards Th2,
produce lower levels of IFN-γ than adult naïve T cells in vitro and are hypermethylated at
CpG and non-CpG sites within the IFN-γ promoter (White et al., 2002). Thus, under adequate
priming conditions such as B-cell lymphoblastoid tumour, cord blood CD4+ T cells can
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rapidly mature into Th1 effectors. In contrast, a significantly lower CD8:CD4+ T-regulatory
ratio, a preponderance of Th2 cells and CD4+ T-regulatory cells may attenuate the anti-
tumour response in the peripheral blood group. Thus, a relative Th2 bias, and increased
number of tumour-infiltrating T-regulatory cells in the peripheral blood group, may impair
the GvL effect mediated by peripheral blood T cells in our tumour model.
Despite the naïve phenotype of cord blood T cells, we observed a similar percentage of
central memory and effector memory CD8+ T cells in the cord blood and peripheral blood
TILs. Interestingly, circulating cord blood T cells remained naive, unlike the circulating
peripheral blood T cells, which were found to have an increased percentage of effector
memory T cells, compared with peripheral blood TILs. This confirms that naïve cord blood T
cells mediate anti-tumour responses by rapidly undergoing memory-effector differentiation
within the tumour microenvironment. However, circulating cord blood T cells continue to
retain naïvety; an observation that complements the absence of xeno-reactivity in the cord
blood group.
Peripheral blood T cells mediate xeno-reactivity via murine MHC Class I and II with a
predominantly effector-memory phenotype (King et al., 2009; Ali et al., 2012; Covassin et
al., 2011). However, naïve T cells not only require MHC, but also require priming by co-
stimulatory and differentiation signals for memory-effector differentiation (Janeway, 2005).
These complex interactions for memory-effector differentiation are mediated by human
APCs. In humans, following T-cell replete CBT, cord blood T cells undergo rapid memory-
effector differentiation (Chiesa et al., 2012). However, a lack of human APCs in our model,
and the inability of naïve human T cells to interact with resting murine APCs (Lucas, et al.,
1995), or the defective murine APC in this model with NOD background (Shultz, et al.,
1995), may inhibit memory-effector differentiation. Thus, in the absence of adequate
priming, circulating naïve cord blood T cells may become anergic (Janeway, 2005), and
therefore, fail to cause xeno-reactivity.
In summary, cord blood T cells mediate more potent anti-tumour effects than adult T cells
through the enhanced recruitment of naïve cord blood T cells (particularly cord blood CD8+ T
cells), prompt induction of memory-effector differentiation and gain of cytotoxic-effector
functions in the tumour microenvironment. Delayed infiltration of peripheral blood T cells in
the tumour and skewing of the intra-tumoural balance toward CD4+ T cells, in particular
suppressive T-regulatory and Th2 TILs, may impair the GvL effect mediated by peripheral
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blood T cells in this model. Broadly, this work indicates that foetal-derived (ready-to-learn)
cord blood T cells mediate enhanced allo-reactivity compared with adult-derived (partially-
educated) peripheral blood T cells. The preferential tumour-homing of cord blood T cells
compared to the peripheral blood T cells, is particularly interesting. Not only do these naïve
cord blood T cells infiltrate the tumour, they also differentiate into memory-effectors and
become activated. Although, manipulated tumours have been shown to attract and activate
naïve CD8+ T cells in the tumour microenvironment (Yu et al., 2004; Schrama et al., 2001;
Kim et al., 2004), the role of chemokine receptors in the rapid migration of T cells to the un-
manipulated tumour remains to be elucidated.
The mechanisms of 1) recruitment of cord blood T cells to the tumour, 2) preferential
proliferation of cord blood T cells in the tumour microenvironment, and 3) enhanced anti-
tumour effects in this model remain to be elucidated and will require further work. Cord
blood CD8+ T cells are predominantly CCR7high, compared with a mixture of CCR7high and
CCR7low CD8+ T cells in the peripheral blood. The CD8+ T cells homing the tumour, in both
the cord blood and peripheral blood group, were CCR7high, whereas CCR7low CD8+ T cells
from the peripheral blood group remained in circulation. It is, therefore, possible that the high
expression of CCR7 in cord blood CD8+ T cells may facilitate enhanced tumour homing.
In summary, cord blood T cells mediate more potent anti-tumour effects than adult T cells in
this B-cell lymphoma model. The findings that cord blood T cells mediated an enhanced GvL
effect without exhibiting xeno-reactivity, parallel the clinical situation in humans, where CBT
may exert a powerful GvL effect, but with reduced rates of GvHD. Our work supports the
omission or minimization of serotherapy from the preparative regimens of CBT recipients for
high-risk haematological malignancies to enhance T-cell mediated GvL. Whilst we recognize
the limitations in extrapolating from this model system to the clinical setting, and that
following cord blood grafts, other immune cells, such as natural killer cells, may also mediate
a GvL effect (Gardiner et al., 1998; Xing et al., 2010). These findings nonetheless provide a
mechanistic insight into how cord blood T cells may mediate the potent GvL effects observed
after T-cell-replete CBT.
Model of GvL after cord blood transplantation
My work suggests that cord blood T cells mediate enhanced anti-leukaemic responses in this
lymphoblastoid tumour model. Majority of the tumour-infiltrating cord blood T cells were
CD8+ T cells and tumour-infiltrating cord blood T cells underwent rapid T-cell
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differentiation with Tc1-Th1 bias. Therefore, an important question is the role of cord blood
CD4+ T cells play in mediating the enhanced GvL effect. Effective antigen presentation is
required for GvL effect. Lymphoblastoid cells have antigen presenting ability similar to
mature dendritic cells (Issekutz et al., 1982). Therefore, a standard model of GvL similar to
that of chronic myeloid leukaemia is a possibility [Figure 87]. This means that the allogeneic
interaction between the TCR on naïve cord blood CD4+ T cells and MHC Class II on tumour
cells may activate the lymphoblastoid cells to efficiently present Class I antigens. The
presentation of Class I antigens may activate the naïve cord blood CD8+ T cells leading to
memory-effector differentiation, and hence cytotoxicity. Although, tumour infiltrating cord
blood CD4+ T cells were low in numbers, they were all Th1-biased. The extent of
contribution of CD4+ T cells in mediating GvL was not tested in this model.
Figure 87: Mechanism of GvL in this tumour model is shown. Allogeneic cord blood CD4+
T cells interact with MHC Class II molecules on lymphoblastoid cells. This interaction
activates lymphoblastoid cells leading to efficient presentation of MHC Class I molecules,
and hence leading to activation of CD8+ T cells leading to differentiation and anti-tumour
response. (red, blue and yellow circle represent cytokines, blue T cells are naïve and orange T
cells are memory/effectors)
Therefore, another model where direct interaction between MHC Class I and naïve cord
blood CD8+ T cells is also a possibility. To test the contribution of CD4+ and CD8+ T cells
in mediating GvL effect, one would have to perform experiments with population of CD4+ T
cells and CD8+ T cells injected in separate groups of mice with appropriate control mice, and
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thus answer an important question whether CD8+ T cells can mediate GvL in the absence of
CD4+ T cells.
Summary
Unrelated CBT without in vivo T-cell depletion is increasingly used to treat high-risk
haematological malignancies. Following T-cell-replete CBT, naïve cord blood T cells
undergo rapid peripheral expansion with memory-effector differentiation. Emerging data
suggest that unrelated CBT, particularly in the context of HLA-mismatch and a T-cell-replete
graft may reduce leukaemic relapse. To study the role of cord blood T cells in mediating
graft-versus-tumour responses, and elucidate the underlying immune mechanisms for this, the
ability of HLA-mismatched cord blood and adult peripheral blood T cells to eliminate
Epstein-Barr virus (EBV)-driven human B-cell lymphoma was compared in a xenogeneic
NOD/SCID/IL2rgnull mouse model. Cord blood T cells mediated enhanced tumour rejection
compared to equal numbers of peripheral blood T cells, leading to improved survival in the
cord blood group (p<0.0003). This anti-tumour effect was mediated by allo-reactive rather
than EBV-specific T cells, as shown by comparing lymphoma autologous cord blood T cells
with allogeneic ones. Analysis of tumour-infiltrating lymphocytes demonstrated that cord
blood T cells mediated this enhanced anti-tumour effect by the rapid infiltration of the tumour
with CCR7+ CD8+ T cells, and the prompt induction of cytotoxic CD8+ and CD4+ Th1 T cells
in the tumour microenvironment. In contrast, in the peripheral blood group, this anti-
lymphoma effect is impaired because of the delayed tumoural infiltration of peripheral blood
T cells, and a relative bias toward suppressive Th2 and T-regulatory cells. Our data suggest
that, despite being naturally programmed toward tolerance, reconstituting cord blood T cells
may provide superior Tc1-Th1 anti-tumour effects against high-risk haematological
malignancies.
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Clinical applications
Upregulated TCR signals in cord blood CD4+ T cells may mediate enhanced immune
reconstitution and potent allo-reactivity, and hence a robust anti-leukaemic effect, as
demonstrated by our work. We have shown that cord blood transplantation without
serotherapy mediates a robust anti-leukaemic effect against acute myeloid leukaemia
(Admiraal et al., 2016). This study consolidates the idea of enhanced GvL and antiviral
responses after cord blood transplant compared to an adult graft. I, therefore, envisage a
retrospective European society of blood and marrow transplantation (EBMT) study to assess
the role of cord blood transplantation in high-risk myeloid malignancies. It will be interesting
to study the effect of in vivo depletion on the risk of relapse in high-risk myeloid
malignancies.
Vaccination for acute myeloid leukaemia
Cord blood transplantation provides a platform for naïve and foetal T-cell therapy. Despite
robust GvL effects, mediated by cord blood T cells, a substantial proportion of patients (30 to
40%) relapse after cord blood transplantation. Therefore, a cord blood transplant platform
could be explored to enhance GvL using vaccination strategies. One possibility is to develop
cord dendritic cell-AML tumour hybridoma vaccine, as described below.
The supernatant of cord blood washings and cord blood bags after infusion of the product
contains 10 to 15 million cells. These cells could be isolated, and adherent cells cultured with
granulocyte-macrophage colony stimulating factor GMCSF), IL-4, and TNF-α. The dendritic 
cells and AML preparations would be analyzed using immune-cytochemical staining and co-
cultured with polyethylene glycol to generate DC/AML fusions, as previously described
(Rosenblatt et al., 2011). The irradiated dendritic cell-AML hybridoma vaccine could be
injected one month after a cord blood transplant to enhance the GvL response. The vaccine
induced immunologic response would be serially studied in the pre- and post-vaccination
samples.
Check point blockade
Relapse of leukaemia after HCT may occur because of immune escape, and immune-
checkpoint inhibitory pathways may play a role in this. Immune-checkpoint receptors, such
as CTLA-4 and PD-1 have been shown to play a crucial role in tumour evasion of the donor
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immune system (Davids et al., 2016). The role of a checkpoint blockade in relapse following
cord blood transplant has not been explored.
Off the shelf cord blood CAR T cells
CAR T-cell technology has exploded in recent years. The technology has been a great
success in CD19+ B-cell acute lymphoblastic leukaemia. However, autologous CAR T cells
are not possible in all patients, and such patients could benefit from ‘off the shelf’ allogeneic
CAR T cells. Off the shelf allogeneic CAR T cells, derived from peripheral lymphocytes
have been manufactured using multiplex editing technology such as transcription activator–
like effector nuclease (TALEN), as previously described (Poirot et al., 2015; Qasim., et al
2017). It is likely that cord blood CAR T cells may mediate potent effects compared to
peripheral blood CAR T cells, because of their proliferative potential. Off the shelf cord
blood CAR T cells targeting antigens overexpressed in high risk malignancies is another
potential area of development in the near future.
Relevance to Health and Disease in the Neonate
The ability of cord blood T cells, particularly CD4+ T cells, to proliferate rapidly in the post-
transplant setting, converting from naïve to functional memory/effector cells with anti-viral
and anti-leukaemic properties may have relevance to health and disease in the neonatal
period. Clearly the ability to deal effectively with viruses in this period is vital to the
newborn. However, new-borns are susceptible to viral infections. Is there a period of immune
compromise during the switch over from foetal to adult lymphoid program? Could these
unique properties be deleterious to the child if such cells persist in the post-natal environment
i.e. lead to increased autoimmunity or diseases such as necrotising enterocolitis. The findings
of these unique properties of feotal derived cord blood CD4+ lymphocytes warrant further
study away from the transplant setting in the neonatal period.
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